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The majority of urinary bladder cancer (UBC) cases are diagnosed as non-muscle 
invasive malignancies, having a favourable prognosis in terms of overall 5-year 
survival. However, non-muscle invasive bladder cancer (NMIBC) cases show high 
recurrence and progression rates and inconsistencies within the NMIBC risk group, 
resulting in a substantial burden on patients and health systems.  
The evidence for genetic risk factors having a role in NMIBC susceptibility and 
prognosis make NMIBC a good candidate for personalised medicine approaches; 
however, multiple genome-wide association studies (GWAS) have primarily focused 
on NMIBC risk alone, even though investigating prognostic factors would arguably 
yield more benefit.  
It is recognised that genetic variation contributes to complex traits in the form of 
multiple effects of low-penetrance, as well as interacting not only with each other, but 
with various environmental factors as well, resulting in a complex problem to resolve.  
In a setting of a bladder cancer patient cohort, our project aims to identify genetic 
variants of genome-wide significance that might be associated with certain NMIBC 
characteristics at diagnosis, and potential gene-environment interaction effects with 
smoking. Furthermore, we aim to address the importance of replication in genetic 
association studies by utilising a resource of UK Biobank, whilst introducing a novel 
approach for identifying prognostic events from routinely collected data.  
In conclusion, the current thesis provides additional evidence to the field of bladder 
cancer genetics and suggests further research topics of interest that could lead to 
optimising NMIBC patients’ care.  
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1.1 EPIDEMIOLOGY OF URINARY BLADDER CANCER  
 
Urinary bladder cancer (UBC) accounts for approximately 430,000 new cases and 
165,000 deaths worldwide annually [1], placing as the 9th most common cancer (6th 
among men and 19th among women) [2]. Importantly, the management of UBC places 
burden on medical systems due to high monetary costs, and UBC has been estimated 
to account for 3% of all cancer-related healthcare costs in the European Union in 2012 
[3].  
The incidence of UBC varies significantly between and within populations, as well as 
across different sets of characteristics. As in the case of many cancers, age is one of 
the strongest predictors for developing UBC. The risk of disease increases steadily 
during lifetime, reaching a median age at the time of diagnosis of 65-70 years [1, 4].  
Males are consistently observed to have a higher UBC incidence in comparison to 
females, no matter the geographic region (gender ratio of roughly 3.5 to 1) [1, 2].  
UBC is mostly a disease of countries with high human development index (HDI), with 
55% of all new cases and 45% of all deaths being registered in North America and 
Europe [1, 2]. Some African and Asian regions also exhibit high UBC rates, which are 
mostly attributed to Schistosoma infections [2, 5]. Divergent disease aetiology reflects 
the distribution of UBC cancer types between these regions; urothelial carcinoma is 
the prevailing type in HDI countries, whilst African regions observe a much higher rate 
of other histological types, mainly squamous-cell carcinomas [5]. Overall, global 
incidence and mortality rates have a temporal decreasing trend, except for countries 
undergoing rapid economic development [2]. Recent changes have been mostly 
attributed to reduced prevalence of smoking, the most significant risk factor for UBC 
[2, 5]. It is unknown whether the decline will be sustained, as it is also heavily 
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influenced by other counteracting factors. For example, the old age at the time of 
diagnosis is expected to cause a slight incidence surge in the upcoming decades. As 
life expectancy increases, the population at-risk becomes larger, which highlights that 
the health burden caused by UBC is likely to persist [5].  
Nonetheless, a direct comparison of UBC incidence rates poses a challenge due to 
the large disparity in cancer registration practices. Globally, most registries tend to 
include both invasive and non-invasive forms of bladder cancer [6]. Non-muscle-
invasive bladder cancer (NMIBC) is diagnosed more often and has a much better 
prognosis in comparison to tumours that have invaded into the detrusor muscle. 
Hence, comparing UBC distribution, especially in terms of mortality and prevalence, 
is subject to a careful evaluation on whether the considered countries and/or regions 
have included all UBC cases or have limited their reports to only muscle-invasive 
bladder cancer (MIBC) [6]. 
 
1.2. RISK FACTORS FOR DEVELOPING UBC 
 
1.2.1. Smoking 
The principal risk factor for UBC development is tobacco use, which is estimated to 
account for almost 50% of all new UBC cases [5-7]. Smoking results in high exposure 
to many carcinogenic substances with DNA-damaging capabilities [8]. Among those, 
aromatic amines have been specifically linked to bladder cancer [6-9]. Aromatic 
amines are powerful DNA-damaging compounds, and since they are excreted via the 
urinary system, the carcinogenic effect on the bladder epithelium is substantial [6, 7]. 
When not repaired, the aromatic amine-induced cellular DNA damage may lead to 
mutations, resulting in dysregulation of key biological processes and, ultimately, 
urothelial cell transformation [8, 9]. In addition to these genotoxic effects, aromatic 
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amines, like many other chemical carcinogens, induce epigenetic changes that are 
also involved in bladder carcinogenesis [10, 11].  
Given the widespread use of tobacco in many countries, it poses a serious public 
health problem. Moreover, as the latency period between smoking exposure and UBC 
development spans over two to three decades [5, 7], the true consequences are 
delayed and hence difficult to assess. Current estimates suggest smoking results in 
three- to four-fold increase in UBC risk, when compared to never-smokers [5, 7]. In 
addition, smokers of black (air-cured) tobacco have a higher bladder cancer risk than 
smokers of blond tobacco (flue-cured) due to the higher levels of the aromatic amines 
in black tobacco smoke in comparison to blond tobacco smoke [9]. Former tobacco 
users have a slightly lower risk of developing UBC (Relative Risk (RR)≈2) [5, 7], which 
shows smoking cessation interventions are a promising tactic in reducing UBC 
incidence and mortality. For example, the slight reduction in global UBC incidence and 
mortality rates worldwide has been attributed to decreasing use of tobacco in many 
Western countries. However, some Eastern European and Baltic countries have had 
a slower reduction of tobacco use prevalence, and a correspondent UBC incidence 
decline is expected only after a few more decades [2]. 
 
1.2.2. Occupational exposure 
Smoking is not the only source of aromatic amines, and additional exposure can be 
related to various workplaces, for instance, during the production of textiles, dyes, 
paints, inks, rubbers, cables, solvents, and leather dusts [6, 7]. However, occupational 
exposures are not limited to aromatic amines, and are also found to be rich with other 
carcinogens, namely benzidine, metal working fluids, polyaromatic hydrocarbons, 
diesel exhaust, 2-naphtylamine, 2-chloroaniline, 4-aminobiphenyl, ortho-toluidine, 
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tetrachloroethylene, and combustion products from natural gas [6, 7, 12]. The 
occupation-related attributable risk for bladder cancer varies, and is reported to be as 
low as 5% [6] and as high as 20% [7]. The exact extent of occupation exposure 
influence on UBC development is problematic for many reasons – the average 
workplace has multiple factors affecting health, and measurement of all exposures is 
subject to a significant error. Nonetheless, the evidence is consistent with some 
industries (tobacco, metallurgy, dye) being associated with an increased risk of UBC 
(lowest reported RR:1.72 (tobacco workers), highest RR=13.4 (dye workers)) [6].  
 
1.2.3. Dietary factors 
The role of nutrition in bladder cancer has been investigated in numerous studies; 
however, findings remain inconsistent, mostly due to the difficulty of accurately 
measuring the effect of specific nutrients, individual foods, or product groups.  
Water intake has been hypothesised to have a protective effect on bladder cancer, by 
increasing urine volume and daily excretion frequency, thus reducing carcinogen 
exposure to the urothelium [6, 7]. Alternatively, chlorinated tap water may actually 
introduce carcinogens - trihalomethanes - and contribute to an increased risk of UBC 
[13]. Moreover, the effect of various beverages, such as alcohol, tea, coffee, cola, and 
dairy products has been investigated separately to adjust for active ingredients in each 
product. The estimates between studies vary [14], but meta-analyses of observational 
studies indicate there is little to suggest that any of the mentioned fluids have a 
convincing link with bladder cancer risk [6, 7, 15].  
Conflicting results are also observed for specific foods and dietary patterns. Not 
surprisingly, higher fruit and vegetable consumption is linked with lower risk of urinary 
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bladder cancer [16, 17], but the protective effect is not supported by all reported meta-
analyses [6, 18, 19].   
Pooling studies on red meat consumption and bladder cancer risk has shown no 
significant effect, but high intake of processed meat is suggestive of an increased rate 
of UBC [20, 21].  
Overall, it is widely recognised that diet plays an essential role in human health. 
However, when considering all published evidence as a whole, it seems that the 
generic dietary advice [22] provided for prevention of all - communicable and non-
communicable diseases – is also relevant for bladder cancer. More studies on dietary 
patterns with consistent results are needed before any targeted recommendations can 
be made for preventive use of diet for bladder cancer. Nevertheless, such studies can 
be challenging to conduct. 
Research on micronutrients in relation to bladder cancer is assisted by a few 
randomised controlled trials (RCTs). Supplementation with various compounds has 
been reported in the literature, mostly on vitamins A, B, C, D, E, beta-carotene, and 
selenium) [6, 7, 23]. However, a recent meta-analysis of 14 RCTs found no effect of 
any supplementation [23], as well as a Cochrane review on selenium [24]. 
Interestingly, subgroup analyses consisting of 3 RCTs showed beta-carotene may 
have a harmful effect and increase the risk of UBC (RR=1.44, 95%CI: 1.00-2.09). In 
addition, observational studies investigating baseline levels of various micronutrients 
have also failed to show consistent associations with bladder cancer risk [6].  
 
1.2.4. Non-modifiable risk factors 
UBC is also associated with a variety of non-modifiable factors. The most prominent 
of such factors is gender. Bladder cancer is diagnosed almost three times more 
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frequently in men than women [1, 2]. Extensive previous research on causes for the 
inter-gender gap has mostly considered sex-specific smoking behaviours and 
hormones [7], but they fail to fully explain the observed patterns [25]. Fortunately, new 
evidence shows the cause may be linked to a gene on the X chromosome, KDM6A 
[26]. KDM6A escapes the process of X chromosome inactivation and is highly 
expressed in women. Evidence suggests KDM6A acts as a tumour suppressor and 
reduces the likelihood of developing UBC [26]. Moreover, women with low expression 
of KDM6A have worse prognostic UBC outcomes. Importantly, an elegant study by 
Kaneko et al. [26] highlights sex chromosomes and hormones as having independent 
roles that amplify each other’s effects, further enhancing UBC disparities between 
males and females.  
The concept of genetics playing a role in bladder cancer was first recognised having 
observed almost a two-fold increased risk of developing UBC among first-degree 
family members [27]. The genetic contribution to UBC diagnosis has been further 
investigated in larger datasets, estimating the heritability to be roughly 12% [28]. 
Importantly, investigations into smoking-related cancers have shown that genetic loci 
related to tobacco use also make a significant contribution to bladder cancer 
heritability (~3%) [28]. This finding implies that some people have a genetic tendency 
to smoke or smoke in higher quantities, and this behaviour contributes to developing 
bladder cancer. In concordance with these observations, the heritability of UBC is 
slightly lower among never-smokers than in those with any history of smoking [28]. 
These patterns underscore the complex nature of genetic determinants, since some 
act upon the outcome directly, whilst others may exert effects in a more complex path 
[28].  
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The number of currently reported loci for genetic predisposition to bladder cancer is 
such that the word limitations of the current thesis do not allow the full discussion of 
each. Most consistently validated associations include genes GSTM1 and NAT2, 
responsible for regulating detoxification of various substances [29, 30]. Although 
GSTM1 and NAT2 proteins are both stage II-detoxifiers, they seem to play different 
roles in bladder cancer. NAT2 is heavily involved in tobacco-related compound 
clearance, and an impaired function leads to longer carcinogen exposure. This 
hypothesis is supported by studies on gene-environment (GxE) interaction between 
NAT2 polymorphisms and smoking, which conclude that NAT2 mutations only 
contribute to UBC risk among ever smokers [30]. On the other hand, GSTM1-null 
genotype has been associated with an increased UBC risk regardless of smoking 
behaviour, suggesting it is involved in the detoxification of carcinogens not limited to 
tobacco [29]. 
Moreover, the presence of gene-gene interaction has also been implied in multiple 
studies, showing variants in some genes have a different combined effect in 
comparison to their individual consequences. Specifically, there have been suggested 
multiplicative interactions between NAT2 slow-acetylator and GSTM1-null [31], and 
between GSTM1- and GSTT1-null genotypes [32].  
Multiple other genes have been shown to alter the risk of bladder cancer, but only a 
handful have been analysed in meta-analyses. When multiple studies have been 
considered, evidence shows that the implicated genes vary widely in their function. 
Some regulate overarching processes, such as DNA repair (ERCC2/XPD [33-36], 
XRCC1 [37-40], XRCC3 [41-43], XRCC4 [44], XPC [45-48], NBS1 [49]), cell cycle 
progression (CCND1 [45, 50], MYC [51, 52]), telomere integrity (TERT-CLPTM1L [53, 
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54]), mRNA translation (MIR146A [55]), apoptosis (Survivin/BIRC5 [56, 57]), and cell 
adhesion (CDH1 [58]). 
Other genes are implicated in specific mechanisms, such as regulating immune 
function (IL10 [59], IL6 [60], TNF-α [61], CCR2 [62]), prostate-related protein coding 
(PSCA [52, 63, 64]), sulphate conjugation of many compounds (SULT1A1 [65, 66]), 
detoxification (NQO1  [67-70] , GSTP1 [71, 72], GPX1 [73, 74], UGT1A7 [75], nitric 
oxide production (eNOS/NOS3 [76]), extracellular matrix breakdown (MMP1, MMP2, 
MMP7 [77, 78]), catecholamine metabolism (COMT [79]), drug metabolism and 
production of steroids, lipids, and cholesterol (CYP1A1 [80], CYP2E1 [81], and 
regulating well-known tumour suppressor proteins (TP53 [82, 83]). 
In addition, pooling the published studies is also useful in clarifying which associations 
are likely to be false positives. Specifically, meta-analyses report various 
polymorphisms in genes ERCC6 [84], MSH3 [85], MDM2 [86], APE1 [87], CYP1A2 
[88], XRRC7 [89], NKFB1 [90], HIF-1α [91], XPG/ERCC5 [92], CYP1B1 [93], and 
TGFBR1*6A/9A [94] have little to suggest their importance in UBC development.  
However, the direct interpretation of any reports, including meta-analyses, is burdened 
by many limitations, such as comparing different ethnicities and the use of divergent 
methodologies. Several loci were found to be associated with bladder cancer only 
among people of certain ethnic backgrounds, for example, single nucleotide 
polymorphisms (SNPs) in MTHFR [95], SULT1A1 [65], CYP2E1 [81], MDM2 [96], 
BIRC5 [56], XRCC3 [43], UGT1A7 [75], and TP53 [97-99]. These reports carry even 
further uncertainty, as some meta-analyses have found variants (e.g. XRCC1) to be 
significant only in ethnic subgroups [39, 40]), whilst others have concluded the effect 
is present regardless of ethnicity [100]. 
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Group-specific loci may also become apparent when considering gene-environment 
interactions with various external exposures: the genetic associations will be evident 
only in specific populations, but not overall, for example, SNPs in hOGG1 ([101, 102]) 
and NAT2 [30].  
Moreover, meta-analyses on variants differ extensively in their strength. For example, 
one meta-analysis on CYP1B1 concluded an overall association with urinary cancers, 
alongside an acknowledged presence of publication bias and a very small number of 
studies [103]. The persisting challenges are further reflected in reports contradicting 
each other. For example, a few meta-analyses have stated that a mutation in CYP1A2 
(rs762551) has a protective effect on bladder cancer [88, 104], and another one 
concluded that there is no evidence to support such findings [105]. The same 
inconsistency is present for rs1048943 in CYP1A1 [80, 106], rs1801133 in MTHFR 
[95, 107, 108], and rs1800566 in NQO1 [109, 110]. 
Finally, several polymorphisms in the same gene have been observed to have 
associations in different directions, even for the same outcome. For example, rs25487 
(R399Q) in XRCC1 seems to be protective for bladder cancer among smokers, but 
variants rs1799782 (R194W) and rs25489 (R280H) show increased risk of UBC 
among Asians [38].  
To conclude, various inconsistencies in genetic association studies demonstrate the 
topic is multi-faceted and complex. Further investigations, accompanied by advances 
in methodology, will be essential to calibrate our current knowledge of the relationship 
between genetics and UBC development. 
 
1.3. BLADDER CANCER PATHOPHYSIOLOGY  
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1.3.1. Molecular pathophysiology 
Although NMIBC and MIBC share topography, there is substantial evidence for them 
to be considered separate types of cancers [5, 111, 112]. Current research shows that 
they may develop in distinct pathways – papillary (NMIBC) and non-papillary (MIBC) 
– that overlap to a degree, but clinically result in two different forms of UBC [111] 
(Figure 1.1).  
Papillary cancer is often characterised by mutations in FGFR3, alongside deletions on 
chromosome 9 (9q). These genomic changes are considered to be a precursor for 
urothelial hyperplasia, that later give rise to NMIBC or remain benign and can be 
discovered as urothelial papilloma [5, 113].  
In contrast, MIBC mostly develops via a non-papillary pathway and makes up for 20-
25% of all new UBC cases [5]. A precursor for MIBC is thought to be urothelial 
dysplasia and/or carcinoma in situ (CIS), which in time may develop into high-grade 
and non-papillary urothelial cancer [111, 113, 114]. These tumours have a high 
propensity for penetrating the detrusor muscle and forming distant metastases, which 
signals an unfavourable outcome [111]. In addition, MIBC shows distinct genetic 
mutations, mostly in genes functioning as tumour suppressors – TP53, PTEN, and 
RB1, among other [5, 112, 113] (Figure 1.1) 
It is important to mention these pathways are not entirely independent; for example, 
roughly 15% of low-grade Ta tumours become genetically unstable and develop into 
high-grade Ta tumours. These tumours show signs of both hyperplasia and dysplasia, 
and have alterations in RB1 and TP53 genes [5, 112]. Moreover, FGFR3 mutations 
are not exclusive to NMIBC; as 40% of MIBC tumours also demonstrate FGFR3 
overexpression [5, 113].  
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1.3.2. Molecular subtypes 
In practice, bladder cancer is often present not just as a single tumour, but as multiple 
neoplasms, scattered across the bladder lining [5]. Multifocality raises the question of 
whether all tumours are independent of one another or have a single cell of origin. 
Whole-bladder mapping studies have shown UBC is a highly heterogeneous disease, 
and it is most likely a result of multiple pathogenic processes, working in parallel [112].  
 
Figure 1.1. Molecular pathophysiology of bladder cancer. CIS-carcinoma in situ.  
 
The urothelium consists of three main tissue layers – basal, intermediate, and luminal. 
The basal layer is considered to harness stem cells that are capable of self-
regeneration and show least differentiation. Intermediate cells show a higher level of 
differentiation, but the proliferation potential is much lower than that of the basal layer. 
Finally, the luminal cells are fully differentiated and make up the top layer of the 
urothelium. Each cell type has a specific protein expression profile, which makes it 
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possible to infer the developmental origin of bladder tumours [112]. In fact, a few 
important studies investigated transcriptional profiles of both NMIBC and MIBC and 
have provided guidelines for UBC molecular subtyping. Although the exact categories 
identified by each group differ (Figure 1.2), there are a few overlapping patterns that 
are likely to be pivotal in future UBC management [5, 112].   
 
Figure 1.2. Molecular subtypes of urinary bladder cancer. Adapted from Sanli et 
al. [5]. MDA–MD Anderson, MIBC–muscle-invasive bladder cancer, NMIBC–non-
muscle-invasive bladder cancer, SCC-squamous cell carcinoma, TCGA-The 
Cancer Genome Atlas Program, UNC-University of North Carolina.  
 
NMIBC samples have been included in two studies [115, 116], and both show low-
grade papillary tumours (Ta) can be defined by markers of high differentiation, early-
cell cycle and FGFR3 gene signatures [5, 115, 116]. Alternatively, high-grade and T1 
NMIBC has been observed to retain markers of high differentiation, but were also 
genetically unstable and expressed markers of late cell-cycles [5, 115, 116].  
Molecular subtypes of MIBC have been exclusively reported by three studies [5, 117-
119]. The number of subtypes ranges from two [119] to four [117], but the main 
similarity among all is distinguishing luminal and basal MIBC. Similarly to NMIBC, 
luminal invasive bladder cancer expresses markers of cell differentiation, early cell 
cycle genes, and FGFR3 signature. In contrast, basal tumours are accompanied by 
markers of basal layer of the urothelium [5].  
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Overall, these data provide important insights into the landscape of UBC. Firstly, there 
seems to be two broad categories of luminal and basal cancers, mostly corresponding 
to papillary and non-papillary pathways, respectively [112]. Non-invasive cancers are 
usually present as luminal and have a better prognosis, whilst muscle-invasive 
tumours can be either of basal origin or a mixture of basal and luminal. Invasive UBC 
of luminal type is likely to represent tumours that have initially developed as papillary 
low-grade tumours, but have lost genetic stability and have progressed into high-grade 
papillary cancer [112]. Importantly, although basal cancers are intrinsically more 
aggressive, they are also seemingly more responsive to cisplatin-based 
chemotherapy. At the same time, MIBC type that represents a cross-over of luminal 
and basal types, tagged “p53-like”, were less aggressive, but were resistant to the 
same chemotherapy agents [120].   
To conclude, a growing body of evidence suggests that combining NMIBC and MIBC 
groups in observational and experimental research may be incorrect. 
 
1.4. URINARY BLADDER CANCER IN A CLINICAL SETTING 
 In Western societies, urothelial or transitional cell carcinoma is diagnosed in 75-90% 
of all UBC cases [112]. Other histological types, such as squamous cell carcinoma, 
are associated with an aggressive disease, and usually require specific management 
that cannot be guided with group-level recommendations [5]. In a clinical setting, UBC 
is categorised into broad groups of NMIBC and MIBC, as the level of penetration into 
the detrusor muscle still represents the most important prognostic factor [114] (Figure 
1.3).  
NMIBCs comprise the majority of UBC cases (70-80%) and are usually diagnosed as 
papillary carcinoma [5, 114, 121]. 
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Papillary carcinoma of NMIBC is generally associated with a better outcome, 
especially in terms of mortality. However, the recurrence rates are very high despite 
local therapy (5-year recurrence rate: 50-70%, 5-year progression rate: 10-30%) [7, 
111, 122].  
Painless haematuria is the most common clinical symptom of UBC, which is either 
observed during routine urine tests or by patients themselves [5, 122]. Sometimes 
other, non-specific, urinary tract symptoms (e.g. increased urination frequency, 
dysuria, etc.) may also indicate the presence of a malignant tumour, and are more 
often associated with CIS [5, 122].  
 
Figure 1.3. Urinary bladder cancer staging. CIS-Carcinoma in situ. 
 
The long-standing gold standard for UBC diagnosis is cystoscopy, performed under 
local anaesthesia. A flexible endoscope is inserted into the bladder via the urethra, 
which allows a visual examination of the bladder lining. Suspicious lesions deviating 
from the normal urothelium are biopsied for histological investigation, which further 
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dictates management strategy [5]. Cystoscopy is an invasive and expensive 
procedure, and uncomfortable for patients. Hence, many efforts are directed towards 
finding an alternative diagnostic tool. As tumour cells and DNA are shed into the urine, 
it can theoretically be used for UBC detection. Regardless of the potential, no urine-
based biomarkers have yet reached sufficient sensitivity and specificity metrics, 
leaving as cystoscopy the principal diagnostic tool for the time-being [123].  
If cystoscopy is suspicious of cancer, the first order of action is a transurethral 
resection of bladder tumour (TURBT) (unless cystoscopy suggests MIBC; in that case, 
additional staging techniques might be used before TURBT, such as Computed 
Tomography (CT) or Magnetic Resonance Imaging (MRI)) [124]. During TURBT, not 
only is the tumour removed, but additional investigation is carried out to better describe 
the disease. Urothelium is assessed for multifocal tumours, lesion size, and a biopsy 
of detrusor muscle deep to the tumour is taken to rule out an invasive cancer [124]. 
Treatment differs substantially for MIBC and NMIBC cases. MIBC is a high-risk 
disease, and, therefore, necessitates early radical treatment. Based on specific 
characteristics of individual cases, radical therapy includes either full removal of the 
urinary bladder (cystectomy) or radiotherapy [124]. In addition, neoadjuvant cisplatin-
based chemotherapy may be administered prior to radical treatment if appropriate 
[124]. 
NMIBC is a slightly more complex entity, and the treatment depends on a defined risk 
category (low, intermediate, or high) [122, 124]. To assign the risk category, factors of 
stage, grade, size, multifocality, number of previous recurrences, presence of 
concomitant CIS, histological variants, and level of invasion into the lamina propria are 
considered (Figure 1.4). For low-risk NMIBC, TURBT and a one-time instillation of 
chemotherapy (mitomycin C or similar chemotherapeutic) into the bladder is usually 
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sufficient. Cancers falling into the intermediate-risk category require TURBT and 
multiple installations of mitomycin C or Bacillus Calmette-Guerin (BCG) treatment into 
the bladder, but are usually not recommended for more than one year [122]. 
 
Figure 1.4 NMIBC Risk Groups [122]. 
Finally, high-risk NMIBC is treated with a TURBT and intravesicular instillations of 
BCG for a maximum of three years [122, 124]. Some guidelines include consideration 
of a radical cystectomy approach for high-risk NMIBC [124]. All NMIBC cases are 
subject to rigorous post-treatment monitoring, albeit at different frequencies. Patients 
with low-risk NMIBC are advised a cystoscopy at three and 12 months after the 
diagnosis. Intermediate-risk patients should have a cystoscopy at three, nine, and 18 
months after the NMIBC diagnosis, and an annual follow-up until five years. Cases of 
high-risk NMIBC require cystoscopies every three months for the first two years, every 
six months until five years, and once a year for the remaining time (Figure 1.5) [122, 
124].  
However, it is important to highlight there are several guidelines for NMIBC 
management, and although they overlap to a high degree, differences between all of 
the approaches remain [125]. 
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Figure 1.5. NMIBC patient cystoscopy follow-up schedule. 
 
1.5. INDIVIDUAL PREDICTIVE AND PROGNOSTIC TOOLS FOR URINARY 
BLADDER CANCER OUTCOME 
As the management of NMIBC cases is not a homogenous process and differs based 
on various characteristics, there have been multiple attempts for developing 
instruments that would best predict individual outcomes and optimise treatment 
strategies.  
The European Organization for Research and Treatment of Cancer (EORTC) has 
developed a tool to predict individual outcomes for patients who only underwent a 
single intervention of TURBT. The scoring system estimates per-person probability 
rates of recurrence and progression events, and relies on six clinical factors: tumour 
size, stage, grade, presence of CIS, number of tumours, and prior recurrence rate 
(Table 1.1) [122]. Every factor is assigned a different weight, indicating the relative 
importance of each (Table 1.2). 
A separate scoring system has been jointly developed by the Club Urologico 
Espanolde Tratamiento Oncologico (CUETO) and EORTC, that only applies to BCG-
treated patients [126]. The system considers gender, age, recurrence status, number 
of tumours, T stage, presence of concomitant CIS, and tumour grade (Table 1.3). 
These factors are then transferred into an algorithm that estimates recurrence and 
progression probabilities at one, two, and five years.  
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Table 1.1. Probability of urinary bladder cancer recurrence and progression 
based on the EORTC score [122, 127].  
Probability of 
the event at 1 
year 
Probability of 
the event at 5 
years 
% 95% CI % 95% CI 
Recurrence 
score: 
    
0 15 10-19 31 24-37 
1-4 24 21-26 46 42-49 
5-9 38 35-41 62 58-65 
10-17 61 55-67 78 73-84 
Progression 
score: 
    
0 0.2 0-0.7 0.8 0-1.7 
2-6 15 0.4-1.6 62 5-8 
7-13 5 4-7 17 14-20 
14-23 17 10-24 45 35-55 
CI=confidence interval. 
 
Table 1.2. Weights used to calculate NMIBC recurrence and progression scores 
[122, 127].  
Factor Levels Recurrence Progression 
Number of 
tumours 
Single 0 0 
2-7 3 3 
≥8 6 3 
Tumour 
diameter, cm 
<3 0 0 












Ta 0 0 
T1 1 4 
Concomitant 
CIS 
No 0 0 
Yes 1 6 
Grade 
G1 0 0 
G2 1 0 
G3 2 5 
Total scores 0-17 0-23 
CIS-Carcinoma in situ; NMIBC-non-muscle-invasive bladder cancer. 
On average, the CUETO scoring system estimates lower progression and recurrence 




Table 1.3. CUETO scoring system for BCG-treated bladder cancer patients 
[126]. 
Factor Levels Recurrence Progression 
Gender 
Male 0 0 
Female 3 0 
Age, years 
< 60 0 0 
60-70 1 0 
> 70 2 2 
Recurrent 
tumour 
No 0 0 
Yes 4 2 
Number of 
tumours 
≤3 0 0 
>3 2 1 
T stage 
Ta 0 0 
T1 0 2 
Concomitant 
CIS 
No 0 0 
Yes 2 1 
Grade 
G1 0 0 
G2 1 2 
G3 3 6 
Total scores   
BCG-Bacillus Calmette–Guérin; CIS-Carcinoma in situ. 
Although the current used prognostic tools are useful, the individual accuracy of 
estimates varies considerably, receiving fair criticism for the lack of precision [129, 
130]. Additional characteristics were investigated to upgrade the current tools; 
however, none of those satisfy criteria of robustness and accuracy to be used in 
practice [131, 132]. Other studies were carried out in specific populations (Table 1.4) 
and hence are difficult to generalise for guidelines [122]. 
 
1.6. OTHER POTENTIAL FACTORS FOR NMIBC PROGNOSTICATION 
 
1.6.1. Smoking 
Smoking is the most important external risk factor for developing UBC, that accounts 
for approximately 50% of all new cases [4, 7, 114, 133]. Besides increasing the risk of 
UBC, smoking also has been shown to worsen UBC prognosis, and is associated with 
higher risks of NMIBC recurrence and MIBC mortality [134-136]. 
 21 
Table 1.4. Additional prognostic factors for NMIBC [122]. 
Sample Prognostic factor 
In patients with T1 
tumours 
Lymphovascular invasion [137], level of invasion to lamina 
propria [138-141] 
In patients with T1G2 
tumours treated with 
TURBT 
Recurrence at 3 months was the most important predictor of 
progression [142]  
In patients with T1G3 
tumours: 
Bladder (pseudo) diverticulum because of an absence of 
muscle layer in the diverticular wall [143];  
   those treated with an 
induction course of BCG 
Female sex, CIS in the prostatic urethra in patients treated 
with an induction course of BCG [144]; 
   those treated with 
BCG  
Age, tumour size, and concurrent CIS [145];  
In patients with high-risk 
disease 
Tumour stage at the time of the second TURBT [146, 147];  
In patients treated with 
TURBT 
Presence of lymphovascular invasion [148]; 
All UBC patients Histological variants other than papillary (micropapillary, 
plasmocytoid, nested, sarcomatoid, squamous, 
adenocarcinoma) [149-153]; 
All UBC patients Molecular markers, particularly FGFR3 mutation status, are 
promising but need further evaluation [140, 154-157]. 
BCG-Bacillus Calmette–Guérin; CIS-carcinoma in situ; UBC-urinary bladder cancer; TURBT-
transurethral resection of bladder tumour. 
 
NMIBC progression and mortality have also shown to be affected by smoking, 
although to a lesser extent [134, 136]. Moreover, lifetime smoking has been associated 
with specific baseline characteristics at the time of UBC diagnosis that contribute 
towards a worse prognosis, namely higher stage and grade, larger tumour size, and 
lower age at the time of diagnosis [158].  
 
1.6.2. Diet and diet-related factors 
Various dietary components have been investigated for their potential effect on NMIBC 
prognosis. As elegantly summarised in a recent review [159], there is no good-
standing evidence for the effect of various dietary components (e.g. Vitamins A, E, 
cruciferous vegetables, total fluid intake, etc.) or supplements (e.g. multivitamins) on 
reduced likelihood of NMIBC recurrence, progression, or overall survival. However, 
diet’s contribution to NMIBC prognosis cannot be ruled out, and additional studies will 
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further advance the current knowledge. In fact, it is likely that dietary patterns (e.g. a 
generic Western diet, high in fried foods and red meat), rather than individual 
components, may propose a more robust prediction [160]. 
Furthermore, high body mass index (BMI), has been shown to be a predictor of  
NMIBC recurrence, but not progression [159]. 
 
1.6.3. Genetic determinants  
As the interest in genetics expands beyond the identification of risk variants, studies 
have also investigated germline variation having an influence on UBC outcomes, 
rather than only risk. Initially, UBC susceptibility polymorphisms were also queried for 
their association with UBC outcomes. The results are not straightforward – none of 
the UBC susceptibility loci have shown association with NMIBC recurrence; whether 
overall or in groups of low- and high-risk NMIBC [161]. Being an exception, a SNP in 
MYC (8q24, rs9642880) has shown promise in predicting NMIBC progression. FGFR3 
potentially alters risk of low-grade NMIBC recurrence, but the results are inconsistent 
[161, 162].  
Candidate-gene (CG) studies have also investigated UBC outcomes directly, resulting 
in over 100 reported associations with various endpoints [161, 163-175]. 
Nevertheless, very few have been successfully replicated in independent samples 
[163, 176, 177]. A recent study showed only six of the 114 SNPs could have been 
successfully validated [163] (NMIBC progression: rs6678136 (RGS4) and rs11585883 
(RGS5); NMIBC recurrence among BCG-treated: rs1799793 (ERCC2) and rs187238 
(IL18); MIBC overall survival: rs12035879 (RGS5) and rs2075786 (TERT)). 
Previously reported genetic associations for NMIBC outcomes cannot necessarily be 
viewed as false positives if they lack validation, and cannot be held positively true if 
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validation was successful. The only way to calibrate existing knowledge is to add more 
evidence from other discovery and replication studies to further guide scientifically 
valid hypotheses. The fast-evolving field of genetics has shown that translation of 
germline variation into an observed phenotype is anything but straightforward. It is 
now widely recognised that genetic associations are highly dependent on outcome 
definition and external exposures, making the issue far more complex.  
 
1.6.4. Gene-environment interactions for UBC prognosis 
Smoking is the strongest single risk factor for UBC [178], and it has been shown to 
interact with UBC susceptibility loci [179]. It is important to know whether prognostic 
genetic variants bear the same relevance for people of different smoking background, 
as it may eventually alter policies of clinical NMIBC management.  
Moreover, GxE interaction for NMIBC outcomes has already been observed 
previously. Increased risk of NMIBC recurrence among smokers was observed in 
multiple studies, associations mapping to genes responsible for phase II detoxification 
processes (GSTM1, UGT1A1 [180], NAT2 [161]). Additionally, never-smokers have 
exhibited lower rates of recurrence with an allele change in FGFR3 (4p16.3, rs798766) 
[161].   
Reports on GxE for NMIBC remain scarce, and it is difficult to form current evidence 
into a comprehensive summary. Moreover, it is virtually unknown whether any GxE 
with tobacco is present for baseline characteristics of prognostic relevance (e.g. grade, 
stage). This represents an important gap in previous analyses, as there might be 




1.7. THIS THESIS  
 
As UBC mostly comprises of highly-recurrent NMIBC cases, the main burden of UBC 
comes from NMIBC being suboptimally managed [121], leading to high monetary and 
emotional costs [3]. Diagnosis of NMIBC requires an ongoing, expensive, and 
burdensome patient-surveillance scheme, that makes use of frequent, sometimes 
lifelong, cystoscopies [121, 122, 181]. Economic evaluations have showed that one of 
the main routes to reducing the high costs of bladder cancer would be advances in 
managing individual NMIBC cases [181]. As such, accurate disease prognostication 
is a highly-prioritised research field, where developments in current practice would 
greatly benefit both medical systems and patients.  
The currently-used prognostic NMIBC tools carry a promise of the useful 
categorisation of patients, permitting application of an evidence-based treatment 
strategy. In reality, that promise is mainly unfulfilled, since the assumption of such 
tools being accurate is has not yet been met [182]. These inaccuracies do not call for 
discontinuing their use; instead, they serve as a rationale for further tool calibration, 
whilst using previously unavailable data (e.g. genomics) and analytical techniques. 
The current thesis aims to broaden our knowledge of the role of genetic variation in 
NMIBC prognosis. As the methodology of genetic association studies is meticulous, 
detail-oriented, and is a great predictor of research validity, quality control (QC) and 
data preparation are described first in Chapter 2.  
To best summarise the current evidence on genetic associations and prognostic 
factors of UBC, a systematic review of relevant published studies is presented in 
Chapter 3. 
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Chapter 4 describes a genome-wide association study (GWAS) on clinical NMIBC 
characteristics (tumour stage, grade, size, and patient’s age) that have prognostic 
properties. Although these characteristics carry important weight in clinical decision-
making, none of those were investigated as primary outcomes of interest, especially 
in a GWAS setting.  
It is clear that bladder cancer is one of few cancers for which GxE interaction has been 
observed repeatedly. However, GxE interaction with smoking for developing a tumour 
with specific features (e.g. larger size) has not yet been studied. Chapter 5 describes 
our investigation of whether the discovered variants from a GWAS analysis (Chapter 
4) may have a differential effect on tumour and patient characteristics at the time of 
NMIBC diagnosis among people of different smoking habits.  
The strength of new evidence is always tested under the scrutiny of replication and 
consistency. To explore the validity of genetic associations with bladder cancer 
prognosis, Chapter 6 describes efforts for result replication. The previously reported 
associations that were summarised in the systematic review (Chapter 3) are tested in 
a UBC cohort that was identified using data from the UK Biobank. This work also 
highlights the possibility of modelling outcomes using Hospital Episode Statistics 
(HES) that are not collected routinely (e.g. UBC recurrence). A newly developed 
algorithm can be used in other studies, and is hoped to help extend the use of large 
publicly-available clinical datasets in the future.  
Chapter 7 aims to best summarise all described analyses, contextualise the results, 




[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin 
DM, Forman D, Bray F. Cancer Incidence and Mortality Worldwide: Sources, 
Methods and Major Patterns in Globocan 2012. International journal of cancer. 
2015;136(5):E359-86. 
[2] Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder 
Cancer Incidence and Mortality: A Global Overview and Recent Trends. European 
urology. 2017;71(1):96-108. 
[3] Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic Burden of 
Bladder Cancer across the European Union. Eur Urol. 2016;69(3):438-47. 
[4] Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, 
Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M, Weider J. 
Bladder Cancer: Epidemiology, Staging and Grading, and Diagnosis. Urology. 
2005;66(6, Supplement 1):4-34. 
[5] Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, 
Lotan Y. Bladder Cancer. Nature reviews Disease primers. 2017;3:17022. 
[6] Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, 
Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF. Epidemiology of 
Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 
2018. European urology. 2018;74(6):784-95. 
[7] Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, 
Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and Risk 
Factors of Urothelial Bladder Cancer. European Urology. 2013;63(2):234-41. 
[8] Ma B, Stepanov I, Hecht SS. Recent Studies on DNA Adducts Resulting from 
Human Exposure to Tobacco Smoke. Toxics. 2019;7(1). 
[9] Besaratinia A, Tommasi S. Genotoxicity of Tobacco Smoke-Derived Aromatic 
Amines and Bladder Cancer: Current State of Knowledge and Future Research 
Directions. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology. 2013;27(6):2090-100. 
[10] Vantaku V, Amara CS, Piyarathna DWB, Donepudi SR, Ambati CR, Putluri V, 
Tang W, Rajapakshe K, Estecio MR, Terris MK, Castro PD, Ittmann MM, Williams 
SB, Lerner SP, Sreekumar A, Bollag R, Coarfa C, Kornberg MD, Lotan Y, Ambs S, 
Putluri N. DNA Methylation Patterns in Bladder Tumors of African-American Patients 
Point to Distinct Alterations in Xenobiotic Metabolism. Carcinogenesis. 2019. 
[11] Schulz WA, Goering W. DNA Methylation in Urothelial Carcinoma. 
Epigenomics. 2016;8(10):1415-28. 
[12] Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. Bladder Cancer 
Risk from Occupational and Environmental Exposures. Urologic oncology. 
2012;30(2):199-211. 
[13] Villanueva CM, Cantor KP, King WD, Jaakkola JJ, Cordier S, Lynch CF, Porru 
S, Kogevinas M. Total and Specific Fluid Consumption as Determinants of Bladder 
Cancer Risk. International journal of cancer. 2006;118(8):2040-7. 
[14] Yu EY, Wesselius A, van Osch F, Stern MC, Jiang X, Kellen E, Lu CM, 
Pohlabeln H, Steineck G, Marshall J, Allam MF, La Vecchia C, Johnson KC, 
Benhamou S, Zhang ZF, Bosetti C, Taylor JA, Zeegers MP. The Association 
between Coffee Consumption and Bladder Cancer in the Bladder Cancer 
Epidemiology and Nutritional Determinants (Blend) International Pooled Study. 
Cancer causes & control : CCC. 2019;30(8):859-70. 
 27 
[15] Hong X, Xu Q, Lan K, Huang H, Zhang Y, Chen S, Chi Z, Lin J, Zhou Y, Wu 
W, Liu G, Lin W, Zhang Y. The Effect of Daily Fluid Management and Beverages 
Consumption on the Risk of Bladder Cancer: A Meta-Analysis of Observational 
Study. Nutrition and cancer. 2018;70(8):1217-27. 
[16] Liu H, Wang XC, Hu GH, Guo ZF, Lai P, Xu L, Huang TB, Xu YF. Fruit and 
Vegetable Consumption and Risk of Bladder Cancer: An Updated Meta-Analysis of 
Observational Studies. European journal of cancer prevention : the official journal of 
the European Cancer Prevention Organisation (ECP). 2015;24(6):508-16. 
[17] Yao B, Yan Y, Ye X, Fang H, Xu H, Liu Y, Li S, Zhao Y. Intake of Fruit and 
Vegetables and Risk of Bladder Cancer: A Dose-Response Meta-Analysis of 
Observational Studies. Cancer causes & control : CCC. 2014;25(12):1645-58. 
[18] Xu C, Zeng XT, Liu TZ, Zhang C, Yang ZH, Li S, Chen XY. Fruits and 
Vegetables Intake and Risk of Bladder Cancer: A Prisma-Compliant Systematic 
Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. Medicine. 
2015;94(17):e759. 
[19] Vieira AR, Vingeliene S, Chan DS, Aune D, Abar L, Navarro Rosenblatt D, 
Greenwood DC, Norat T. Fruits, Vegetables, and Bladder Cancer Risk: A Systematic 
Review and Meta-Analysis. Cancer medicine. 2015;4(1):136-46. 
[20] Li F, An S, Hou L, Chen P, Lei C, Tan W. Red and Processed Meat Intake 
and Risk of Bladder Cancer: A Meta-Analysis. International journal of clinical and 
experimental medicine. 2014;7(8):2100-10. 
[21] Wang C, Jiang H. Meat Intake and Risk of Bladder Cancer: A Meta-Analysis. 
Medical oncology (Northwood, London, England). 2012;29(2):848-55. 
[22] Ahmed T, Nawaz S, Noreen R, Bangash KS, Rauf A, Younis M, Anwar K, 
Khawaja MA, Azam M, Qureshi AA, Akhter S, Kiemeney LA, Qamar R, Ali SHB. A 3' 
Untranslated Region Polymorphism Rs2304277 in the DNA Repair Pathway Gene 
Ogg1 Is a Novel Risk Modulator for Urothelial Bladder Carcinoma. Annals of human 
genetics. 2018;82(2):74-87. 
[23] Park SJ, Myung SK, Lee Y, Lee YJ. Effects of Vitamin and Antioxidant 
Supplements in Prevention of Bladder Cancer: A Meta-Analysis of Randomized 
Controlled Trials. Journal of Korean medical science. 2017;32(4):628-35. 
[24] Vinceti M, Filippini T, Del Giovane C, Dennert G, Zwahlen M, Brinkman M, 
Zeegers MP, Horneber M, D'Amico R, Crespi CM. Selenium for Preventing Cancer. 
The Cochrane database of systematic reviews. 2018;1:Cd005195. 
[25] Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat 
SF, Zlotta AR, Boorjian SA. Gender and Bladder Cancer: A Collaborative Review of 
Etiology, Biology, and Outcomes. European urology. 2016;69(2):300-10. 
[26] Kaneko S, Li X. X Chromosome Protects against Bladder Cancer in Females 
Via a Kdm6a-Dependent Epigenetic Mechanism. Science advances. 
2018;4(6):eaar5598. 
[27] Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, 
Kiemeney LA. Familial Aggregation of Urothelial Cell Carcinoma. International 
journal of cancer. 2002;98(2):274-8. 
[28] Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan 
Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, 
Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, 
Albanes D, Amary MF, An SJ, Andersson U, Andriole G, Jr., Andrulis IL, Angelucci 
E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas 
DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, 
Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-
 28 
Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, 
Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, 
Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-
Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen 
KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, 
Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, 
Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, 
Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, 
Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan 
AM, Foretova L, Fraumeni JF, Jr., Freedman ND, Beane Freeman LE, Fuchs C, 
Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, García-
Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles 
GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, 
Gross M, Grubb R, 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman 
CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, 
Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford 
TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD, 3rd, 
Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip 
PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, 
Johnson A, Jung YJ, Kaaks R, Kamineni A, Kane E, Kang CH, Karagas MR, Kelly 
RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara 
CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Kricker 
A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, 
Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, 
Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di 
Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, 
Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, 
Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, 
Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh IJ, Olson SH, 
Palli D, Pao W, Park IK, Park JY, Park KH, Patiño-Garcia A, Pavanello S, Peeters 
PH, Perng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, 
Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, 
Rodabough R, Roman E, Roupret M, Ruder AM, Sanjose S, Scelo G, Schned A, 
Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, 
Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, 
Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasesúmaga L, Sihoe AD, Skibola CF, 
Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, 
Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, 
Tan W, Tang W, Tardón A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, 
Tjønneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, 
Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, 
Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, 
Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, 
Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, 
Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, 
Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y, Zhao X, Zhao Z, Zheng H, 
Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, 
Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai 
J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman 
DT, Slager SL, Chanock SJ, Chatterjee N. Analysis of Heritability and Shared 
 29 
Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. 
J Natl Cancer Inst. 2015;107(12):djv279. 
[29] Zhou T, Li HY, Xie WJ, Zhong Z, Zhong H, Lin ZJ. Association of Glutathione 
S-Transferase Gene Polymorphism with Bladder Cancer Susceptibility. BMC cancer. 
2018;18(1):1088. 
[30] Ma C, Gu L, Yang M, Zhang Z, Zeng S, Song R, Xu C, Sun Y. Rs1495741 as 
a Tag Single Nucleotide Polymorphism of N-Acetyltransferase 2 Acetylator 
Phenotype Associates Bladder Cancer Risk and Interacts with Smoking: A 
Systematic Review and Meta-Analysis. Medicine. 2016;95(31):e4417. 
[31] Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein 
DW, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Castano-Vinyals G, 
Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Tora M, 
Fernandez F, Real FX, Rothman N. Nat2 Slow Acetylation, Gstm1 Null Genotype, 
and Risk of Bladder Cancer: Results from the Spanish Bladder Cancer Study and 
Meta-Analyses. Lancet. 2005;366(9486):649-59. 
[32] Lee SJ, Cho SH, Park SK, Kim SW, Park MS, Choi HY, Choi JY, Lee SY, Im 
HJ, Kim JY, Yoon KJ, Choi H, Shin SG, Park TW, Rothman N, Hirvonen A, Kang D. 
Combined Effect of Glutathione S-Transferase M1 and T1 Genotypes on Bladder 
Cancer Risk. Cancer letters. 2002;177(2):173-9. 
[33] Li SX, Dai QS, Chen SX, Zhang SD, Liao XY, Deng X, Chi HB, Li FJ, Zhu JH, 
Jiang YY. Xeroderma Pigmentosum Complementation Group D (Xpd) Gene 
Polymorphisms Contribute to Bladder Cancer Risk: A Meta-Analysis. Tumour biology 
: the journal of the International Society for Oncodevelopmental Biology and 
Medicine. 2014;35(4):3905-15. 
[34] Wu Y, Yang Y. Complex Association between Ercc2 Gene Polymorphisms, 
Gender, Smoking and the Susceptibility to Bladder Cancer: A Meta-Analysis. 
Tumour biology : the journal of the International Society for Oncodevelopmental 
Biology and Medicine. 2014;35(6):5245-57. 
[35] Li S, Zeng XT, Ruan XL, Liu TZ, Wang XH. Association between Xpd 
Lys751gln Polymorphism and Bladder Cancer Susceptibility: An Updated and 
Cumulative Meta-Analysis Based on 6,836 Cases and 8,251 Controls. Molecular 
biology reports. 2014;41(6):3621-9. 
[36] Xiong T, Yang J, Wang H, Wu F, Liu Y, Xu R, Lv Z, Xue P, Cao W, Zhang Y. 
The Association between the Lys751gln Polymorphism in the Xpd Gene and the 
Risk of Bladder Cancer. Molecular biology reports. 2014;41(4):2629-34. 
[37] Zhang M, Li W, Hao Z, Zhou J, Zhang L, Liang C. Association between 
Twelve Polymorphisms in Five X-Ray Repair Cross-Complementing Genes and the 
Risk of Urological Neoplasms: A Systematic Review and Meta-Analysis. 
EBioMedicine. 2017;18:94-108. 
[38] Li S, Peng Q, Chen Y, You J, Chen Z, Deng Y, Lao X, Wu H, Qin X, Zeng Z. 
DNA Repair Gene Xrcc1 Polymorphisms, Smoking, and Bladder Cancer Risk: A 
Meta-Analysis. PloS one. 2013;8(9):e73448. 
[39] Yang D, Liu C, Shi J, Wang N, Du X, Yin Q, Wang Y. Association of Xrcc1 
Arg399gln Polymorphism with Bladder Cancer Susceptibility: A Meta-Analysis. 
Gene. 2014;534(1):17-23. 
[40] Liu C, Yin Q, Li L, Jiao G, Wang M, Wang Y. Xrcc1 Arg194trp and Arg280his 
Polymorphisms in Bladder Cancer Susceptibility: A Meta-Analysis. Critical reviews in 
eukaryotic gene expression. 2013;23(4):339-54. 
[41] Ma Q, Zhao Y, Wang S, Zhang X, Zhang J, Du M, Li L, Zhang Y. Genetic 
Polymorphisms of Xrcc3 Thr241met (C18067t, Rs861539) and Bladder Cancer Risk: 
 30 
A Meta-Analysis of 18 Research Studies. Tumour biology : the journal of the 
International Society for Oncodevelopmental Biology and Medicine. 
2014;35(2):1473-80. 
[42] Peng Q, Mo C, Tang W, Chen Z, Li R, Zhai L, Yang S, Wu J, Sui J, Li S, Qin 
X. DNA Repair Gene Xrcc3 Polymorphisms and Bladder Cancer Risk: A Meta-
Analysis. Tumour biology : the journal of the International Society for 
Oncodevelopmental Biology and Medicine. 2014;35(3):1933-44. 
[43] He XF, Wei W, Li JL, Shen XL, Ding DP, Wang SL, Liu ZZ, Qin JB, Wu LX, 
Xie DL. Association between the Xrcc3 T241m Polymorphism and Risk of Cancer: 
Evidence from 157 Case-Control Studies. Gene. 2013;523(1):10-9. 
[44] Shao N, Jiang WY, Qiao D, Zhang SG, Wu Y, Zhang XX, Hua LX, Ding Y, 
Feng NH. An Updated Meta-Analysis of Xrcc4 Polymorphisms and Cancer Risk 
Based on 31 Case-Control Studies. Cancer biomarkers : section A of Disease 
markers. 2012;12(1):37-47. 
[45] Wang Y, Li Z, Liu N, Zhang G. Association between Ccnd1 and Xpc 
Polymorphisms and Bladder Cancer Risk: A Meta-Analysis Based on 15 Case-
Control Studies. Tumour biology : the journal of the International Society for 
Oncodevelopmental Biology and Medicine. 2014;35(4):3155-65. 
[46] Dou K, Xu Q, Han X. The Association between Xpc Lys939gln Gene 
Polymorphism and Urinary Bladder Cancer Susceptibility: A Systematic Review and 
Meta-Analysis. Diagnostic pathology. 2013;8:112. 
[47] Dai QS, Hua RX, Zeng RF, Long JT, Peng ZW. Xpc Gene Polymorphisms 
Contribute to Bladder Cancer Susceptibility: A Meta-Analysis. Tumour biology : the 
journal of the International Society for Oncodevelopmental Biology and Medicine. 
2014;35(1):447-53. 
[48] Sankhwar M, Sankhwar SN, Bansal SK, Gupta G, Rajender S. 
Polymorphisms in the Xpc Gene Affect Urinary Bladder Cancer Risk: A Case-Control 
Study, Meta-Analyses and Trial Sequential Analyses. Scientific reports. 
2016;6:27018. 
[49] Zhang Y, Huang YS, Lin WQ, Zhang SD, Li QW, Hu YZ, Zheng RL, Tang T, Li 
XZ, Zheng XH. Nbs1 Glu185gln Polymorphism and Susceptibility to Urinary System 
Cancer: A Meta-Analysis. Tumour biology : the journal of the International Society for 
Oncodevelopmental Biology and Medicine. 2014;35(11):10723-9. 
[50] Li J, Luo F, Zhang H, Li L, Xu Y. The Ccnd1 G870a Polymorphism and 
Susceptibility to Bladder Cancer. Tumour biology : the journal of the International 
Society for Oncodevelopmental Biology and Medicine. 2014;35(1):171-7. 
[51] Zhao Y, Qi JG, Yang N, Lin YL, Liang J, Zhu X. Association between Myc 
Rs9642880[T] Allele and Bladder Cancer Risk: A Meta-Analysis. Genetics and 
molecular research : GMR. 2015;14(4):14745-51. 
[52] Gao J, Yang PT, Diao Y, Kang HF, Zhao Y, Lin S, Wang ZM, Wang M, Wang 
XJ, Dai ZJ. Effects of Psca Rs2294008 (C/T) and C-Myc Rs9642880 (G/T) 
Polymorphisms on Bladder Cancer: Evidence from a Meta-Analysis. International 
journal of clinical and experimental medicine. 2015;8(2):2156-64. 
[53] Zhang M, Wu X, Lu W, Ge Y, Wang X, Cai Z, Wu S. Rs401681 Polymorphism 
in Tert-Clptm1l Was Associated with Bladder Cancer Risk: A Meta-Analysis. Iranian 
journal of basic medical sciences. 2015;18(11):1130-6. 
[54] Yin J, Li Y, Yin M, Sun J, Liu L, Qin Q, Li X, Long L, Nie S, Wei S. Tert-
Clptm1l Polymorphism Rs401681 Contributes to Cancers Risk: Evidence from a 
Meta-Analysis Based on 29 Publications. PloS one. 2012;7(11):e50650. 
 31 
[55] Nikolic ZZ, Savic Pavicevic DL, Vucic NL, Romac SP, Brajuskovic GN. 
Association between a Genetic Variant in the Hsa-Mir-146a Gene and Cancer Risk: 
An Updated Meta-Analysis. Public health genomics. 2015;18(5):283-98. 
[56] Xu L, Zhou X, Xu L, Yin R. Survivin Rs9904341 (G>C) Polymorphism 
Contributes to Cancer Risk: An Updated Meta-Analysis of 26 Studies. Tumour 
biology : the journal of the International Society for Oncodevelopmental Biology and 
Medicine. 2014;35(2):1661-9. 
[57] Zhu Y, Li Y, Zhu S, Tang R, Liu Y, Li J. Association of Survivin 
Polymorphisms with Tumor Susceptibility: A Meta-Analysis. PloS one. 
2013;8(9):e74778. 
[58] Wang Y, Kong CZ, Zhang Z, Yang CM, Li J. Role of Cdh1 Promoter 
Polymorphism and DNA Methylation in Bladder Carcinogenesis: A Meta-Analysis. 
DNA and cell biology. 2014;33(4):205-16. 
[59] Shi X, Xie X, Xun X, Jia Y, Li S. Associations of Il-10 Genetic Polymorphisms 
with the Risk of Urologic Cancer: A Meta-Analysis Based on 18,415 Subjects. 
SpringerPlus. 2016;5(1):2034. 
[60] Xu B, Niu XB, Wang ZD, Cheng W, Tong N, Mi YY, Min ZC, Tao J, Li PC, 
Zhang W, Wu HF, Zhang ZD, Wang ZJ, Hua LX, Feng NH, Wang XR. Il-6 -174g>C 
Polymorphism and Cancer Risk: A Meta-Analysis Involving 29,377 Cases and 
37,739 Controls. Molecular biology reports. 2011;38(4):2589-96. 
[61] Cai J, Yang MY, Hou N, Li X. Association of Tumor Necrosis Factor-Alpha 
308g/a Polymorphism with Urogenital Cancer Risk: A Systematic Review and Meta-
Analysis. Genetics and molecular research : GMR. 2015;14(4):16102-12. 
[62] Huang Y, Chen H, Wang J, Bunjhoo H, Xiong W, Xu Y, Zhao J. Relationship 
between Ccr2-V64i Polymorphism and Cancer Risk: A Meta-Analysis. Gene. 
2013;524(1):54-8. 
[63] Zhao Y, Gui ZL, Liao S, Gao F, Ge YZ, Jia RP. Prostate Stem Cell Antigen 
Rs2294008 (C>T) Polymorphism and Bladder Cancer Risk: A Meta-Analysis Based 
on Cases and Controls. Genetics and molecular research : GMR. 2014;13(3):5534-
40. 
[64] Geng P, Li J, Wang N, Ou J, Xie G, Liu C, Zhao X, Xiang L, Liao Y, Liang H. 
Psca Rs2294008 Polymorphism with Increased Risk of Cancer. PloS one. 
2015;10(8):e0136269. 
[65] Su CM, Chen MC, Lin IC, Chen HA, Huang MT, Wu CH, Shen KH, Wang YH. 
Association between the Sult1a1 Arg213his Polymorphism and the Risk of Bladder 
Cancer: A Meta-Analysis. Tumour biology : the journal of the International Society for 
Oncodevelopmental Biology and Medicine. 2014;35(7):7147-53. 
[66] Li W, Gu M. Sult1a1 Arg213his Polymorphism Is Associated with Bladder 
Cancer Risk: A Meta-Analysis. Medical science monitor : international medical 
journal of experimental and clinical research. 2014;20:1590-5. 
[67] Mandal RK, Dubey S, Panda AK, Mittal RD. Genetic Variants of Nqo1 Gene 
Increase Bladder Cancer Risk in Indian Population and Meta-Analysis. Tumour 
biology : the journal of the International Society for Oncodevelopmental Biology and 
Medicine. 2014;35(7):6415-23. 
[68] Gong M, Yi Q, Wang W. Association between Nqo1 C609t Polymorphism and 
Bladder Cancer Susceptibility: A Systemic Review and Meta-Analysis. Tumour 
biology : the journal of the International Society for Oncodevelopmental Biology and 
Medicine. 2013;34(5):2551-6. 
 32 
[69] Yang S, Jin T, Su HX, Zhu JH, Wang DW, Zhu SJ, Li S, He J, Chen YH. The 
Association between Nqo1 Pro187ser Polymorphism and Bladder Cancer 
Susceptibility: A Meta-Analysis of 15 Studies. PloS one. 2015;10(1):e0116500. 
[70] Zhang Y, Yang D, Zhu JH, Chen MB, Shen WX, He J. The Association 
between Nqo1 Pro187ser Polymorphism and Urinary System Cancer Susceptibility: 
A Meta-Analysis of 22 Studies. Cancer investigation. 2015;33(2):39-40. 
[71] Wang Z, Xue L, Chong T, Li H, Chen H, Wang Z. Quantitative Assessment of 
the Association between Glutathione S-Transferase P1 Ile105val Polymorphism and 
Bladder Cancer Risk. Tumour biology : the journal of the International Society for 
Oncodevelopmental Biology and Medicine. 2013;34(3):1651-7. 
[72] Wu K, Wang X, Xie Z, Liu Z, Lu Y. Glutathione S-Transferase P1 Gene 
Polymorphism and Bladder Cancer Susceptibility: An Updated Analysis. Molecular 
biology reports. 2013;40(1):687-95. 
[73] Men T, Zhang X, Yang J, Shen B, Li X, Chen D, Wang J. The Rs1050450 C > 
T Polymorphism of Gpx1 Is Associated with the Risk of Bladder but Not Prostate 
Cancer: Evidence from a Meta-Analysis. Tumour biology : the journal of the 
International Society for Oncodevelopmental Biology and Medicine. 2014;35(1):269-
75. 
[74] Cao M, Mu X, Jiang C, Yang G, Chen H, Xue W. Single-Nucleotide 
Polymorphisms of Gpx1 and Mnsod and Susceptibility to Bladder Cancer: A 
Systematic Review and Meta-Analysis. Tumour biology : the journal of the 
International Society for Oncodevelopmental Biology and Medicine. 2014;35(1):759-
64. 
[75] Han SX, Wang L, Wu DQ. The Association between Ugt1a7 Polymorphism 
and Cancer Risk: A Meta-Analysis. Cancer epidemiology. 2012;36(4):e201-6. 
[76] Gao X, Wang J, Wang W, Wang M, Zhang J. Enos Genetic Polymorphisms 
and Cancer Risk: A Meta-Analysis and a Case-Control Study of Breast Cancer. 
Medicine. 2015;94(26):e972. 
[77] Yan Y, Liang H, Li T, Li M, Li R, Qin X, Li S. The Mmp-1, Mmp-2, and Mmp-9 
Gene Polymorphisms and Susceptibility to Bladder Cancer: A Meta-Analysis. 
Tumour biology : the journal of the International Society for Oncodevelopmental 
Biology and Medicine. 2014;35(4):3047-52. 
[78] Tao L, Li Z, Lin L, Lei Y, Hongyuan Y, Hongwei J, Yang L, Chuize K. Mmp1, 
2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis. 
Genetic testing and molecular biomarkers. 2015;19(10):548-55. 
[79] Zhou Q, Wang Y, Chen A, Tao Y, Song H, Li W, Tao J, Zuo M. Association 
between the Comt Val158met Polymorphism and Risk of Cancer: Evidence from 99 
Case-Control Studies. OncoTargets and therapy. 2015;8:2791-803. 
[80] Wang Y, Kong CZ, Zhang Z, Yang CM, Li J. Relationships between Cyp1a1 
Genetic Polymorphisms and Bladder Cancer Risk: A Meta-Analysis. DNA and cell 
biology. 2014;33(3):171-81. 
[81] Deng XD, Gao Q, Zhang B, Zhang LX, Zhang W, Mu Er ZE, Xie Y, Ma Y, Liu 
Y. Functional Rsai/Psti Polymorphism in Cytochrome P450 2e1 Contributes to 
Bladder Cancer Susceptibility: Evidence from a Meta-Analysis. Asian Pacific journal 
of cancer prevention : APJCP. 2014;15(12):4977-82. 
[82] Li DB, Wei X, Jiang LH, Wang Y, Xu F. Meta-Analysis of Epidemiological 
Studies of Association of P53 Codon 72 Polymorphism with Bladder Cancer. 
Genetics and molecular research : GMR. 2010;9(3):1599-605. 
 33 
[83] Jiang DK, Ren WH, Yao L, Wang WZ, Peng B, Yu L. Meta-Analysis of 
Association between Tp53 Arg72pro Polymorphism and Bladder Cancer Risk. 
Urology. 2010;76(3):765.e1-7. 
[84] Hong Z, Wu J, Li Q, Zhang S, Shi Z. Meta-Analysis Reveals No Significant 
Association between Ercc6 Polymorphisms and Bladder Cancer Risk. The 
International journal of biological markers. 2017;32(1):e113-e7. 
[85] Miao HK, Chen LP, Cai DP, Kong WJ, Xiao L, Lin J. Msh3 Rs26279 
Polymorphism Increases Cancer Risk: A Meta-Analysis. International journal of 
clinical and experimental pathology. 2015;8(9):11060-7. 
[86] Ding H, Dai Y, Ning Z, Fan N, Wang Z, Li P, Zhang L, Tao Y, Wang H. Murine 
Double Minute 2 Snp T309g Polymorphism and Urinary Tract Cancer Risk: A Meta-
Analysis. Medicine. 2016;95(12):e2941. 
[87] Zhong JH, Zhao Z, Liu J, Yu HL, Zhou JY, Shi R. Association between Ape1 
Asp148glu Polymorphism and the Risk of Urinary Cancers: A Meta-Analysis of 18 
Case-Control Studies. OncoTargets and therapy. 2016;9:1499-510. 
[88] Sun WX, Chen YH, Liu ZZ, Xie JJ, Wang W, Du YP, Chen Y, Shen XL, He 
XF, Wu LX, Wei W, Zhang L. Association between the Cyp1a2 Polymorphisms and 
Risk of Cancer: A Meta-Analysis. Molecular genetics and genomics : MGG. 
2015;290(2):709-25. 
[89] Xiao M, Shen Y, Chen L, Liao Z, Wen F. The Rs7003908 (T>G) 
Polymorphism in the Xrcc7 Gene and the Risk of Cancers. Molecular biology reports. 
2014;41(6):3577-82. 
[90] Duan W, Wang E, Zhang F, Wang T, You X, Qiao B. Association between the 
Nfkb1-94ins/Del Attg Polymorphism and Cancer Risk: An Updated Meta-Analysis. 
Cancer investigation. 2014;32(7):311-20. 
[91] Hu X, Fang Y, Zheng J, He Y, Zan X, Lin S, Li X, Li H, You C. The 
Association between Hif-1alpha Polymorphism and Cancer Risk: A Systematic 
Review and Meta-Analysis. Tumour biology : the journal of the International Society 
for Oncodevelopmental Biology and Medicine. 2014;35(2):903-16. 
[92] Liu C, Yin Q, Hu J, Weng J, Wang Y. Quantitative Assessment of the 
Association between Xpg Asp1104his Polymorphism and Bladder Cancer Risk. 
Tumour biology : the journal of the International Society for Oncodevelopmental 
Biology and Medicine. 2014;35(2):1203-9. 
[93] Liu Y, Lin CS, Zhang AM, Song H, Fan CC. The Cyp1b1 Leu432val 
Polymorphism and Risk of Urinary System Cancers. Tumour biology : the journal of 
the International Society for Oncodevelopmental Biology and Medicine. 
2014;35(5):4719-25. 
[94] Liao RY, Mao C, Qiu LX, Ding H, Chen Q, Pan HF. Tgfbr1*6a/9a 
Polymorphism and Cancer Risk: A Meta-Analysis of 13,662 Cases and 14,147 
Controls. Molecular biology reports. 2010;37(7):3227-32. 
[95] Shi R, Zhao Z, Zhou H, Zhou J, Tan W. Lack of Association between Mthfr 
Ala222val and Glu429ala Polymorphisms and Bladder Cancer Risk: A Meta-Analysis 
of Case-Control Studies. Biomedical reports. 2014;2(3):396-403. 
[96] Wang HG, Wu QY, Zhou H, Peng XS, Shi MJ, Li JM, Zhou YF. The Mdm2 
Snp309t>G Polymorphism Increases Bladder Cancer Risk among Caucasians: A 
Meta-Analysis. Asian Pacific journal of cancer prevention : APJCP. 
2014;15(13):5277-81. 
[97] Xu T, Xu ZC, Zou Q, Yu B, Huang XE. P53 Arg72pro Polymorphism and 
Bladder Cancer Risk--Meta-Analysis Evidence for a Link in Asians but Not 
 34 
Caucasians. Asian Pacific journal of cancer prevention : APJCP. 2012;13(5):2349-
54. 
[98] Yang Z, Nie S, Zhu H, Wu X, Jia S, Luo Y, Tang W. Association of P53 
Arg72pro Polymorphism with Bladder Cancer: A Meta-Analysis. Gene. 
2013;512(2):408-13. 
[99] Liu ZH, Bao ED. Quantitative Assessment of the Association between Tp53 
Arg72pro Polymorphism and Bladder Cancer Risk. Molecular biology reports. 
2013;40(3):2389-95. 
[100] Mao Y, Xu X, Lin Y, Chen H, Wu J, Hu Z, Zhu Y, Xu X, Xie L. Quantitative 
Assessment of the Associations between Xrcc1 Polymorphisms and Bladder Cancer 
Risk. World journal of surgical oncology. 2013;11:58. 
[101] Wenjuan C, Jianzhong L, Chong L, Yanjun G, Keqing L, Hanzhang W, 
Zhiping W. The Hogg1 Ser326cys Gene Polymorphism and Susceptibility for Bladder 
Cancer: A Meta-Analysis. International braz j urol : official journal of the Brazilian 
Society of Urology. 2016;42(5):883-96. 
[102] Ji C, Liu Z, Chen H, Guo H, Liu C. An Association between Hogg1 Ser326cys 
Polymorphism and the Risk of Bladder Cancer in Non-Smokers: A Meta-Analysis. 
BMC cancer. 2012;12:335. 
[103] Jiang W, Sun G, Xiong J, Xi X, Shi Z. Association of Cyp1b1 L432v 
Polymorphism with Urinary Cancer Susceptibility: A Meta-Analysis. Diagnostic 
pathology. 2014;9:113. 
[104] Zeng Y, Jiang HY, Wei L, Xu WD, Wang YJ, Wang YD, Liu C. Association 
between the Cyp1a2 Rs762551 Polymorphism and Bladder Cancer Susceptibility: A 
Meta-Analysis Based on Case-Control Studies. Asian Pacific journal of cancer 
prevention : APJCP. 2015;16(16):7249-54. 
[105] Vukovic V, Ianuale C, Leoncini E, Pastorino R, Gualano MR, Amore R, Boccia 
S. Lack of Association between Polymorphisms in the Cyp1a2 Gene and Risk of 
Cancer: Evidence from Meta-Analyses. BMC cancer. 2016;16:83. 
[106] Lu Y, Zhang XL, Xie L, Li TJ, He Y, Peng QL, Deng Y, Wang J, Qin X, Li S. 
Lack of Association between Cyp1a1 Polymorphisms and Risk of Bladder Cancer: A 
Meta-Analysis. Asian Pacific journal of cancer prevention : APJCP. 2014;15(9):4071-
7. 
[107] You W, Li Z, Jing C, Qian-Wei X, Yu-Ping Z, Weng-Guang L, Hua-Lei L. Mthfr 
C677t and A1298c Polymorphisms Were Associated with Bladder Cancer Risk and 
Disease Progression: A Meta-Analysis. DNA and cell biology. 2013;32(5):260-7. 
[108] Xu W, Zhang H, Wang F, Wang H. Quantitative Assessment of the 
Association between Mhtfr C677t (Rs1801133, Ala222val) Polymorphism and 
Susceptibility to Bladder Cancer. Diagnostic pathology. 2013;8:95. 
[109] Lajin B, Alachkar A. The Nqo1 Polymorphism C609t (Pro187ser) and Cancer 
Susceptibility: A Comprehensive Meta-Analysis. British journal of cancer. 
2013;109(5):1325-37. 
[110] Zhang H, Wen X, Lu X, Zhang H. Association between Nad(P)H:Quinone 
Oxidoreductase 1 Rs1800566 Polymorphism and Risk of Bladder Cancer. Tumour 
biology : the journal of the International Society for Oncodevelopmental Biology and 
Medicine. 2013;34(6):3377-81. 
[111] Czerniak B, Dinney C, McConkey D. Origins of Bladder Cancer. Annual 
review of pathology. 2016;11:149-74. 
[112] Guo CC, Czerniak B. Bladder Cancer in the Genomic Era. Archives of 
pathology & laboratory medicine. 2019;143(6):695-704. 
 35 
[113] Knowles MA, Hurst CD. Molecular Biology of Bladder Cancer: New Insights 
into Pathogenesis and Clinical Diversity. Nature reviews Cancer. 2015;15(1):25-41. 
[114] Eble J.N. SG, Epstein J.I., Sesterhenn I.A. (Eds.). World Health Organization 
Classification of Tumours. Pathology and Genetics of Tumours of the Urinary 
System and Male Genital Organs: IARC Press: Lyon; 2004. 
[115] Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, Patschan 
O, Aine M, Ferno M, Ringner M, Mansson W, Liedberg F, Lindgren D, Hoglund M. A 
Molecular Taxonomy for Urothelial Carcinoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 2012;18(12):3377-86. 
[116] Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, Vang S, 
Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, 
Segersten U, Aine M, Hoglund M, Birkenkamp-Demtroder K, Fristrup N, Borre M, 
Hartmann A, Stohr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, 
Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg 
EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmstrom PU, Malats 
N, Real FX, Zwarthoff EC, Orntoft TF, Dyrskjot L. Comprehensive Transcriptional 
Analysis of Early-Stage Urothelial Carcinoma. Cancer cell. 2016;30(1):27-42. 
[117] Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma. 
Nature. 2014;507(7492):315-22. 
[118] Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, 
Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, 
Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification 
of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with 
Different Sensitivities to Frontline Chemotherapy. Cancer cell. 2014;25(2):152-65. 
[119] Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh 
JJ, Milowsky MI, Iyer G, Parker JS, Kim WY. Intrinsic Subtypes of High-Grade 
Bladder Cancer Reflect the Hallmarks of Breast Cancer Biology. Proceedings of the 
National Academy of Sciences of the United States of America. 2014;111(8):3110-5. 
[120] McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn 
P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene 
Expression Signature in the Molecular Classification of Chemotherapy-Naive 
Urothelial Cancer Is Predictive of Clinical Outcomes from Neoadjuvant 
Chemotherapy: A Phase 2 Trial of Dose-Dense Methotrexate, Vinblastine, 
Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 
2016;69(5):855-62. 
[121] Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, Guo 
CC, Lotan Y, Kassouf W. Bladder Cancer. Lancet (London, England). 
2016;388(10061):2796-810. 
[122] Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, 
Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup 
V, Sylvester RJ, Zigeuner R. Eau Guidelines on Non-Muscle-Invasive Urothelial 
Carcinoma of the Bladder: Update 2016. Eur Urol. 2016. 
[123] D'Costa JJ, Goldsmith JC, Wilson JS, Bryan RT, Ward DG. A Systematic 
Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in 
Urothelial Bladder Cancer. Bladder Cancer (Amsterdam, Netherlands). 
2016;2(3):301-17. 
[124] Bladder Cancer: Diagnosis and Management of Bladder Cancer: (C) Nice 
(2015) Bladder Cancer: Diagnosis and Management of Bladder Cancer. BJU 
international. 2017;120(6):755-65. 
 36 
[125] Power NE, Izawa J. Comparison of Guidelines on Non-Muscle Invasive 
Bladder Cancer (Eau, Cua, Aua, Nccn, Nice). Bladder cancer (Amsterdam, 
Netherlands). 2016;2(1):27-36. 
[126] Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, 
Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, 
Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntanola P, Gimeno A, Blas M, 
Martinez-Pineiro JA. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and 
Progression in Patients Treated with Bacillus Calmette-Guerin: The Cueto Scoring 
Model. The Journal of urology. 2009;182(5):2195-203. 
[127] Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, 
Denis L, Newling DW, Kurth K. Predicting Recurrence and Progression in Individual 
Patients with Stage Ta T1 Bladder Cancer Using Eortc Risk Tables: A Combined 
Analysis of 2596 Patients from Seven Eortc Trials. European urology. 
2006;49(3):466-5; discussion 75-7. 
[128] Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea 
A, Portillo J, Montesinos M, Gonzalez M, Pertusa C, Rodriguez-Molina J, Camacho 
JE, Rabadan M, Astobieta A, Isorna S, Muntanola P, Gimeno A, Blas M, Martinez-
Pineiro JA. The Eortc Tables Overestimate the Risk of Recurrence and Progression 
in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus 
Calmette-Guerin: External Validation of the Eortc Risk Tables. European urology. 
2011;60(3):423-30. 
[129] Sylvester RJ. How Well Can You Actually Predict Which Non-Muscle-Invasive 
Bladder Cancer Patients Will Progress? Eur Urol. 2011;60(3):431-3; discussion 3-4. 
[130] Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh 
QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, Shariat SF. 
Accuracy of the Eortc Risk Tables and of the Cueto Scoring Model to Predict 
Outcomes in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. British 
journal of cancer. 2013;109(6):1460-6. 
[131] van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms 
BC, Kirkels WJ, Lockwood GA, Boeve ER, Jobsis AC, Zwarthoff EC, van der Kwast 
TH. Molecular Grade (Fgfr3/Mib-1) and Eortc Risk Scores Are Predictive in Primary 
Non-Muscle-Invasive Bladder Cancer. European urology. 2010;58(3):433-41. 
[132] Alkhateeb SS, Neill M, Bar-Moshe S, Rhijn BV, Kakiashvili DM, Fleshner N, 
Jewett M, Petein M, Schulman C, Hanna S, Bostrom PJ, Roumeguere T, Shariat SF, 
Rorive S, Zlotta AR. Long-Term Prognostic Value of the Combination of Eortc Risk 
Group Calculator and Molecular Markers in Non-Muscle-Invasive Bladder Cancer 
Patients Treated with Intravesical Bacille Calmette-Guerin. Urology annals. 
2011;3(3):119-26. 
[133] Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. 
Association between Smoking and Risk of Bladder Cancer among Men and Women. 
JAMA : the journal of the American Medical Association. 2011;306(7):737-45. 
[134] van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. 
Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and 
Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. The Journal of 
urology. 2016;195(4p1):872-9. 
[135] Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of 
Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the 
Literature. European urology. 2014;65(4):742-54. 
 37 
[136] Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, 
Kogevinas M, Real FX, Malats N. Epidemiology of Urinary Bladder Cancer: From 
Tumor Development to Patient's Death. World journal of urology. 2007;25(3):285-95. 
[137] Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J, Lee KH. 
Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of 
Progression and Metastasis in Patients with Newly Diagnosed T1 Bladder Urothelial 
Cancer. The Journal of urology. 2009;182(6):2625-30. 
[138] Orsola A, Trias I, Raventos CX, Espanol I, Cecchini L, Bucar S, Salinas D, 
Orsola I. Initial High-Grade T1 Urothelial Cell Carcinoma: Feasibility and Prognostic 
Significance of Lamina Propria Invasion Microstaging (T1a/B/C) in Bcg-Treated and 
Bcg-Non-Treated Patients. European urology. 2005;48(2):231-8; discussion 8. 
[139] Andius P, Johansson SL, Holmang S. Prognostic Factors in Stage T1 Bladder 
Cancer: Tumor Pattern (Solid or Papillary) and Vascular Invasion More Important 
Than Depth of Invasion. Urology. 2007;70(4):758-62. 
[140] van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, van 
der Aa MN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Bapat B, van der 
Kwast TH, Zlotta AR. Prognostic Value of Molecular Markers, Sub-Stage and 
European Organisation for the Research and Treatment of Cancer Risk Scores in 
Primary T1 Bladder Cancer. BJU international. 2012;110(8):1169-76. 
[141] van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders 
GJ, Bostrom PJ, van der Aa MN, Kakiashvili DM, Bangma CH, Jewett MA, Zlotta AR. 
A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. 
European urology. 2012;61(2):378-84. 
[142] Palou J, Rodriguez-Rubio F, Millan F, Algaba F, Rodriguez-Faba O, Huguet J, 
Villavicencio H. Recurrence at Three Months and High-Grade Recurrence as 
Prognostic Factor of Progression in Multivariate Analysis of T1g2 Bladder Tumors. 
Urology. 2009;73(6):1313-7. 
[143] Golijanin D, Yossepowitch O, Beck SD, Sogani P, Dalbagni G. Carcinoma in a 
Bladder Diverticulum: Presentation and Treatment Outcome. The Journal of urology. 
2003;170(5):1761-4. 
[144] Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, Villavicencio 
H. Female Gender and Carcinoma in Situ in the Prostatic Urethra Are Prognostic 
Factors for Recurrence, Progression, and Disease-Specific Mortality in T1g3 Bladder 
Cancer Patients Treated with Bacillus Calmette-Guerin. European urology. 
2012;62(1):118-25. 
[145] Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, 
Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo 
R, Briganti A, Babjuk M, Malmstrom PU, Oderda M, Irani J, Malats N, Baniel J, Mano 
R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea 
B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. Prognostic 
Factors and Risk Groups in T1g3 Non-Muscle-Invasive Bladder Cancer Patients 
Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter 
Study of 2451 Patients. European urology. 2015;67(1):74-82. 
[146] Dalbagni G, Vora K, Kaag M, Cronin A, Bochner B, Donat SM, Herr HW. 
Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 
Bladder Cancer. European urology. 2009;56(6):903-10. 
[147] Bishr M, Lattouf JB, Latour M, Saad F. Tumour Stage on Re-Staging 
Transurethral Resection Predicts Recurrence and Progression-Free Survival of 
Patients with High-Risk Non-Muscle Invasive Bladder Cancer. Canadian Urological 
 38 
Association journal = Journal de l'Association des urologues du Canada. 2014;8(5-
6):E306-10. 
[148] Kim HS, Kim M, Jeong CW, Kwak C, Kim HH, Ku JH. Presence of 
Lymphovascular Invasion in Urothelial Bladder Cancer Specimens after 
Transurethral Resections Correlates with Risk of Upstaging and Survival: A 
Systematic Review and Meta-Analysis. Urologic oncology. 2014;32(8):1191-9. 
[149] Comperat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaid I, Cussenot 
O, Samaratunga H. Micropapillary Urothelial Carcinoma of the Urinary Bladder: A 
Clinicopathological Analysis of 72 Cases. Pathology. 2010;42(7):650-4. 
[150] Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, 
Detry MA, Robinson TL, Pisters LL. The Case for Early Cystectomy in the Treatment 
of Nonmuscle Invasive Micropapillary Bladder Carcinoma. The Journal of urology. 
2006;175(3 Pt 1):881-5. 
[151] Amin A, Epstein JI. Noninvasive Micropapillary Urothelial Carcinoma: A 
Clinicopathologic Study of 18 Cases. Human pathology. 2012;43(12):2124-8. 
[152] Wasco MJ, Daignault S, Zhang Y, Kunju LP, Kinnaman M, Braun T, Lee CT, 
Shah RB. Urothelial Carcinoma with Divergent Histologic Differentiation (Mixed 
Histologic Features) Predicts the Presence of Locally Advanced Bladder Cancer 
When Detected at Transurethral Resection. Urology. 2007;70(1):69-74. 
[153] Blochin EB, Park KJ, Tickoo SK, Reuter VE, Al-Ahmadie H. Urothelial 
Carcinoma with Prominent Squamous Differentiation in the Setting of Neurogenic 
Bladder: Role of Human Papillomavirus Infection. Modern pathology : an official 
journal of the United States and Canadian Academy of Pathology, Inc. 
2012;25(11):1534-42. 
[154] Fristrup N, Ulhoi BP, Birkenkamp-Demtroder K, Mansilla F, Sanchez-Carbayo 
M, Segersten U, Malmstrom PU, Hartmann A, Palou J, Alvarez-Mugica M, Zieger K, 
Borre M, Orntoft TF, Dyrskjot L. Cathepsin E, Maspin, Plk1, and Survivin Are 
Promising Prognostic Protein Markers for Progression in Non-Muscle Invasive 
Bladder Cancer. The American journal of pathology. 2012;180(5):1824-34. 
[155] Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. 
Protein Expression Patterns of Ezrin Are Predictors of Progression in T1g3 Bladder 
Tumours Treated with Nonmaintenance Bacillus Calmette-Guerin. European 
urology. 2009;56(5):829-36. 
[156] van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, 
Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B. The Fgfr3 
Mutation Is Related to Favorable Pt1 Bladder Cancer. The Journal of urology. 
2012;187(1):310-4. 
[157] Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM. Prognostic 
Significance of the 2004 Who/Isup Classification for Prediction of Recurrence, 
Progression, and Cancer-Specific Mortality of Non-Muscle-Invasive Urothelial 
Tumors of the Urinary Bladder: A Clinicopathologic Study of 1,515 Cases. American 
journal of clinical pathology. 2010;133(5):788-95. 
[158] van Roekel EH, Cheng KK, James ND, Wallace DM, Billingham LJ, Murray 
PG, Bryan RT, Zeegers MP. Smoking Is Associated with Lower Age, Higher Grade, 
Higher Stage, and Larger Size of Malignant Bladder Tumors at Diagnosis. 
International journal of cancer. 2013;133(2):446-54. 
[159] Westhoff E. Body Mass Index, Diet-Related Factors, and Bladder Cancer 
Prognosis: A Systematic Review and Meta-Analysis.4(1):91-112. 
[160] Westhoff E, Wu X, Kiemeney LA, Lerner SP, Ye Y, Huang M, Dinney CP, 
Vrieling A, Tu H. Dietary Patterns and Risk of Recurrence and Progression in Non-
 39 
Muscle-Invasive Bladder Cancer. International journal of cancer. 2018;142(9):1797-
804. 
[161] Grotenhuis AJ, Dudek AM, Verhaegh GW, Witjes JA, Aben KK, van der Marel 
SL, Vermeulen SH, Kiemeney LA. Prognostic Relevance of Urinary Bladder Cancer 
Susceptibility Loci. PloS one. 2014;9(2):e89164. 
[162] Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, 
Thorleifsson G, Gudbjartsson DF, Stacey SN, Gudmundsson J, Zanon C, Kostic J, 
Masson G, Bjarnason H, Palsson ST, Skarphedinsson OB, Gudjonsson SA, Witjes 
JA, Grotenhuis AJ, Verhaegh GW, Bishop DT, Sak SC, Choudhury A, Elliott F, 
Barrett JH, Hurst CD, de Verdier PJ, Ryk C, Rudnai P, Gurzau E, Koppova K, Vineis 
P, Polidoro S, Guarrera S, Sacerdote C, Campagna M, Placidi D, Arici C, Zeegers 
MP, Kellen E, Gutierrez BS, Sanz-Velez JI, Sanchez-Zalabardo M, Valdivia G, 
Garcia-Prats MD, Hengstler JG, Blaszkewicz M, Dietrich H, Ophoff RA, van den 
Berg LH, Alexiusdottir K, Kristjansson K, Geirsson G, Nikulasson S, Petursdottir V, 
Kong A, Thorgeirsson T, Mungan NA, Lindblom A, van Es MA, Porru S, Buntinx F, 
Golka K, Mayordomo JI, Kumar R, Matullo G, Steineck G, Kiltie AE, Aben KKH, 
Jonsson E, Thorsteinsdottir U, Knowles MA, Rafnar T, Stefansson K. A Sequence 
Variant at 4p16.3 Confers Susceptibility to Urinary Bladder Cancer. Nature genetics. 
2010;42(5):415-9. 
[163] Grotenhuis AJ, Dudek AM, Verhaegh GW, Aben KK, Witjes JA, Kiemeney LA, 
Vermeulen SH. Independent Replication of Published Germline Polymorphisms 
Associated with Urinary Bladder Cancer Prognosis and Treatment Response. 
Bladder Cancer (Amsterdam, Netherlands). 2016;2(1):77-89. 
[164] Masson-Lecomte A, Lopez de Maturana E, Goddard ME, Picornell A, Rava M, 
Gonzalez-Neira A, Marquez M, Carrato A, Tardon A, Lloreta J, Garcia-Closas M, 
Silverman D, Rothman N, Kogevinas M, Allory Y, Chanock SJ, Real FX, Malats N. 
Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer 
Prognosis: A Multimarker Bayesian Assessment. Cancer epidemiology, biomarkers 
& prevention : a publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology. 2016;25(7):1144-50. 
[165] Lopez de Maturana E, Picornell A, Masson-Lecomte A, Kogevinas M, 
Marquez M, Carrato A, Tardon A, Lloreta J, Garcia-Closas M, Silverman D, Rothman 
N, Chanock S, Real FX, Goddard ME, Malats N. Prediction of Non-Muscle Invasive 
Bladder Cancer Outcomes Assessed by Innovative Multimarker Prognostic Models. 
BMC cancer. 2016;16:351. 
[166] Xu ZC, Cai HZ, Li X, Xu WZ, Xu T, Yu B, Zou Q, Xu L. Ercc1 C118t 
Polymorphism Has Predictive Value for Platinum-Based Chemotherapy in Patients 
with Late-Stage Bladder Cancer. Genetics and molecular research : GMR. 
2016;15(2). 
[167] Lenormand C, Couteau J, Nouhaud FX, Maillet G, Bou J, Gobet F, Pfister C. 
Predictive Value of Nramp1 and Hgpx1 Gene Polymorphism for Maintenance Bcg 
Response in Non-Muscle-Invasive Bladder Cancer. Anticancer research. 
2016;36(4):1737-43. 
[168] O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, 
Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, 
Vijai J, Offit K, Stadler WM, Bajorin DF. Clinical Evaluation of Cisplatin Sensitivity of 
Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. 
Clinical genitourinary cancer. 2016;14(6):511-7. 
[169] Ryk C, Koskela LR, Thiel T, Wiklund NP, Steineck G, Schumacher MC, de 
Verdier PJ. Outcome after Bcg Treatment for Urinary Bladder Cancer May Be 
 40 
Influenced by Polymorphisms in the Nos2 and Nos3 Genes. Redox biology. 
2015;6:272-7. 
[170] Deng X, Yang X, Cheng Y, Liu X, Li X, Zhao R, Qin C, Lu Q, Yin C. Gstp1 and 
Gsto1 Single Nucleotide Polymorphisms and the Response of Bladder Cancer 
Patients to Intravesical Chemotherapy. Scientific reports. 2015;5:14000. 
[171] Li P, Zhang X, Deng X, Tao J, Qin C, Yang X, Cheng Y, Lu Q, Wang Z, Yin C. 
Pharmacogenetic Association between Xrcc1 Polymorphisms and Improved 
Outcomes in Bladder Cancer Patients Following Intravesical Instillation of Epirubicin. 
International journal of clinical and experimental medicine. 2015;8(7):11167-73. 
[172] Zhou B, Zhang P, Tang T, Liao H, Zhang K, Pu Y, Chen P, Song Y, Zhang L. 
Polymorphisms and Plasma Levels of Il-27: Impact on Genetic Susceptibility and 
Clinical Outcome of Bladder Cancer. BMC cancer. 2015;15:433. 
[173] Buffen K, Oosting M, Quintin J, Ng A, Kleinnijenhuis J, Kumar V, van de 
Vosse E, Wijmenga C, van Crevel R, Oosterwijk E, Grotenhuis AJ, Vermeulen SH, 
Kiemeney LA, van de Veerdonk FL, Chamilos G, Xavier RJ, van der Meer JW, Netea 
MG, Joosten LA. Autophagy Controls Bcg-Induced Trained Immunity and the 
Response to Intravesical Bcg Therapy for Bladder Cancer. PLoS pathogens. 
2014;10(10):e1004485. 
[174] Zhou B, Zhang P, Tang T, Zhang K, Wang Y, Song Y, Liao H, Zhang L. 
Prognostic Value of Pdcd6 Polymorphisms and the Susceptibility to Bladder Cancer. 
Tumour biology : the journal of the International Society for Oncodevelopmental 
Biology and Medicine. 2014;35(8):7547-54. 
[175] Teo MT, Dyrskjot L, Nsengimana J, Buchwald C, Snowden H, Morgan J, 
Jensen JB, Knowles MA, Taylor G, Barrett JH, Borre M, Orntoft TF, Bishop DT, Kiltie 
AE. Next-Generation Sequencing Identifies Germline Mre11a Variants as Markers of 
Radiotherapy Outcomes in Muscle-Invasive Bladder Cancer. Annals of oncology : 
official journal of the European Society for Medical Oncology. 2014;25(4):877-83. 
[176] Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang 
X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, 
Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic Variations in 
the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-Muscle-Invasive 
Bladder Cancer. Cancer prevention research (Philadelphia, Pa). 2010;3(10):1235-
45. 
[177] Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, Wei H, Huang M, Chang DW, 
Dinney CP, Wu X. Genetic Variations in Micro-Rna Biogenesis Genes and Clinical 
Outcomes in Non-Muscle-Invasive Bladder Cancer. Carcinogenesis. 
2013;34(5):1006-11. 
[178] Wu X, Ros MM, Gu J, Kiemeney L. Epidemiology and Genetic Susceptibility 
to Bladder Cancer. BJU international. 2008;102(9 Pt B):1207-15. 
[179] Lubin JH, Kogevinas M, Silverman D, Malats N, Garcia-Closas M, Tardon A, 
Hein DW, Garcia-Closas R, Serra C, Dosemeci M, Carrato A, Rothman N. Evidence 
for an Intensity-Dependent Interaction of Nat2 Acetylation Genotype and Cigarette 
Smoking in the Spanish Bladder Cancer Study. Int J Epidemiol. 2007;36(1):236-41. 
[180] Lacombe L, Fradet V, Levesque E, Pouliot F, Larue H, Bergeron A, Hovington 
H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C. Phase Ii Drug-
Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-
Invasive Bladder Cancer: A Gene-Smoking Interaction. Cancer prevention research 
(Philadelphia, Pa). 2016;9(2):189-95. 
 41 
[181] Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, Lotan Y. 
The Economics of Bladder Cancer: Costs and Considerations of Caring for This 
Disease. Eur Urol. 2014;66(2):253-62. 
[182] Zamboni S, Moschini M, Simeone C, Antonelli A, Mattei A, Baumeister P, 
Xylinas E, Hakenberg OW, Aziz A. Prediction Tools in Non-Muscle Invasive Bladder 








PREPARATION OF THE DATA: QUALITY CONTROL 
AND GENOTYPE IMPUTATION 
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2.1. STUDY PARTICIPANTS 
 
The West Midlands Bladder Cancer Prognosis Programme (BCPP) 
Subjects for the main study were obtained from the West Midlands Bladder Cancer 
Prognosis Programme [1]. BCPP is a prospective cohort initiated by the Cancer 
Research UK Bladder Cancer Group at the University of Birmingham that focuses on 
investigating prognostic factors for urinary bladder cancer (UBC). Besides identifying 
determinants for UBC recurrence and progression, the initiative aimed to use the 
collected data for developing a more accurate prognostic tool for predicting adverse 
UBC outcomes.  
Subjects were initially recruited from the West Midlands region during the period 
between 2005 to 2011, resulting in 1,544 eligible participants. Patients were identified 
at haematuria clinics, and were deemed eligible if they had cystoscopy that was 
suggestive of a UBC diagnosis. All enrolled participants had a pathological UBC 
diagnosis confirmation. Patients with cancer diagnosis of the urinary system (bladder, 
urethra, ureter, renal pelvis) within the last decade were excluded in the recruitment 
process.  
BCPP has three broad aims, each focusing on different determinants for UBC 
prognosis: modifiable exposures (e.g. smoking, diet), quality of life, and molecular 
markers. Data on lifestyle factors and various exposures (e.g. smoking, occupation, 
diet, medication use, social descriptors) were collected via semi-structured face-to-
face interviews and questionnaires. Trained research nurses carried out the interviews 
at baseline, whilst additional ongoing information was provided by patients submitting 
questionnaires by post afterwards [1]. Specific clinical characteristics on tumour stage 
and grade were retrieved from medical records to complete the pathological data. The 
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size of the largest tumour was established visually whilst performing TURBT. 
Biological samples included urine, tumour tissue, and blood specimens, all collected 
at baseline. In total, blood samples for 888 UBC patients were genotyped using 
Illumina HumanOmniExpress BeadChip at deCODE Genetics [2] (Reykjavik, Iceland). 
All analyses in BCPP were limited to the non-muscle-invasive bladder cancer (NMIBC) 
patients (N=712), corresponding to stages pTa, pT1, and pTis. 
Nottingham Multi-Centre Research Ethics Committee provided the ethical approval for 
the BCPP study (reference number: 06/MRE04/65; clinicaltrials.gov registration 
number: NCT00553215). Informed consent at baseline was obtained from all 
participants.  
 
The Nijmegen Bladder Cancer Study (NBCS) 
Participants for the NBCS were selected from the regional Cancer Registry, covering 
the Eastern part of the Netherlands. Recruitment took place between years 1995 and 
2006, and targeted UBC cases under the age of 75.  
Clinical data were obtained via medical records, whilst other information was collected 
using self-administered lifestyle questionnaires.  
Following informed consent, patients also provided blood samples for genotyping, 
which was carried out on the on the HumanHap300 and HumanHapCNV370 
BeadChip panel (Illumina, Inc., San Diego, USA). Initially, full genotype and clinical 
data were available for circa 1,200 UBC patients, all of European descent. Additional 





UK Biobank is a large, population-based cohort in the United Kingdom, containing data 
on more than 500,000 participants [4]. Recruitment took place 2006-2010 and 
included people aged 40-69 years. The cohort includes a variety of data sources, 
which allowed us to analyse a sample of 1,534 UBC cases via the data from Cancer 
Registry. The codes used to identify bladder cancer patients included C67.0-C67.9 
(International Classification of Diseases (ICD) 10) and 1880, 1882, 1884, 1886, 1888, 
1889, 2337 (ICD9). 
Clinical data were obtained from Hospital Episode Statistics (HES), whilst 
demographic data were recorded via self-administered questionnaires. Genotyping 
was carried out on a specifically-developed UK Biobank Axiom Array [5] . All analyses 
were limited to White British participants, as defined by the UK Biobank study. Our use 
of the UK Biobank data has been registered under Application Number 42772. 
Additional procedures on data collection and processing are described in detail 
elsewhere [4, 5].  
 
2.2 QUALITY CONTROL (QC) 
 
Pre-imputation data cleaning was divided into two main steps: per-individual and per-
marker QC. This approach helps to retain a higher number of genetic markers used in 
the analyses, as exclusion of a participant virtually has little impact on the count of 
total single nucleotide polymorphism (SNP) panel; however, marker exclusion 
prevents testing them for an association in the whole sample. Hence, individuals with 
overall flawed data are identified first. 
All QC procedures were carried out using PLINK v1.90 (released 17th November 2016) 
[6, 7].  
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2.2.1 Per-individual QC 
Per-individual QC [8-10] covers the following steps:  
a) Genetic sex check; 
b) Estimation of missing genotypes per individual; 
c) Evaluating genotype heterozygosity rate; 
d) Identifying related and duplicated individuals; 
e) Detecting population stratification. 
 
a) A genetic sex check primarily yields to identify the discordance between 
phenotypically-assigned and de-facto gender. The procedure is very useful for 
identifying potential sample swaps or accidental errors and allows to prevent further 
misclassification. Moreover, it can help to identify individuals with karyotypic 
chromosome abnormalities that may have a significant impact on study results.  
Genetic sex is determined by the X chromosome homozygosity rate, otherwise called 
an F statistic. The rationale is that females have two X chromosomes and are expected 
to be highly heterozygous in their genotypes (due to the presence of many two-allele 
combinations from both chromosomes). Hence, females’ X chromosome genotypes 
are expected to follow a Hardy-Weinberg equilibrium (HWE) and result in an F statistic 
of homozygosity <0.2. Males, on the other hand, have only one X chromosome and 
are expected to be mostly homozygous (reaching F>0.8) [9-11].  
However, there are some occasions in which individuals fall in between those 
thresholds, yielding an “inconclusive” genetic sex call. That might be a result of 
multiple causes: low individual genotyping rate, mosaicism (where only a fraction of 
cells carry an abnormal karyotype, whilst the rest are normal), loss of heterozygosity 
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in females’ X chromosome, or karyotype anomalies (i.e. males with Kleinfelter 
syndrome (XXY), females with Turner syndrome (XO)) [10]. Whilst the homozygosity 
rate is a good indication for identifying individuals that might skew the results of an 
analysis, it is worth clarifying the F statistic itself does not provide specifics on the 
cause of the discrepancy. However, it can be investigated further with access to 
clinical (e.g. checking for any reported genetic conditions) or array data (e.g. X 
chromosome probe intensity plots, referred to as LogR ratios in Illumina platform or 
probe intensity in Affymetrix) [10].  
Since our dataset did not have gender assigned phenotypically, no sample swaps 
could have been identified, even if those had taken place. However, the procedure 
identified three individuals with inconclusive calls on gender (yielding F statistic values 
of 0.77, 0.56, and 0.62). Although a definite reason for the discordance is difficult to 
give, it is worth noting that these three samples also come up in sequential QC steps 
as well, most likely indicating low-quality samples. Therefore, the three samples were 
added to the list for exclusion.  
 
b) High missing genotype rate per individual indicates low sample quality and 
might bias the association result (e.g. if missingness differs for the categories of a 
studied phenotype). It is more often observed in case-control or multi-centre studies, 
where different sets of samples were collected and/or genotyped separately. Cohort 
studies, such as BCPP, suffer less from this problem; however, they are not immune 
to low-quality samples. An exact threshold level for excluding individuals varies on a 
study-to-study basis; it was usual to apply a threshold of 3-7% for missing genotypes 
per individual for exclusion [10], whereas nowadays it is reasonable to apply a more 
stringent criterion. In our sample, 49 individuals have failed the QC step due to having 
more than 2% of their genotype missing. Missing genotype fraction per individual is 
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also presented in a histogram (Figure 2.1), which shows most individuals have a high 
genotype rate (approximately 99%). 
 
Figure 2.1. Missing genotype rate per individual.  
c) Excessively increased or reduced proportion of heterozygous genotypes in the 
sample might also signal the presence of sample contamination or inbreeding. Mean 
genotype heterozygosity is calculated using the individual-level information on 
genotype non-missingness (N(NM)) and the number of homozygous genotypes 
(E(HOM)), which can then be used to calculate observed heterozygosity rate per 
person (N(NM)-E(HOM))/N(NM)). Although an exact threshold for excluding 
individuals varies on a study-to-study basis, it is usual to exclude those with observed 
heterozygosity fluctuating 3 standard deviations (SDs) from the mean [8]. In the case 
of BCPP, the mean was equal to 0.3168287, SD=0.0065949; hence all individuals 
exceeding heterozygosity rate of 0.3366134 and having a lower rate than 0.2970440 
were identified for further exclusion (N=12). Figure 2.2 shows the sample distribution 
under thresholds of excessive missingness and heterozygosity. 
 
d) Genetic association study assumes all tested individuals are non-related, and 
failure to adjust for cryptic relatedness may produce clusters of genotypes in an 
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otherwise random collection of participants. For that reason, any related individuals 
and duplicates should be identified and excluded from the sample. 
 
Figure 2.2. Observed heterozygosity and missing genotype rates (red lines 
indicate applied thresholds). 
 
Even though all people share genomic regions (referred to as identical-by-state (IBS)), 
being related increases the magnitude of IBS regions. In return, estimated IBS metric 
provides information on the level of relatedness, i.e. identity-by-decent (IBD). An IBS 
equal to 1 indicates sample duplication, whilst IBS of 0.5 signifies first-degree relative 
[8]. Before calculating IBS, it is essential to first exclude regions of high linkage-
disequilibrium (LD) [12] and correlated regions (R2>0.2), as those result in 
identification of falsely-related participants [8]. Afterwards, participant pairs exceeding 
IBS of 0.1875 (showing relatedness halfway between third- and second-degree 
relatives) are identified. As only one individual from a pair is enough to be excluded to 
prevent sample sub-structure, the participant with a lower genotyping rate is listed for 
further data cleaning.  
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Relatedness analysis in the BCPP dataset revealed two pairs of participants who had 
a greater-than-expected IBS level. Out of each pair of related individuals, participants 
with a lower genotype rate were added to the exclusion list.  
 
e) Population stratification is one of the most important forms of confounding in a 
genome-wide association study (GWAS). Allele frequencies differ between the 
populations, and consecutively, so do distributions in phenotypic traits. In a GWAS 
with subpopulations present, detected differences in outcomes might be wrongly 
attributed to a certain genotype when in fact it is caused by population stratification 
[13]. To address the issue, we have carried out a multi-stage principal component 
analysis (PCA). PCA identifies genetic clusters (eigenvectors), which explain 
proportions of genetic variation within the sample. Additionally, all individuals are 
assigned a score (an eigenvalue) for every eigenvector.  
Importantly, BCPP contains self-reported data on ethnic background, but its validity 
was never verified. To investigate if these records are accurate, we have firstly 
compared the self-reported ethnicity records in the BCPP to a publicly-available 
reference panel of 1,000 Genomes (Phase 3, released 2nd May 2013) [14]. Autosomal 
1,000 Genomes data were pruned of high-LD regions and merged with the BCPP 
genome dataset. Afterwards, a PCA analysis was conducted on a combined sample 
of 3,216 people (NMIBC cases in the BCPP (N=712) and 1,000 genomes (N=2,504)). 
Figure 2.3 shows the distribution of individuals across the first 2 principal components 
(PCs) in both samples. Self-reported ethnic background in the BCPP represented five 
categories: Black (Caribbean), Indian, Pakistani, White, and Other; whereas data in 
1000 Genomes can be stratified into five superpopulations: East Asians (EAS), 
Europeans (EUR), Africans (AFR), Ad-mixed Americans (AMR), and South Asians 
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(SAS). As shown in Figure 2.3, the self-reported ethnicities are in an overall 
agreement with the 1,000 Genomes reference panel.  
Furthermore, superpopulations in 1,000 Genomes can be further stratified into smaller 
groups, each of those containing from five to seven ethnic origins:   
• EAS: Chinese Dai in Xishuangbanna (China (CDX)); Han Chinese in Beijing 
(China (CHB)), Southern Han Chinese (CHS), Japanese in Tokyo (Japan (JPT)), Kinh 
in Ho Chi Minh City (Vietnam (KHV));  
 
 
 Figure 2.3. Distribution of individuals against first 2 PCs of a joint PCA 
analysis, presented separately for BCPP and 1,000 Genomes Phase 3 samples. 
• EUR: Utah Residents (CEPH) with Northern and Western European Ancestry 
(CEU), Finnish in Finland (FIN), British in England and Scotland (GBR), Iberian 
Population in Spain (IBS), Toscani in Italia (TSI);  
• AFR: African Caribbeans in Barbados (ACB), Americans of African Ancestry in 
SW USA (ASW), Esan in Nigeria (ESN), Gambian in Western Divisions in the Gambia 
(GWD), Luhya in Webuye (Kenya (LWK)), Mende in Sierra Leone (MSL), Yoruba in 
Ibadan (Nigeria (YRI));  
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• AMR: Colombians from Medellin (Colombia (CLM)), Mexican Ancestry from 
Los Angeles USA (MXL), Peruvians from Lima (Peru (PEL)), Puerto Ricans from 
Puerto Rico (PUR);   
• SAS: Bengali from Bangladesh (BEB), Gujarati Indian from Houston (Texas 
(GIH)), Indian Telugu from the UK (ITU), Punjabi from Lahore (Pakistan (PJL)), Sri 
Lankan Tamil from the UK (STU).  
Figures 2.4 and 2.5 show the eigenvalue distribution for populations of European and 
African origins, respectively. In Figure 2.4, self-reported “White” participants plot 
similarly to European populations in the 1,000 Genomes. Expectedly, most 
eigenvalues in the BCPP correspond to the population of GBR in 1,000 Genomes.  
 
Figure 2.4. Distribution of individuals of European decent against first 2 PCs of 
joint PCA analysis, presented separately for BCPP and 1,000 Genomes Phase 3 
samples. 
As shown in Figure 2.5, BCPP self-identified “Black, Caribbean” participants cluster 
similarly to the ACB population in the 1,000 Genomes (Figure 2.5).   
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Figure 2.5. Distribution of individuals of African descent against first 2 PCs of 
a joint PCA analysis, presented separately for BCPP and 1,000 Genomes 
Phase 3 samples. 
Adding a third PC to visualise genetic distances across individuals in a merged dataset 
shows little new information is added with an additional PC; hence, the first 2 PCs are 
enough to make a decision on population structure (Figure 2.6 and 2.7).  
 
Figure 2.6. First three principal components of merged BCPP and 1,000 
Genomes Phase 3 genotypes. 
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Figure 2.7. First three principal components of merged BCPP and 1,000 
Genomes Phase 3 genotypes; stratified by self-reported ethnicity (BCPP) and 
superpopulation (1,000 Genomes). 
After confirming that the self-reported information on ethnicity in the BCPP is valid, we 
conducted a PCA on BCPP dataset only to clearly identify existing outliers. Plotting 
the two top genetic PCs in BCPP shows at least four individuals do not fall into the 
general cluster, which were added to the list of participants to exclude from further 
analyses (Figure 2.8).  
At the end of all per-individual QC procedures, 59 unique individuals are identified (70, 
including 11 duplicates) and excluded from the dataset, leaving 653 NMIBC cases. 
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Figure 2.8. Top two principal genetic components in BCPP cohort with self-
reported ethnicity.  
 
2.2.2. Per-marker QC 
Generic marker-specific QC consists of the following steps:   
a) Identifying markers with an excessive missing genotype rate; 
b) Checking genotype calls for cases and controls; 
c) Checking for HWE; 
d) Filtering markers with low minor allele frequencies (MAF). 
 
a) Excluding markers with high missing genotype rate is essential to avoid having 
low-quality SNPs in the dataset. Markers that are missing for a large fraction of tested 
individuals might result in a false-positive association and/or reduced power of the 
study, as fewer SNPs are tested overall. It is usual to filter out SNPs with a missing 
rate of 5% or higher [8]; however, in recent years, a more strict threshold of 2% has 
been favoured, which is also used in our study.  
 
b) If the variant is missing at significantly different rates for cases and controls, it 
creates a substructure within the sample, which might be a source of bias in genetic 
association studies. However, our study is designed to consist of bladder cases only, 
without having clearly defined case and control groups. Instead, there are multiple 
outcomes of both categorical and continuous nature, hence this step is omitted from 
QC. 
 
c) HWE describes a distribution of alleles (and genotypes) that remain stable in 
subsequent generations under a specific set of conditions. Deviation from the 
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equilibrium might occur due to events of mutations or inbreeding, but can also indicate 
genotyping errors or population substructure [10, 15]. In case-control designs, only 
controls are tested to see if they comply to HWE, as cases might deviate from the 
distribution if some variants are strongly associated with an outcome [8, 15]. As our 
cohort consists fully of cases, HWE assumption is tested for everyone in the sample.  
 
d) Markers with low MAF are usually excluded, since they are prone to falsely 
appear as significant results just because they are rare. Otherwise, a very large 
sample size is needed to provide enough power for those variants to be analysed. Our 
study is underpowered to discover rare variants; hence, all SNPs with MAFs of  1% 
are excluded [8].  
 
A separate QC pipeline was developed for the X chromosome, as handling variants 
on non-autosomal regions calls for a different approach [16, 17]. Firstly, the X 
chromosome data was split by gender. It is expected that genetic variants on male X 
chromosome will naturally not comply to the HWE; therefore, compliance to HWE is 
only tested in the female group. Both – males’ and females’ - X chromosome variants 
have been additionally pruned for monomorphic and/or rare variants with a MAF 
threshold of 1%, whilst the threshold for genotype missingness was set at 2%.  
All per-marker exclusion criteria have resulted in an exclusion of 158 SNPs due to 
deviations from HWE, 37,912 SNPs with low MAFs, and 14,631 SNPs with missing 
rate higher than or equal to 2% across all individuals. The impact of each criterion on 
a chromosome level can be seen in Table 2.1. 
After completing both quality control steps for individuals and SNPs, a clean dataset 
consisting of 653 individuals and 597,764 markers was available for further analyses.  
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1 52489 0.997383 934 11 3773 47771 
2 51369 0.997316 980 14 2972 47403 
3 42468 0.997163 855 12 2456 39145 
4 36597 0.996885 857 6 1953 33781 
5 38053 0.997269 747 13 1734 35559 
6 43409 0.997101 956 12 2185 40256 
7 34086 0.997152 735 5 1602 31744 
8 33260 0.997375 582 3 1551 31124 
9 29810 0.997347 562 6 1526 27716 
10 35201 0.997455 606 13 2236 32346 
11 32884 0.997385 593 8 1957 30326 
12 32055 0.99726 644 6 1850 29555 
13 25015 0.996979 576 6 1574 22859 
14 21001 0.997341 429 5 1342 19225 
15 19493 0.997579 333 9 1185 17966 
16 20030 0.997704 284 6 1052 18688 
17 17743 0.997411 338 5 1088 16312 
18 19450 0.99718 410 6 1204 17830 
19 12977 0.997142 284 5 698 11990 
20 16383 0.997477 302 2 861 15218 
21 9103 0.997152 191 2 464 8446 
22 9245 0.997522 167 3 479 8596 
Total (22) 632121 0.997281 12365 158 35742 583856 
X (Females) 15253 0.997493 450 0 1078 13725 
X (Males) 15253 0.9908 1816 N/A 1092 12345 
Total (22, X) 647374 0.995895 14631 158 37912 597764*  
*(the number does not equal sum of all above fields due to SNP overlap on X 
chromosome).  
HWE-Hardy-Weinberg Equilibrium; MAF-minor allele frequency; SNP-single 
nucleotide polymorphism; QC-quality control. 
 
After obtaining the final set of individuals to proceed with further analyses, it was 
considered worthy of an additional investigation on residual population stratification in 
the BCPP sample. The exclusion of individuals based on PCA results can be 
considered subjective, and an effort to maintain the balance between high QC and an 
excessive dataset reduction might not always be well preserved. To investigate this, 
a basic preliminary association analysis was undertaken for all outcomes of interest in 
PLINK software to estimate the genomic inflation factor () value, which, if 
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substantially inflated (>1.1 [18], or as recently more strict criteria in GWAS have been 
introduced, >1.05 [19]), indicates potential population stratification. The preliminary 
analysis showed that the lambda metric did not exceed 1.05 for all of the tested 
outcomes (tumour size (cm), grade (G3/G2+G1), stage (T1+Tis/Ta), and patient’s age 
(years), further described in detail in Chapter 4).  
  
2.3 IMPUTATION OF THE BCPP DATA 
 
Despite genetic epidemiology techniques undergoing a remarkable improvement in 
recent years, genotyping arrays usually assay somewhere between 300,000 and 
1,000,000 single-nucleotide variants [20]. Considering that the human genome 
consists of approximately 3 billion base-pairs, a vast majority of the genome is usually 
missing from the analyses, potentially preventing a significant discovery. Genotype 
imputation techniques, which entail predicting a missing genotype based on a 
reference genotype panel (that is much more dense), are very useful in increasing 
study power, fine-mapping observed associations, and conducting meta-analyses 
[21].  
A reference panel of 1000 Genomes Phase 3 (released 2nd May 2013) [14] was 
chosen to carry out imputation in the genome build 19 (GRCh37/hg19). Even though 
the 1000 Genomes data has been remapped into the newest reference of genome 
build (GRCh38/hg38), it is still difficult to obtain all corresponding files needed for a 
successful imputation (e.g. legend files, that carry a specific format). For that reason, 
BCPP data (annotated in the GRCh38 assembly), has been converted into an earlier 
format of GRCh37 (hg19), using a freely-accessible liftOver software [22].  
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The most commonly used imputation software is BEAGLE [23], IMPUTE2 [24], and 
MACH [25]. After referring to detailed reports in the literature comparing each tool’s 
strengths and weaknesses [21, 26, 27], it has been decided to use IMPUTE2. 
Imputation takes the form of a two-step process: genotype phasing and imputing. The 
software tool for phasing recommended by IMPUTE2 is SHAPEIT [28, 29].  However, 
we have chosen to use a newly-released software, Eagle v2.3.2 [30]  (latest release 
used: March 2017), as it has been recently estimated to increase in computational 
speed by 20% and haplotype assignment accuracy by approximately 10%, in 
comparison to SHAPEIT [30]. Due to an efficient algorithm, it has also become a 
default phasing software used in publicly available imputation servers [20, 31].  
As with pre-imputation QC, there are several steps taken to evaluate the quality of 
imputation: 
a) Estimating accuracy (concordance rate); 
b) Filtering variants with low MAF (≤1%). 
 
a) A gold standard measure of imputation quality is the concordance rate between 
imputed and genotyped calls [32]. Concordance rate, or accuracy, makes use of a 
masked analysis [27]. Initially, all directly-genotyped markers are masked and are 
imputed by making a best-guess generated by the algorithm. Afterwards, imputed 
results are compared to the actual genotype to provide a concordance rate in the form 
of a percentage. The accuracy is presented in two ways: as an overall measure for all 
tested SNPs (written in a summary file of IMPUTE2) and as a per-marker score 
(presented in an “info” output in IMPUTE2). It is usually regarded that the overall 
concordance rate of 95% or more indicates high imputation accuracy [27].  
Imputation accuracy is dependent on the use of a reference panel. Evidence shows 
that the Haplotype Research Consortium (HRC) panel, consisting of more than 32,000 
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haplotypes [31] is the most suitable reference for European-population based 
samples. HRC also includes 1,000 Genomes panel, among many other, and has been 
reported to have a substantial increase in imputing variants with low MAF [33].  
Significant improvements in imputation quality have already been documented, during 
a global transition from using HapMap to much bigger 1,000 Genomes data as a 
reference panel [34]. However, time constraints, computational limits, and ethical 
consideration for using an external imputation server have prevented us from using 
the HRC in our analyses. Instead, the optimal choice was to rely on a manual 
imputation process using 1,000 Genomes Phase 3 dataset, containing 2,504 samples.  
Once imputed, the dataset was filtered for SNPs with an info score (i.e. the 
concordance rate) of >0.3 and MAFs of >1%, resulting in a dataset containing 
11,914,228 markers available for genetic association analyses.  
 
2.4 POST-HOC STATISTICAL POWER CALCULATIONS  
 
Our analyses are subject to many limitations, and pots-hoc power calculations provide 
a better context whilst interpreting all results, summarised in chapters hereafter.  
 
Genome-wide association analyses  
To estimate the power of our analyses, we have used methods described in a 
publication by Moore et al [35], which has been implemented in an R package 
“genpwr”.  
All calculations assume an additive model and a statistical significance level of 5e-08. 
Tumour size as a continuous outcome 
Sample size=653 
Assumed effect allele frequency (lowest observed in the analyses) = 0.01 
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Effect size as estimated in the linear regression=0.9 (centimetres of tumour size) and 
standard deviation of 0.5. 
Estimated power at alpha level of 5e-08 = 87%. 
Age at diagnosis as a continuous outcome 
Sample size=653 
Assumed effect allele frequency (lowest observed in the analyses) = 0.04 
Effect size as estimated in the linear regression =0.5 (age in years) and standard 
deviation of 0.5. 
Estimated power at alpha level of 5e-08 = 96%. 
Grade as a categorical variable  
Sample size=653 (N(cases)=207, N(controls)=436) 
Assumed effect allele frequency (lowest observed in the analyses) = 0.06 
Odds ratio as estimated in logistic regression=3.6  
Estimated power at alpha level of 5e-08 = 46%. 
Stage as a categorical variable  
Sample size=653 (N(cases)=209, N(controls)=444) 
Assumed effect allele frequency (lowest observed in the analyses) = 0.02 
Odds ratio as estimated in logistic regression=0.02  
Estimated power at alpha level of 5e-08 = 13%. 
Age as a categorical variable  
Sample size=653 (N(cases)=355, N(controls)=298) 
Assumed effect allele frequency (lowest observed in the analyses) = 0.16 
Odds ratio as estimated in logistic regression=2.5 
Estimated power at alpha level of 5e-08 = 66%. 
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Gene environment interaction with smoking for tumour size as an outcome 
Environment status is assumed to be binary in nature (ever smokers versus never 
smokers). Statistical significance level is set at alpha=0.05.  
Total sample size=546. 
Assumed effect allele frequency (lowest observed in the analyses) = 0.01 
Effect size of the genotype in linear regression=0.5 (centimetres of tumour size) 
Effect size of the gene-environment interaction term in linear regression=4.1 (median 
of all effect sizes reported in our gene-environment interaction analyses)  
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Many germline associations have been reported for urinary bladder cancer (UBC) 
outcomes and prognostic characteristics. It is unclear if there are overlapping genetic 
patterns for various prognostic endpoints. Our objective was to review contemporary 
literature on genetic associations with UBC prognostic outcomes and to identify 
potential overlap in reported genes.  
METHODS 
EMBASE, MEDLINE, and PubMed databases were queried for relevant articles in 
English language without date restrictions.  
RESULTS 
The initial search identified 1,346 articles. After exclusions, 112 studies have been 
summarized. Cumulatively, 316 single nucleotide polymorphisms (SNPs) were 
reported across prognostic outcomes (recurrence, progression, death) and 
characteristics (tumour stage, grade, size, age, risk group). There were considerable 
differences between studied outcomes in the context of genetic associations. The 
most commonly reported SNPs were located in OGG1, TP53, and MDM2. For 
outcomes with the highest number of reported associations (i.e. recurrence and 
death), functional enrichment annotation yields different terms, potentially indicating 
separate biological mechanisms.  
CONCLUSIONS 
In our analysis, UBC prognostic outcomes show significant genetic heterogeneity and 
it might be valuable they are studied as distinct phenotypes. Further validation of most-
promising observations is essential for including the genetic component into predicting 




Urothelial bladder cancer (UBC) results in considerable clinical input and necessitates 
ongoing research to reduce the burden of patients and healthcare providers [1]. 
Current era of genomics offers new insights into UBC pathogenesis [2]. However, due 
to the complex nature of genetics, many studies are difficult to summarize into clear 
recommendations for future research and clinical practice.  
UBC is most frequently diagnosed as a non-muscle-invasive bladder cancer (NMIBC), 
accounting for 70-80 percent of all new cases [3]. NMIBC management is complex 
with appropriate treatment dependent upon multiple clinical and pathological 
components. Importantly, a significant proportion of patients are prone to tumour 
recurrence and/or progression, both events difficult to predict. Previously developed 
multifactorial prognostic NMIBC tools [4] have been useful to describe populations, 
but lack accuracy for individual outcomes and require further advances [5]. Muscle-
invasive bladder cancer (MIBC) cases are equally complex to treat with various 
permutations of chemotherapy, radiotherapy, and cystectomy [6], with an addition of 
recent initiatives in molecular-genomic subtyping [2].  
Although multiple studies have addressed the potential role of genetic variation in UBC 
prognosis, the findings are yet to be implemented into clinical practice. For the most 
part, genetic associations are often reported in small samples and their validity is 
difficult to establish. In addition, the interpretation of the biological relevance over 
many reports is challenging. Furthermore, it is not yet clear if genetic associations 
overlap within and between the groups of direct (recurrence, progression, survival) 
and indirect (stage, grade, tumour size, age at the time of diagnosis) prognostic 
endpoints. Identifying existing genetic similarities between prognostic outcomes would 
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help to potentially decipher underlying pathological mechanisms and guide promising 
directions in research on UBC. 
In the current review, our objective is to summarize genetic associations for UBC 
prognostic phenotypes and to describe any overlap or existing patterns that would 




The systematic review was conducted according to the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) [7] (Supplementary Table 3.1).  
We queried EMBASE, Medline, and PubMed with the following search term: (("urinary 
bladder neoplasms" OR "bladder cancer" OR "urothelial carcinoma") AND (prognosis 
OR survival OR recurrence OR progression OR grade OR stage OR "tumour size" OR 
age) AND (polymorphi* OR SNP OR germline)). The search was limited to articles 
published prior to the 13th November 2018, written in English and describing human 
research only. A detailed flowchart on the selection and search process is presented 
in Figure 3.1. Reference lists of included manuscripts were checked for potentially 
missing reports. Study eligibility was determined by the main author (NL).  
Inclusion criteria were as follows: 
1) Studies assessing single germline single-nucleotide polymorphism (SNP) variants 
(not somatic mutations, insertion/deletions, microsatellites, haplotype analyses, 
dinucleotide polymorphism associations, multiple-SNP prediction models); 
2) Original reports (not meta-analyses, reviews, letters, case reports, other); 
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Figure 3.1. Flow diagram of the study selection used in evidence synthesis. 
SNP-single nucleotide polymorphism. 
 
3) Studies focused on UBC or where UBC data are described distinctly from a broader 
urothelial carcinoma cohort; 
4) Studies reporting an effect size; 
5) Studies reporting significant associations (for characteristics or prognosis); 
6) DNA sequence level variation described; 
7) The described SNPs could be identified. 
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Studies describing diagnostic, methodological procedures, gene-gene and gene-
environment interactions were excluded.  
Each study was assessed for quality by evaluating reporting adequacy. Inconsistency 
was regarded as mismatching data within the study (e.g. different SNP IDs reported 
in article sections). Data completeness was verified if all relevant data fields for a 
genetic associations study [8] were available to extract from the report. The quality 
criteria were part of the study selection process (e.g. studies stating variant relevance 
for an outcome without providing an effect size were regarded as having low quality 
and excluded from further evaluation).  
Data extraction 
Further information was extracted from each eligible study: year of publication, first 
author, patient subgroup (UBC, MIBC, NMIBC, or other), cancer subtype (urothelial 
carcinoma (UC) or other), ethnicity, sample size, SNP ID, locus, gene, effect allele, 
reference allele, effect allele frequency, effect size, corresponding 95% confidence 
intervals, p-value.  
Summarizing overlap in genetic associations and outcomes 
To see if previously reported genes may play a role across multiple UBC outcomes, 
results were put in a ranked table. Genes associated with many UBC endpoints are 
ranked high, whilst genes that were reported for one or few of the outcomes are ranked 
low. As such, we are able to suggest genes that are important for UBC prognosis 
overall and which genes are more likely to be outcome-specific (e.g. only associated 
with cancer recurrence).  
The resulting ranking acted as a guideline for identifying genes that were commonly 
observed for most of the prognostic outcomes and characteristics. Outcomes with at 
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least 20 genes were chosen and their functional roles were further described in 
additional detail.  
 
Functional annotation 
After summarizing the overlap, some outcomes have been associated with multiple 
genes. Every biological process is polygenic, and having bigger sets of identified 
genes helps to elucidate biological pathways behind the studied phenotype. We chose 
outcomes with the largest number of reported genes and submitted those sets to the 
DAVID Functional Annotation Tool [9]. The tool groups genes by their functional 
similarity, using information from well-known databases, such as Gene Ontology (GO) 
for biological mechanisms and KEGG for pathways, among others. Gene clustering 
was carried out with setting the highest level of classification stringency. A high level 
of stringency generates fewer clusters, but genes within them are associated more 
tightly. Moreover, to reduce the likelihood of describing false-positive clusters, only 
gene groups containing pathways with false discovery rates (FDR) of <5% were 
interpreted as valid results.  
Statistical analysis 
Overall, our search has resulted in multiple genes corresponding to various outcomes. 
As such, the resulting data is very difficult to describe in a comprehensive manner. To 
reduce the dimensionality of current data, we have performed a Principal Component 
Analysis (PCA). PCA can be seen as a form of an exploratory analysis to identify 
group-level correlations in the sample. It is a useful tool for improving the interpretation 
of data, as it allows visualizing similarities between groups with regard to chosen 
characteristics. In our analysis, we aimed to investigate the similarity between UBC 
outcomes in terms of their genetic background. 
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We have constructed a binary matrix for UBC outcomes and associated genes. Every 
gene and outcome combination took a value of ‘1’ in case association has been 
reported, and a value of ‘0’ if no associations were published in the literature.  As such, 
clinical outcomes that share genes would plot more closely, whilst an outcome that 
does not share any genes with other endpoints would plot far from other groups. In 
the currently reviewed literature, some outcomes have been investigated more often 
(e.g. recurrence and death), hence we have adjusted the size of data points in a PCA 
plot to represent the number of associated genes. First two principal components were 




For the current review, 373 full-text articles were evaluated in-depth, resulting in a final 
set of 112 articles for further summary (Figure 3.1). In total, 316 associations were 
extracted across all investigated outcomes (age (N=12, [10-21] ), stage (N=79,  [10, 
12, 17, 19, 22-65], tumour size (N=2 [66, 67]), grade (N=49 [10, 17, 26, 28, 31, 32, 34-
36, 41, 46, 49, 53, 57, 61, 65, 66, 68-74]), risk groups (N=15 [11, 13, 16, 23, 24, 29, 
30, 32, 39, 75, 76]), recurrence (N=81 [13, 22, 24, 29, 30, 39, 42, 48, 49, 51, 52, 68, 
70, 77-106]), progression (N=24, [25, 32, 45, 86-88, 106-111]), and death (N(cancer-
specific)= 12 [33, 42, 45, 100, 106, 112-116], N(overall)=42 [33, 42, 49, 55, 88, 89, 
110, 111, 117-121]).  
There was considerable heterogeneity across all associations, including assumed 
patterns of inheritance, studied ethnic populations, and outcome definitions.  
Age was investigated using multiple year cut-offs, namely: 50 [12], 56 [16], 60 [10, 15, 
21], 65 [11, 14, 17-20], and once as a continuous variable [13] (Supplementary Table 
3.2). 
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Tumour size was investigated either as using a cut-off of ≥3 cm [66] or defined as a 
large tumour, corresponding to stages T1-T4 [67] (Supplementary Table 3.3).  
Tumour stage was analysed using multiple combinations. Broadly, we have 
differentiated between stage corresponding to NMIBC and MIBC cases. For studies 
reporting on NMIBC, following endpoints were used: tumours of Tis [60, 64], T1 [36], 
Ta+T1 [12, 17, 35, 38, 53, 57, 61-63, 65], and Ta+T1+Tis [31, 58, 59] (Supplementary 
Table 3.4). As for MIBC, most studies have defined the primary outcome as T2+ 
staged tumours [10, 19, 22-31, 33-56]. However, some associations have been 
reported for a merged group of T2+ and T1 stages [32, 33].  
Most reports on grade can be roughly categorized into containing either low- or high-
grade UBC cases. Low-grade UBC definitions were as follows: G1 [17, 53, 61, 69], G2 
[34, 57, 61, 69], G1+G2 [35], low-grade [68, 70], and G1+G2+papilloma [31]. High-
grade UBC was usually defined as grade 3 UBC [10, 26, 28, 31, 35, 36, 46, 49, 66, 
69, 71-74], a combination of G2 and G3 NMIBC [53, 65], and some studies have 
reported estimates for grade 4 tumours, without a reference for the grading system 
used (G3+G4 [41]) and G2+G3+G4 [32]) (Supplementary Table 3.5).  
It was common for studies to classify UBC as a disease of low- or high-risk, that 
correspond to various combinations of clinical stage and grade. For low-risk, 
researchers used the following definitions: TaG2 [32, 33], TaG1 [32], TaG1-2 [11, 13, 
16]. In contrast, high-risk tumours were defined as: TaG2-3+T1G1-3 [24, 29, 30, 39, 
75], TaG3+T1G2-3 [23], G2-3 with T1-4 [76], and TaG3+T1 [32]. (Supplementary 
Table 3.6). 
For genetic associations with tumour recurrence, studies mostly focused on NMIBC 
cases (except for few reports considering UBC group overall [48] or MIBC [49, 70]). 
NMIBC recurrence was investigated as an overall outcome [48, 68, 77, 88, 89, 93, 96, 
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103, 105], or in specific groups: patients younger than 64 years [97], patients not 
treated with Bacillus Calmette-Guérin (BCG) therapy: [39, 42]; BCG-treated patients: 
[22, 24, 29, 30, 39, 42, 51, 52, 78-82, 84-86, 92, 94, 95, 98, 99, 101, 102, 106], patients 
treated only with transurethral urinary bladder resection (TURBT): [87, 100]; patients 
who have received both TURBT and BCG treatments: [90, 91]; patients having 
received treatments of TURBT and epirubicin [104], and recurrence only among low-
risk NMIBC: [13, 83] (Supplementary Table 3.7).  
Progression was defined as an increase of stage in NMIBC group [32, 108, 109] or 
UBC [107] overall. Also, transition from NMIBC to MIBC or metastatic disease [86-88] 
was considered a disease progression, sometimes expanding the latter definition to 
include cancer-specific death [106, 111]. In other cases, alternative definitions were 
considered, namely occurrence of metastases [25, 45] and a confirmed relapse 
among MIBC [110] (Supplementary Table 3.8).  
In terms of death outcomes, there were two broad groups of overall- [32, 42, 55, 88, 
89, 111, 117-120] and cancer-specific [33, 42, 45, 100, 106, 112-116] survival 
endpoints (Supplementary Table 3.9).   
Retrieved data and detailed study characteristics, including outcome definition for 
each study, are presented in Supplementary Tables 3.2-9.  
Overlap between the outcomes  
A summary table of existing overlap between outcomes and associated genes is 
presented in Table 3.1. OGG1 (rs2304277, rs1052133) was the most commonly 
reported gene, having been associated with patient age [18], tumour stage [53], grade 
[53], recurrence [39, 77], and risk group [39]. Associations on OGG1 and UBC did not 
cluster within a clearly defined subgroup and instead showed relationships with 
various characteristics: increased age at diagnosis (>65 years) [18] and elevated risks 
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of the following: non-muscle-invasive and invasive UBC [53], low- and high-grade 
tumours [53], rate of recurrence [39, 77], and high-risk tumours [39].  






Age / Grade / Recurrence / Risk group / Stage 1 OGG1 
Death / Grade / Recurrence / Risk group / 
Stage 
2 TP53, MDM2 
Age / Grade / Risk group / Stage 1 CCND1 
Age / Recurrence / Risk group / Stage 1 XRCC7(PRKDC) 
Age / Death / Recurrence / Stage 1 XRCC1 
Grade / Progression / Risk group / Stage 1 HRAS 
Death / Grade / Recurrence / Stage 2 PDCD6, XPD(ERCC2) 
Age / Grade / Stage 1 H19 
Age / Death / Stage 1 EGFR 
Grade / Risk group / Stage 1 MSH6 
Death / Risk group / Stage 1 NQO1 
Progression / Recurrence / Stage 1 MIR146A 
Death / Grade / Recurrence 1 IL6 
Grade / Recurrence / Tumour size 1 TSP-1(THBS1) 
Death / Progression / Recurrence 1 NOS3 
Age / Recurrence / Risk group 1 TACC3/FGFR3 
Death / Grade / Stage 2 RAD51, MTHFR 
Recurrence / Risk group / Stage 2 CASP9, IL18 
Grade / Recurrence / Stage 4 CCR2, PPARG, GSTP1, XPC 
Risk group / Stage 1 XRCC5 
Progression / Stage 1 IL4 
Grade / Recurrence 1 IL31 
Progression / Recurrence 1 RGS1 
Age / Risk group 2 CASC11, TP63 
Death / Stage 2 TLR10, IL27 
Death / Recurrence 3 RGS2, GSTO1, XPF(ERCC4) 
Grade / Stage 4 LEPR, IGFBP3, XPG(ERCC5), PSCA 
Recurrence / Stage 4 IL17A, TNFA, GPX1, NAMPT 
Death / Progression 4 NOD2, BCL2, RGS5, ERCC1 
Tumour size 1 WISP1(CCN4) 
Risk group 2 POLG2, BRCA2 
Age 3 PCAT1, POR, HOTAIR 
Grade 6 
MIR143_CARMN, TMEM129_TACC3_FGFR3, 
CLPTM1L, MYC, TNFRSF10A (TRAILR1, DR4), 
CCNE1 
Progression 9 
DGCR8, NOS2, CDKN2A, TGFB1, RGS4, RGS7, 
IL10, UNG, RGS14 
Stage 15 
CD44, SDF1(CXCL12), CXCR4, SLC23A1, 
MATR3, DNAJC18, C13ORF31(LACC1), CD4, 
CFH, XRCC3, IL22, MMP12, COX2(PTGS2), 
P21(CDKN1A), PMS2 
Death 20 
IL8RB(CXCR2), RPTOR, RGS12, GSTO2, MRE11, 
RB1CC1, EPHX1, BCL2L1, GATA3, UGT1A1, 
XRCC4, PIK3R1, DRD4, RGS3, TERT, CD80, 
AURKA, AKT2, TGFBR1, GNB3 
Recurrence 26 
VDR, Survivin(BIRC5), MMP2, GPX4, NFKBIA, 
CDH1, IGF1, GLI2, NEIL2, GLI3, 
RNASEN(DROSHA), IL8(CXCL8), ICAM1, IFN-G, 
SHH, RGS13, RGS16, RGS10, DDX20, GSS, 
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CWC27, SOD1, ERCC6, NRAMP1(SLC11A1), 
ALDH2, TNFRSF10A (TRAILR1, DR4) 
 
A set of two genes (TP53 (rs1042522, rs1154065) and MDM2 (rs2279744) have also 
been reported for multiple endpoints, specifically UBC grade [41, 68], stage [24, 40, 
41], recurrence [24, 68, 100], survival [100, 116], and risk group [24, 75].  For most 
outcomes (death, risk category, grade, stage) the associations for MDM2- and TP53-
related variants were in opposite directions.  
In terms of number of genes corresponding to a single endpoint, tumour recurrence 
was the outcome with the highest sum of genes (N=28) showing associations; followed 
by death (N=21) (Table 3.1).  
To elucidate any unifying pathways between these genes, gene sets for recurrence 
and death were submitted to the functional annotation tool DAVID [9]. 
For recurrence, DAVID identified has identified two gene clusters of similar functions 
that contained pathways with acceptable FDR values (Supplementary Table 3.10). 
The first group (enrichment score=2.72) was formed entirely of RGS family genes 
(RGS10, RGS13, RGS16). The second cluster (enrichment score=2.42) was formed 
by GLI2, GLI3, and SHH genes. Out of ten functional terms within the cluster, one was 
of satisfactory FDR and reached Bonferroni-adjusted <0.05, termed “hindgut 
morphogenesis”.  
For individual enriched pathways, 20 have yielded FDR<5% and are listed in 
Supplementary Table 3.11. Three functional terms – “hindgut morphogenesis”, 
“Pathways in cancer”, and “positive regulation of transcription from RNA polymerase 
II promoter” have shown both low FDR rates and were also below the conventional 
level of statistical significance (p<0.05) after multiple-comparison adjustment.  
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For genes associated with UBC survival, the submitted set retrieved six functional 
clusters in total; however, no individual terms had acceptable FDR values.  
Nonetheless, there were multiple individual functional pathways with FDR<5% were 
identified instead (Supplementary Table 3.12). One term, “Pancreatic cancer”, has 
reached a Bonferroni-adjusted statistical significance (p=0.05).  
Finally, a performed PCA analysis for previously-reported genetic associations 
showed UBC recurrence to be the most distinct outcome (Figure 3.2), with tumour 
stage and grade also showing significant deviations from other endpoints. 
 
Figure 3.2. Principal Component Analysis for Genetic Associations with 
Urinary Bladder Outcomes. Data point sizes are indicative of the number of 




In the current review, we have summarized existing evidence for single-SNP genetic 
associations with UBC characteristics (tumour size, stage, grade, patient’s age) and 
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prognostic outcomes (recurrence, progression, survival). There were multiple 
associations for considered endpoints with limited overlap. Based on these data, we 
have made several observations. 
It is widely accepted that complex disease genetic architecture is highly polygenic 
[122]. However, currently-summarized list of associations for UBC outcomes and 
characteristics is far from exhaustive. It is essential to note future studies with higher 
per-study power will contribute additional associations and will clarify the validity of 
those already reported.  
Importantly, our review underscores the sensitivity of outcome definition in genetic 
studies. It has been demonstrated that genetic variants for UBC risk are unlikely to be 
relevant for prognosis [123], and our report implies prognostic outcomes demonstrate 
further within-group heterogeneity. Interestingly, the PCA revealed the largest 
differences for direct prognostic outcomes: UBC death and progression showed 
similar characteristics, whilst UBC recurrence significantly deviated from the group. 
From a biological perspective, cancer recurrence is not an equivalent to progression 
or death, and it is likely the mechanisms involved are triggered and organised via 
different pathways. Similarly, tumour characteristics (grade, stage, size) and patient 
characteristics (age) are likely different entities in terms of genetic contribution.  
When trying to elucidate unifying pathways for multiple genes involved in certain 
outcomes, UBC recurrence was found to be associated with terms that relate to 
formation of a new tissue (e.g. “hindgut morphogenesis”). In contrast, functional 
pathway terms were different for death as an outcome and indicate a separate 
biological mechanism. Interestingly, the most promising associated term for death was 
“Pancreatic cancer”, which exhibits very low survival rates in comparison to cancers 
of any other site [124].  
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In the light of our analyses, UBC prognosis may represent a complex phenotype, and 
the current review indicates different outcomes imply distinct genetic associations. The 
genetic relationships may overlap but, nonetheless, should be treated as independent 
endpoints.  
Importantly, the review identifies a number of commonly-reported genes, specifically 
OGG1, TP53, and MDM2. Given that they are reported most often, we would suggest 
these targets might be of important interest to investigate in further studies. OGG1 
encodes a protein involved in base excision repair (BER) pathways to protect cells 
from oxidative stress [125]. Although having a clear role in mutagenic processes, 
OGG1-null mice showed only moderate increases in malignancy rate, likely due to 
effective alternative damage repair pathways [126]. Evidence from multiple meta-
analyses [127-129] of OGG1 involvement in UBC cancerogenesis is contradictory; 
and if having a genuine effect, is more likely to play a supporting role in a multi-stage 
process rather than being the main cause of it [126]. It is also probable that the 
establishment of the type and direction of genetic associations requires larger 
populations (underscoring sufficient sample sizes for different ethnicities), not yet 
available to researchers.  
Additionally, the link between TP53 and MDM2 genes has been extensively reported 
in the literature, offering an attractive pharmacological target in cancer treatment [130]. 
P53 protein acts as a tumour suppressor, which is negatively regulated by MDM2 
oncoprotein. The pattern is somewhat mirrored in observed associations, where 
variation in SNPs of the two genes seemed to correspond to effects in opposite 
direction (e.g. SNPs in TP53 increased the risk of T2+ stage, whist alterations in 
MDM2 showed reduced risk of invasive tumours).  
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Collectively, OGG1, TP53, and MDM2 are relevant for multiple essential DNA-
preserving cellular mechanisms, and hence would be expected to have importance for 
a variety of UBC characteristics and outcomes, as observed in our review. 
The limitations of our study are important to acknowledge. Many reports have 
analysed different ethnicities, which alone does not undermine the reported 
associations, but makes inter-population relevance improbable due to differencing 
allele frequencies [131]. Moreover, assumed genetic patterns of inheritance (e.g. 
recessive, dominant, additive) differed highly between the studies, without a clear 
preference for the chosen model. Usually, the reported model was chosen ad hoc as 
a consequence of being statistically significant, making it difficult to be confident the 
reported model reflected true genetic architecture of the association. Since 
associations were highly heterogeneous, we were unable to carry out a meta-analysis 
(which would have provided a preferred summary of these data). Furthermore, the 
majority of included studies were of candidate-gene design; we would expect different 
results if all studies followed an agnostic genome-wide association approach. Finally, 
sample sizes were limited, and it is difficult to establish whether all reported 
associations are robust. 
It is important to note we were only able to analyse reported associations, and it is 
assumed many studies have not been published due to negative results. We aimed to 
include all available publications, but anticipate our results are affected by some level 
of publication bias. The lack of external replication studies for genetic associations is 
detrimental to translating science into practice, as many genetic findings are likely to 
be false-positive [132]. Optimally, only validated variants would be included in review 
studies. We underscore the importance of validation efforts for future studies to be 
able summarizing only unambiguous variants.   
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To conclude, we have summarized existing genetic associations for tumour and 
patient characteristics and disease prognosis for UBC. Multiple loci have been 
identified that demonstrate little consensus and highlight the possibility of UBC 
prognostic outcomes being unique entities in the context of genetic contribution. We 
recommend that further replication of previously identified SNPs should be 
undertaken. Consecutive formal reviews of existing associations will help facilitate 
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Non-muscle-invasive bladder cancer (NMIBC) causes a considerable health burden 
due to the high recurrence and progression rates. Past studies have identified multiple 
candidate loci associated with NMIBC prognosis, albeit lacking validation. Moreover, 
scarce reports exist on genetic susceptibility to independent prognostic predictors of 
NMIBC, such as stage or grade. Our objective was to investigate genetic associations 
with NMIBC tumour and patient characteristics at the time of diagnosis. 
METHODS 
A sample of 653 NMIBC cases come from the Bladder Cancer Prognosis Programme 
(BCPP). Replication of the significant findings was conducted in the Nijmegen Bladder 
Cancer Study (NBCS) cohort (N=,1470). Genome-wide association study (GWAS) 
was carried out for outcomes of tumour size (as continuous variable in centimetres), 
stage (Tis and T1 vs Ta), grade (G3 vs G2 and G1), and age (as continuous (years) 
and dichotomous (70.2 years as a cut-off) variables). 
RESULTS 
Significant (P<5E-08) associations (N=61) with tumour size, stage, grade, and age 
were identified in the GWAS discovery stage. None of the variants were independently 
significantly associated in the replication cohort. A meta-analysis of both cohorts 
suggests rs180940944 (13q13.3 locus, NBEA) was associated with tumour size as a 
continuous variable (ß=0.9 cm, p=2.92E-09). However, other SNPs in this region did 
not show evidence of association in the meta-analysis.  
CONCLUSIONS 
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Our study suggests rs180940944 (NBEA) is associated with an increased NMIBC 
tumour size at the time of diagnosis. Given study limitations, further replication is 
essential to validate the finding. Current study reports on a genome-wide association 
study on non-muscle-invasive bladder cancer tumour and patient characteristics. We 
suggest NBEA gene might be associated with increased tumour size at the time of 




Urinary bladder cancer (UBC) accounts for 430,000 new cases worldwide annually, 
with 70-80% of new cases presenting as non-muscle-invasive bladder cancer 
(NMIBC) [1]. NMIBC causes significant burden on healthcare systems due to high 
recurrence and progression rates (5-year recurrence rate: 50-70%, 5-year progression 
rate: 10-30%) [1]. Considerable clinical improvements could be made by better, even 
personalised, prognostication and risk stratification [1]. There have been several 
attempts to apply different approaches for accurate disease prognostication, and 
although descriptive on a population-level, a substantial lack of precision of individual 
outcomes remains [2], requiring ongoing improvement. 
Few candidate-gene studies of UBC prognosis exist, with limited successful replication 
[3-5].  A recent study reported that out of 114 reported loci for UBC progression and 
prognosis, only six single nucleotide polymorphisms (SNPs) showed significant 
associations in an independent cohort, namely: NMIBC progression (rs6678136 
(RGS4), rs11585883 (RGS5)), recurrence among Bacillus Calmette–Guérin (BCG)-
treated NMIBC patients (rs1799793 (ERCC2), rs187238 (IL18)), and muscle-invasive 
bladder cancer (MIBC) overall survival (rs12035879 (RGS5), rs2075786 (TERT)) [3]. 
Powerful GWAS studies on NMIBC prognosis show promise, but are still ongoing [6]. 
A previous attempt to include genetic variation failed to increase prognostic tool 
performance [7], suggesting the issue is more complex. However, latter study utilised 
a relatively small panel of SNPs (170,000), which has lower power of discovering 
significant loci in comparison to genotype-imputed sets harbouring millions of variants 
for analysis [8]. The inter-study lack of consensus might be due to several reasons: 
spurious findings, lack of statistical power, and variation in outcome definition.  
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Other studies also suggest significant genetic signals might be only present for 
tumours of certain grade or stage [9, 10]. However, reports on genetic associations for 
characteristics that directly influence NMIBC outcome are scarce, precluding further 
investigations on their relevance for NMIBC prognostication.  
To provide more evidence on potential genetic associations, we have performed a 
GWAS on key NMIBC characteristics (stage, grade, size of the tumour, risk category 
assigned by The European Organization for Research and Treatment of Cancer  
(EORTC)), as well as age at the time of diagnosis within the West Midlands’ Bladder 
Cancer Prognosis Programme (BCPP) cohort including replication in the Nijmegen 




Participants and genotyping 
BCPP is a prospective cohort that initially recruited 1,544 eligible patients and is 
described in more detail elsewhere [11]. Clinical data on stage, grade, and size of 
tumours and demographic information (age, gender) were gathered with bespoke 
case report forms. Tumour size of the largest tumour was established visually whilst 
performing transurethral resection of the bladder tumour (TURBT). Blood samples of 
888 participants with confirmed UBC were genotyped on the Illumina Infinium 
OmniExpress-24 BeadChip array at deCODE Genetics (Reykjavik, Iceland).  
Tumours of stages pTa, pT1, or pTis were included to limit our analyses to NMIBC, 
resulting in a dataset of 712 cases. 
 
Quality control (QC)  
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QC procedures were carried out using PLINK v1.90 [12]. The exact thresholds applied 
and number of exclusions per step are outlined in Figure 4.1.  
 
Figure 4.1. A flowchart of the main steps in the GWAS analysis.  
BCPP-Bladder Cancer Prognosis Programme; HWE-Hardy-Weinberg equilibrium; 
MAF-minor allele frequency; MIBC-muscle-invasive bladder cancer; NBCS-Nijmegen 
Bladder Cancer Study; NMIBC-non-muscle-invasive bladder cancer; PCA-principal 
component analysis; QC-quality control; SD-standard deviation; SNP-single 
nucleotide polymorphism; UBC-urinary bladder cancer. 
 
Generic QC procedures per individual excluded those with an inconclusive gender 
call, excessive genotype missingness rate, increased or reduced genotype 
heterozygosity rate, duplicate samples, and related individuals. 
To avoid any bias introduced by population stratification, a principal component 
analysis (PCA) was carried out. Investigation of PCA plots resulted in exclusion of 
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clear population outliers. Genomic inflation factor () value was estimated for all 
outcomes of interest; none of the values exceeded 1.03.  
Marker-specific QC procedures covered excluding SNPs deviating from the Hardy-
Weinberg equilibrium, exceeding acceptable missing rate, and rare variants.  




Imputation utilised a two-step approach: haplotype phasing by Eagle v2.3.2 [13], 
followed by genotype imputation with IMPUTE2 [14], using 1000 Genomes Phase 3 
[15] as a reference panel in the genome build 19 (GRCh37/hg19). Once imputed, the 
dataset was filtered for SNPs with info values (an imputation accuracy measure) of 
>0.3 and MAFs of >1%, resulting in a dataset containing 11,914,228 markers available 
for genetic association analyses.   
 
Statistical analysis 
Statistical analyses were performed using SNPtest v2.5.2 [8] and R statistical package 
(v3.3.2) [16]. 
To establish the relation between germline variation and tested outcomes, linear 
regression was used for continuous variables and logistic regression for all binary 
endpoints. Age was tested as a continuous (years) and binary variable (mean was 
considered as a cut-off value for categorisation (resulting in strata of </ 70 years)). 
Tumour size (cm) was tested as a continuous and categorical variable (</ 3cm [17]). 
Stage (Tis and T1 versus Ta) and grade (G3 versus G2 and G1) were treated as binary 
variables. In addition, low-, intermediate-, and high-risk EORTC categories were 
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assigned to each NMIBC case and were tested as a dichotomous variable of high- 
versus low- and intermediate-risk groups [17].  
All analyses were adjusted for participant gender and first five genetic principal 
components to increase estimate precision and to adjust for any potential residual 
population stratification bias. An association was held significant if p-value <5E-08, 
and promising if below 5E-06. 
Post-GWAS power calculations were carried out in web-based GAS Power Calculator 
[18].  
Manhattan and Quantile-quantile (QQ) graphs were plotted for each tested outcome. 
For significant hits, regional association plots were constructed using LocusZOOM tool 
[19], except for hits that have not yet been assigned an ID (rsID). 
 
Functional annotation  
Identified significant SNPs were mapped using a web-based SNPnexus tool [20], with 
Ensembl [21] (Version 74) as a functional annotation system.  
 
Replication 
Genome-wide significant hits were attempted to replicate in a sample of 1,470 NMIBC 
cases from the NBCS [22] (Figure 4.1). Briefly, the NBCS recruited UBC patients via 
the population-based cancer registry in the Nijmegen region. Eligible cases were 
diagnosed during 1995-2006 and were under the age of 75; additional data was 
collected via linkage with hospital-patient records [22], including tumour size, which 
was reported after visual evaluation during cystoscopy. Details of genotype data 
cleaning and initial analysis is provided in detail elsewhere [22].  
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We used META [23] software to perform meta-analysis on association results of both 
cohorts and calculated a combined p-value per SNP. An inverse-variance method was 
used, assuming a random-effects model. I2 index and p-value were calculated to 




Baseline clinical characteristics of the discovery and replication cohorts are shown in 
Table 4.1. 
Majority of cases in BCPP were male (78.1%), with an average age of 70 years. 
Tumour size mean was 2.5 cm, and most of the participants were diagnosed with 
stage Ta (68%) and T1 (30.5%) tumours. More than a third of cases presented as G2 
(37.5%), followed by G3 (31.7%) and G1 (29.2%) NMIBC. The distribution of variable 
categories and measures were similar between the BCPP and NBCS cohorts.  
In the discovery-stage analysis, a total of 61 SNPs, corresponding to 29 different 
regions, showed genome-wide statistically significant associations with at least one of 
the outcomes. Out of those, 20 loci were mapped to genes (all intronic regions) 
(Table 4.2). Significant associations were observed for size and age as continuous 
variables, as well as for binary outcomes of stage, grade, and age. 
Most of the SNPs (N=47) were found to be associated with tumour size, the effect 
sizes ranging from 0.65 (rs35225990 in FAM194B, p= 2.85E-08) to 2.6 (rs370572716 











Age, years     
Mean (SD) 70.2 (10.5) 62.5 (9.7) 
Median (range) 
71.5 (34.3 - 
91.5) 
64 (25.0 - 91.0) 
Age, years     
<70 (%) 298 (45.6) 329 (22.4) 
≥70 (%) 355 (54.4) 1141 (77.6) 
Sex     
Males (%) 510 (78.1) 1208 (82.2) 
Females (%) 143 (21.9) 262 (17.8) 
Tumour size (cm)     
Mean (SD) 2.5 (1.9) 2.4 (1.3) 
Median (range) 2.0 (0.2-15.0) 2.0 (0.05 - 7.5) 
Missing (%) 20 (3.1) 1168 (79.5) 
Stage     
Ta (%) 444 (68.0) 1056 (71.8) 
T1 (%) 199 (30.5) 349 (23.7) 
Tis (%) 10 (1.5) 65 (4.4) 
Grade     
G1 (%) 191 (29.2) 401 (27.3) 
G2 (%) 245 (37.5) 618 (42.0) 
G3 (%) 207 (31.7) 304 (20.7) 
Missing (%) 10 (1.5) 147 (10.0) 
EORTC risk 
category 
    
Low (%) 66 (10.1) NA 
Intermediate (%) 276 (42.3) NA 
High (%) 311 (47.6) NA 
BCPP-Bladder Cancer Prognosis Programme; EORTC-European Organisation for 
Research and Treatment of Cancer; SD-standard deviation; NA-Not available; 




Table 4.2. Genetic associations with NMIBC tumour and patient characteristics at baseline in the discovery (BCPP) and 
replication (NBCS) stages and a joint analysis. Most promising SNP is marked in bold. 
      Discovery cohort (BCPP) Replication cohort (NBCS)    
Phenotype rsID BP Locus REF EFF MAF  ß (SD)  
OR  
(95% CI) 





P (joint) Annotation 
Size (cm) rs180940944 35950093 13q13.3 C T 0.03 
0.97 
(0.16) 
  6.73E-09 0.004 
0.71 
(0.80) 
  0.38 2.92E-09 NBEA 
Size (cm) rs113705641 5375733 3p26.1 A G 0.02 
1.38 
(0.25) 
  2.99E-08 0.02 
0.50 
(0.34) 
  0.14 0.03 - 
Size (cm) rs74603364 79509518 6q14.1 C T 0.02 
1.38 
(0.22) 
  6.54E-10 0.02 
0.50 
(0.31) 
  0.10 0.03 - 
Size (cm) rs143076258 136382230 4q28.3 G A 0.02 
1.18 
(0.20) 
  9.21E-09 0.01 
0.35 
(0.38) 
  0.36 0.04 - 
Size (cm) rs4646911 34856662 6p21.31 G A 0.01 
1.67 
(0.30) 
  3.76E-08 0.01 
0.47 
(0.53) 
  0.37 0.05 TAF11 
Size (cm) rs180910528 79821806 6q14.1 A C 0.01 
1.74 
(0.28) 
  4.67E-10 0.01 
0.43 
(0.36) 
  0.23 0.09 - 
Size (cm) rs187040828 79802426 6q14.1 T C 0.01 
1.74 
(0.28) 
  4.89E-10 0.02 
0.36 
(0.34) 
  0.29 0.12 - 
Size (cm) rs80026656 53756380 18q21.2 A G 0.01 
1.50 
(0.26) 
  1.27E-08 0.02 
0.29 
(0.31) 
  0.34 0.13 CTD-2008L17.2 
Size (cm) rs35225990 46117489 13q14.13 C T 0.07 
0.65 
(0.12) 
  2.85E-08 0.06 
0.11 
(0.17) 
  0.51 0.14 FAM194B 
Size (cm) rs144383242 79489625 6q14.1 G T 0.01 
1.66 
(0.26) 
  1.88E-10 0.01 
0.30 
(0.34) 
  0.37 0.14 - 
Size (cm) rs117587674 79432536 6q14.1 G A 0.01 
1.67 
(0.26) 
  1.70E-10 0.01 
0.30 
(0.34) 
  0.37 0.14 - 
Size (cm) rs180991319 36850863 19q13.12 T A 0.01 
1.87 
(0.33) 
  2.35E-08 0.00 
0.12 
(0.98) 
  0.90 0.14 ZFP14 
Size (cm) rs117407537 35652859 13q13.3 G A 0.03 
0.98 
(0.17) 
  2.16E-08 0.02 
0.15 
(0.30) 
  0.62 0.15 NBEA 
Size (cm) rs77827766 35808410 13q13.3 G C 0.03 
1.00 
(0.18) 
  1.58E-08 0.02 
0.15 
(0.30) 
  0.61 0.15 NBEA 
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Size (cm) rs117318492 35776449 13q13.3 T C 0.03 
1.00 
(0.18) 
  1.58E-08 0.02 
0.15 
(0.30) 
  0.61 0.15 NBEA 
Size (cm) rs112579236 35742893 13q13.3 A G 0.03 
0.96 
(0.17) 
  3.47E-08 0.02 
0.14 
(0.29) 
  0.62 0.15 NBEA 
Size (cm) rs117989790 35758974 13q13.3 G C 0.03 
1.01 
(0.18) 
  1.47E-08 0.02 
0.15 
(0.30) 
  0.61 0.15 SCAND3P1 
Size (cm) rs117286929 35804780 13q13.3 A G 0.03 1.01(0.18)   1.52E-08 0.02 0.15(0.30)   0.61 0.15 NBEA 
Size (cm) rs200899670 46170799 15q21.1 TCAAA T 0.01 
2.47 
(0.34) 
  1.63E-12 0.03 
0.42 
(0.29) 
  0.16 0.16 RP11-718O11.1 
Size (cm) rs143664498 35919424 13q13.3 C A 0.03 
0.99 
(0.17) 
  1.84E-08 0.02 
0.12 
(0.29) 
  0.69 0.18 NBEA 
Size (cm) rs117382849 35924241 13q13.3 A G 0.03 
0.99 
(0.17) 
  1.90E-08 0.02 
0.12 
(0.29) 
  0.69 0.18 NBEA 
Size (cm) rs117576619 35887557 13q13.3 T C 0.03 
1.00 
(0.17) 
  1.66E-08 0.02 
0.12 
(0.29) 
  0.69 0.18 NBEA 
Size (cm) rs144366722 35845426 13q13.3 A G 0.03 
1.00 
(0.18) 
  1.57E-08 0.02 
0.12 
(0.29) 
  0.69 0.18 NBEA 
Size (cm) rs116854115 35865482 13q13.3 T C 0.03 
1.01 
(0.18) 
  1.57E-08 0.02 
0.12 
(0.29) 
  0.69 0.18 NBEA 
Size (cm) rs151184057 5665859 2p25.2 C T 0.01 
1.51 
(0.27) 
  3.88E-08 0.02 
0.19 
(0.35) 
  0.59 0.19 - 
Size (cm) rs78813710 3160739 7p22.2 T G 0.01 
1.57 
(0.28) 
  3.12E-08 0.01 
0.15 
(0.41) 
  0.72 0.21 - 
Size (cm) rs117889651 35987813 13q13.3 A G 0.03 
0.92 
(0.17) 
  3.91E-08 0.03 
0.06 
(0.26) 
  0.83 0.24 NBEA 
Size (cm) rs148373773 14919905 6p23 AC A 0.03 
0.96 
(0.17) 
  3.17E-08 0.05 
0.07 
(0.20) 
  0.72 0.24 - 
Size (cm) rs75585701 2194093 3p26.3 C G 0.02 
1.60 
(0.22) 
  2.66E-12 0.02 
0.09 
(0.33) 
  0.79 0.25 CNTN4 
Grade (G3 
vs G2 and 
G1)  




5.13E-09 0.05   
1.11  
(0.74-1.65) 
0.60 0.26 TRAV16 
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Size (cm) rs75801131 70017072 18q22.3 C A 0.02 
1.53 
(0.25) 
  2.08E-09 0.02 
0.04 
(0.32) 
  0.90 0.28 - 
Age (years) rs142492877 98482828 9q22.32 A G 0.04 
-0.95 
(0.16) 
  1.05E-08 0.03 
-0.03 
(0.12) 
  0.79 0.29 - 
Size (cm) rs76779534 11737232 10p14 A G 0.02 
1.30 
(0.22) 
  5.57E-09 0.01 
-0.09 
(0.50) 
  0.86 0.33 - 
Size (cm) rs73570873 11737713 10p14 T A 0.02 
1.30 
(0.22) 
  4.97E-09 0.01 
-0.10 
(0.50) 
  0.84 0.34 - 
Size (cm) rs12265817 11738801 10p14 C T 0.02 
1.28 
(0.22) 
  6.82E-09 0.01 
-0.13 
(0.50) 
  0.79 0.36 - 
Grade (G3 
vs G2 and 
G1)  
rs116923391 22406144 14q11.2 C T 0.06   
3.86(2.38-
6.26) 
2.07E-10 0.06   
0.93(0.64-
1.37) 
0.69 0.37 - 




1.96E-08 0.15   
0.93 
(0.72-1.19) 
0.59 0.40 - 




1.62E-08 0.15   
0.92 
(0.72-1.18) 
0.57 0.40 AC000370.2 




1.95E-08 0.15   
0.92 
(0.72-1.18) 
0.56 0.41 - 




2.05E-08 0.15   
0.92 
(0.72-1.18) 
0.55 0.41 - 




1.97E-08 0.15   
0.92 
(0.72-1.18) 
0.53 0.41 - 




1.95E-08 0.15   
0.92 
(0.72-1.18) 
0.53 0.41 - 




2.18E-08 0.15   
0.91 
(0.71-1.17) 
0.50 0.42 - 




1.95E-08 0.15   
0.91 
(0.71-1.17) 
0.49 0.42 - 
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Stage (Tis 
and T1 vs 
Ta) 




4.18E-08 0.02   
1.39 
(0.84-2.32) 
0.10 0.44 SLCO1B1 
Stage (Tis 
and T1 vs 
Ta) 




4.23E-08 0.02   
1.39 
(0.84-2.32) 
0.10 0.44 SLCO1B1 
Size (cm) rs141965746 46544198 21q22.3 T G 0.02 
1.27 
(0.23) 
  3.61E-08 0.02 
-0.21 
(0.28) 
  0.45 0.47 ADARB1 
Stage (Tis 
and T1 vs 
Ta) 





3.73E-08 0.01   
1.13 
(0.50-2.56) 
0.76 0.48 ANKS6 
Size (cm) rs188958632 38266174 14q21.1 G A 0.01 
1.53 
(0.27) 
  1.42E-08 0.03 
-0.39 
(0.22) 
  0.08 0.56 TTC6 
Size (cm) rs189352109 145555946 2q22.3 T C 0.01 
1.46 
(0.26) 
  3.77E-08 0.01 
-0.75 
(0.45) 
  0.10 0.73 TEX41 
Size (cm) rs3752175 2516839 19p13.3 G A 0.01 
2.14 
(0.38) 
  3.57E-08 NA NA NA NA NA GNG7 
Size (cm) rs182792180 3164492 7p22.2 C T 0.01 
1.59 
(0.28) 
  2.18E-08 NA NA NA NA NA - 
Size (cm) rs117108730 35735418 13q13.3 T C 0.02 
1.10 
(0.19) 
  5.83E-09 NA NA NA NA NA NBEA 
Size (cm) rs117215187 35950090 13q13.3 C T 0.03 0.97(0.16)   6.73E-09 NA NA NA NA NA NBEA 
Size (cm) 14 38247577 14q21.1 CTGG C 0.01 
2.21 
(0.37) 
  2.46E-09 NA NA NA NA NA TTC6 
Size (cm) rs183885923 38310637 19q13.13 G A 0.01 
1.96 
(0.33) 
  5.64E-09 NA NA NA NA NA CTD-2554C21.2 
Size (cm) rs370572716 38920614 9p13.1 T A 0.01 
2.59 
(0.43) 
  4.04E-09 NA NA NA NA NA - 
Size (cm) rs2937268 66553607 1p31.3 C T 0.04 
0.94 
(0.16) 
  1.07E-08 NA NA NA NA NA PDE4B 
Size (cm) X 117703032 23q24 C T 0.01 
1.05 
(0.18) 
  7.93E-09 NA NA NA NA NA DOCK11 
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Size (cm) rs76670367 136254151 4q28.3 G T 0.02 
1.16 
(0.21) 
  2.97E-08 NA NA NA NA NA - 
Size (cm) rs151220146 180402493 2q31.2 CA C 0.01 
2.03 
(0.31) 
  8.03E-11 NA NA NA NA NA ZNF385B 
BP-base-pair; BCPP-Bladder Cancer Prognosis Programme; CI-confidence interval; EFF-effect allele; MAF-minor allele frequency 
(corresponds to the alternative allele); NBCS-Netherlands Bladder Cancer Study; NMIBC-non-muscle-invasive bladder cancer; OR-
odds ratio; REF-reference allele; rsID-SNP ID; SE-standard error, SD-Standard deviation. 
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One SNP in 9q22.32, rs142492877, showed statistically significant association with 
decreased age at diagnosis of almost one year (ß=-0.95, SE=0.16, p=1.05E-08). Age 
as a binary trait showed associations in the same direction, although in a different 
genomic region (7q31.33) with an odds ratio (OR) ranging between 2.46 (rs17149580, 
p=2.18E-08) and 2.51 (rs17149636, p=1.62E-08) across eight SNPs.  
The 14q11.2 locus showed strong associations with being diagnosed with a higher 
grade of NMIBC (rs15091489 in the TRAV16 gene (OR=3.42, 95%CI: 2.11-5.55, 
p=5.13E-09) and rs116923391 (OR=3.86, 95% CI: 2.38-6.26, p=2.07E-10)). 
Several protective variants for tumour stage were observed, namely: rs117248430 in 
ANKS6 (OR=0.003, 95%CI=1.71E-09-3895.6, p=3.73E-08), and two markers in the 
SLCO1B1 gene (rs76497895 (OR=0.03, 95%CI=0.001-0.83, p=4.18E-08); 
rs116946525 (OR=0.03, 95%CI=0.001-0.83, p=4.23E-08)). The strength of the effect 
and corresponding confidence intervals in ANKS6 might be explained by a very low 
MAF (<0.01%) among cases. 
A Manhattan plot for tumour size as a continuous outcome (Figure 4.2) also shows 
there are several polymorphisms in linkage disequilibrium (LD) with the leading SNP 




Figure 4.2. Manhattan and quantile-quantile plots for tumour size (cm) in the BCPP cohort. Blue and red horizontal lines indicate p 
values of <5E-06 and <5E-08, respectively. Highlighted variant shows the SNP reaching statistical significance in the meta-analysis of 
BCPP and NBCS (independent association was observed in the BCPP, and no significant effect was detected among NBCS 
participants only).  
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Figure 4.3. Manhattan and Quantile-quantile plots for age (years) in the BCPP cohort. Blue and red horizontal lines indicate 
p values of <5E-06 and <5E-08, respectively. 
 
Figure 4.4. Manhattan and Quantile-quantile plots for age (<70.2/≥70.2 years) in the BCPP cohort. Blue and red horizontal 
lines indicate p values of <5E-06 and <5E-08, respectively. 
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Figure 4.5. Manhattan and Quantile-quantile plots for tumour grade (G3 vs G2 and G1) in the BCPP cohort. Blue and red 
horizontal lines indicate p values of <5E-06 and <5E-08, respectively. 
 
Figure 4.6 Manhattan and Quantile-quantile plots for tumour stage (Tis and T1 vs Ta) in the BCPP cohort. Blue and red 
horizontal lines indicate p values of <5E-06 and <5E-08, respectively. 
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Figure 4.7. Manhattan and Quantile-quantile plots for EORTC risk category (High vs Low and Intermediate) in the BCPP 
cohort. Blue and red horizontal lines indicate p values of <5E-06 and <5E-08, respectively. 
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Regional association plot of 13q13.3 (Figure 4.8) in the BCPP confirms high LD with 
surrounding variants, all mapping to the NBEA gene (although they did not reach the 
statistical significance). Regional association plots for the remaining SNPs identified 
in the discovery stage are presented in Figures 4.9-4.35.  
In the replication stage, 50 out of 61 SNPs were available to test in NBCS (Table 4.2).  
None of these SNPs were significantly associated with the same outcomes in NBCS. 
A meta-analysis of both cohorts showed variant rs180940944 in 13q13.3 locus to be 
associated with increased tumour size at diagnosis (ß=0.96, SE=0.16, p=2.92E-09), 
although the effect is likely driven by BCPP data. Nevertheless, low I2 estimate (I2=0%, 
p(heterogeneity)=0.75) indicated there was no significant heterogeneity. 
 
Figure 4.8. Regional association plot for 13q13.3 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort (annotated SNP has reached statistical 
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Figure 4.9. Regional association plot for 
1p31.3 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.10. Regional association plot for 
2p25.2 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.11. Regional association plot for 
2q22.3 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.12. Regional association plot for 
2q31.2 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.13. Regional association plot for 
3p26.1 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.14. Regional association plot for 
3p26.3 locus with tumour size (cm) in 
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Figure 4.15. Regional association plot for 
4q28.3 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.16. Regional association plot for 
6p21.31 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.17. Regional association plot for 
6p23 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.18. Regional association plot for 
6q14.1 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.19. Regional association plot for 
7p22.2 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.20. Regional association plot for 
9p13.1 locus with tumour size (cm) in 
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Figure 4.21. Regional association plot for 
10p14 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.22. Regional association plot for 
13q14.3 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.23. Regional association plot for 
14q21.1 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.24. Regional association plot for 
15q21.1 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.25. Regional association plot for 
18q21.2 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.26. Regional association plot for 
18q22.3 locus with tumour size (cm) in 
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Figure 4.27. Regional association plot for 
19p13.3 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.28. Regional association plot for 
19q13.12 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
 
Figure 4.29. Regional association plot for 
19q13.13 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.30. Regional association plot for 
21q22.3 locus with tumour size (cm) in 
NMIBC patients of the BCPP cohort. 
 
Figure 4.31. Regional association plot for 
7q31.3 locus with age as a binary trait 
(</≥ 70.2 years) in NMIBC patients of the 
BCPP cohort. 
 
Figure 4.32. Regional association plot for 
9q22.32 locus with age (years) in NMIBC 
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Figure 4.33. Regional association plot for 
9q22.33 locus with stage as a binary trait 
(Tis and T1 vs Ta) in NMIBC patients of 
the BCPP cohort. 
 
Figure 4.34. Regional association plot for 
12p12.1 locus with stage as a binary trait  
Figure 4.35. Regional association plot for 
14q11.2 locus with grade as a binary trait 
(G3 vs G2 and G1) in NMIBC patients of 
the BCPP cohort 
 
. (Tis and T1 vs Ta) in NMIBC patients of 
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We have investigated genetic associations with NMIBC tumour (size, stage, grade) 
and patient (age, EORTC risk category) characteristics at the time of diagnosis within 
the BCPP cohort.  
Multiple loci were identified in the discovery stage that are novel in the context of 
NMIBC. One SNP, rs180940944, has reached statistical significance in a meta-
analysis of two NMIBC cohorts, mapping to the intronic region of the NBEA gene on 
13q13.3. However, associations of other SNPs in the NBEA have failed to be 
reproduced.  
NBEA proteins have been mostly observed to play a significant role in synapse 
development and function [24]. NBEA dysregulation does not affect the establishment 
of synapses per se, but rather their intra-cellular organisation [24]. An in-depth analysis 
revealed impaired synaptic ability was mostly due to the inappropriate distribution of 
actin, a protein essential for synapse cytoskeleton structure [24]. The effect is most 
likely present due to alterations in the Golgi-dependent processes of inter- and intra-
cellular compound trafficking, including actin and neural receptors [24].  
The synaptic alterations are likely to be the contributing cause of autism spectrum 
disorders [24]; however, the Golgi-related pathway may have a wider phenotypic 
manifestation [25], including cancer. The prognostic utility of NBEA has been 
investigated in gastric cancer [26] and oropharyngeal squamous cell carcinomas 
(OPSCC) [27], with promising results. Collectively, these observations implicate the 
pleiotropic nature of NBEA effect across a variety of traits. 
In our study, we suggest there is an association between NBEA and increased NMIBC 
tumour size. The role of Golgi complex in cancer progression has been reported 
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independently, and disruptions in normal protein transportation can contribute to 
increased tumour size and, eventually, progression [25].  
Our findings should be interpreted cautiously. Substantial sample sizes of specific 
phenotypes such as ours are rare, and suffer from limited power to capture true 
genetic associations, and spurious associations due to random effects cannot be ruled 
out. Our post-hoc power calculations [18], underscore the importance of current 
analysis being ran on bigger cohorts (e.g. association rs150914897 (14q11.2) of an 
OR=3.42 had power of 79%, but it drops to only 16% for an OR=2.5, hence we may 
have missed existing associations of more modest effect size).  Moreover, observed 
statistically significant results may represent synthetic associations that are driven by 
rare alleles. In our analyses, all alleles that have a frequency of <1% were excluded 
to reduce the likelihood of false-positive results. However, investigation of the regional 
association plots shows many significant SNPs seem to be isolated hits in a genetic 
locus, which warrants their careful consideration. The associated SNPs that show to 
be in low correlation with surrounding variants may point towards them being spurious 
results or indicating an association with rare variants, which were not tested in the 
current study.  
Furthermore, tumour size measurements are subject to variability, degree of which is 
difficult to establish. The lack of any genome-wide significant associations for 
categorised tumour size (</≥ 3 cm [17]) adds substantial caution in consideration of 
our main findings and study power. However, clinically-relevant tumour size categories 
may not be adequate in a genetic context, and different categorisation may be used 
in future analyses.  
Our study only focused on NMIBC instead of a merged group of UBC, and we are 
unable to comment on whether these genetic loci are relevant for advanced UBC. 
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Given considered limitations, we see this study as true to the GWAS design of 
hypothesis-generating nature, instead of one offering conclusive findings. Hence, 
further replication is of essence to establish validity of described results.  
The 13q13.3 locus has not been observed in prior studies on NMIBC. It might be due 
to us using an independent prognostic marker of NMIBC (i.e. tumour size) instead of 
recurrence and/or progression as an outcome. Larger tumour indicates a worse 
disease course [17], but there are other components that contribute to NMIBC 
prognosis. In a clinical setting, each tumour characteristic (e.g. size) carries a different 
weighting [17], collectively contributing to an endpoint (e.g. recurrence). Importantly, 
our sample had a low number of Carcinoma in situ (CIS) tumours (N=10), and could 
not be analysed as a separate category. However, it must be underscored these 
tumours show a high likelihood of progression (Table 1.2), and should be considered 
as an independent endpoint if sample size permits such investigations.  
Importantly, powerful studies on UBC risk have already shown some signals to only 
be associated with MIBC (UBC of T2-T4) [10]. Furthermore, a genome-wide 
methylation investigation on high-grade NMIBC cases revealed epigenetic changes 
different from their low-grade counterparts [9]. Direct comparability of these reports is 
limited, but we see the unravelling genetic complexity within UBC being a connecting 
thread between all studies. We therefore believe it is likely separate genetic 
relationships are present for NMIBC determinants, rather than overall prognostic 
outcomes. Our study suggests variations in 13q13.3 locus may contribute to an 
increased NMIBC tumour size in a European population. Further studies are 
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Multiple genetic loci have been identified as potentially conferring increased risk of 
urinary bladder cancer (UBC). Although evidence for gene-environment (GxE) 
interactions with smoking exist for overall UBC risk, few studies have investigated 
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outcomes that could indicate non-muscle-invasive bladder cancer (NMIBC) prognosis. 
In the current study, we have investigated if smoking status and/or smoking intensity 
interact with the effect of discovered variants on key NMIBC characteristics of tumour 
grade, stage, size, and age within the Bladder Cancer Prognosis Programme (BCPP) 
cohort. 
METHODS 
Analysed sample consisted of 546 NMIBC patients with valid smoking data from the 
BCPP.  
In a previous genome-wide association study (GWAS), we have identified 61 single 
nucleotide polymorphism (SNPs) potentially associated with the NMIBC 
characteristics of tumour stage, grade, size, and patient’s age. In the current analysis, 
we have tested those 61 associations for potential GxE interaction with smoking. 
RESULTS 
Ten out of 61 SNPs reached showed suggestion (statistical significance level of 
p<0.05) for GxE with NMIBC tumour size.  
CONCLUSIONS 
Our study suggests interaction between genetic variance and smoking behaviour for 
increased NMIBC tumour size at the time of diagnosis. Further replication is required 




Multiple genetic loci have been identified as potentially conferring increased risk of 
urinary bladder cancer (UBC), and it is hypothesized that these associations might be 
altered by environmental exposures, such as smoking [1-4]. However, it remains 
unknown if any gene-environment interactions (GxE) are also present for UBC 
outcomes, which may permit improvements in the clinical management of UBC 
patients.  
To date, studies on gene-tobacco (GxT) interactions for UBC have only considered 
the overall risk of developing UBC as an outcome of interest. These investigations 
have resulted in overlapping findings, collectively reporting multiple loci interacting 
with tobacco [2-4]. Some of the most commonly reported genes for GxT interaction on 
UBC risk (NAT2, UGT1A6) are regulatory of phase II detoxification, a pathway for 
metabolising tobacco-related carcinogens (i.e. aromatic amines) [2, 3, 5]. Alterations 
in smoking-related carcinogen clearance result in increased risk in tobacco users, 
whilst the effect is reduced [2] or virtually missing for never smokers [5]. In addition, 
the overall risk of developing UBC has been shown to increase with smoking intensity, 
revealing an important pattern of certain genotypes interacting with smoking in a dose-
dependent manner [2, 4-7].  
Other genotypes, namely GSTM1-null status [3], appear more important for non-
smokers, although significant effects are present regardless of tobacco use. 
Expectedly, the effect of these genotypes on UBC risk does not vary within smoking 
intensity categories [6].  
UBC is one of few cancers with an established gene-environment interaction [4], yet 
previous research has not distinguished between muscle-invasive (MIBC) and non-
 129 
muscle-invasive (NMIBC) groupings. Given our continually-evolving knowledge of the 
pathogenesis of MIBC and NMIBC [8], not stratifying for these categories in genetic 
analyses could result in overlooking important biological mechanisms. Furthermore, it 
is now known that genetic loci for UBC risk are not relevant for UBC prognosis [9], 
which continues to highlight the complexity of genetic associations. Finally, little 
evidence is present for genetic associations with specific characteristics such as 
tumour size, grade, stage or patient age [2, 5]. However, these characteristics are 
especially influential for NMIBC outcomes [10], and are more specific entities than the 
more broadly-defined prognostic outcomes such as recurrence or progression. 
We have previously carried out a genome-wide association study (GWAS) on NMIBC 
tumour and patient characteristics in the Bladder Cancer Prognosis Programme 
(BCPP) cohort, identifying potentially novel genetic associations [11]. In the current 
study, we have investigated if smoking status and/or smoking intensity interact with 
the effect of discovered variants on key NMIBC characteristics of tumour 




Participants and genotyping 
BCPP 
BCPP is a prospective cohort, recruiting 1,544 patients from December 2005 to April 
2011 [12]. Baseline clinical tumour characteristics (stage, grade, size) were collected 
from medical records, whilst demographic and smoking data were retrieved from 
records of semi-structured interviews that were conducted at baseline. Blood samples 
of 888 participants were genotyped on the Illumina Infinium OmniExpress-24 
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BeadChip array (previously known as The HumanOmniExxpress-24 BeadChip) at 
deCODE genetics (Reykjavik, Iceland) [13].  
 
Nijmegen Bladder Cancer Study (NBCS) 
In NBCS, patients were recruited between years 1995-2006 via the population-based 
cancer registry operating in the Nijmegen area [14]. For confirmed UBC cases, clinical 
and demographic data were collected via self-administered questionnaires. Additional 
information was retrieved via linkage to the medical records. Genotyping on the 
Illumina HumanHapCNV370 BeadChip panel was performed for patients who have 
consented to donating a blood sample [9]. Quality control and analytic procedures on 
genetic data have been presented previously [14]. 
A total of 303 NMIBC patients with valid data on tumour size and smoking were 
included in the replication.  
 
Quality control (QC) 
Quality control for the initial GWAS was carried out in PLINK v1.90 (released 17 th 
November 2016) [15, 16] and is described in more detail elsewhere [11]. In brief, 
genotype samples yielding inconclusive gender calls, excessive missingness, low or 
increased heterozygosity rate were excluded from the analysis. Related individuals 
and participants presenting as population outliers (as identified in the principal 
component analysis (PCA)) were additionally excluded from the study. Genetic 
markers deviating from the Hardy-Weinberg equilibrium (HWE), those with high 
missingness rate and low minor allele frequency (MAF) were excluded. All QC steps 
resulted in a pre-imputed dataset consisting of 653 individuals and 597,764 single 
nucleotide polymorphisms (SNPs). 
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Imputation 
A two-step imputation was performed with Eagle v2.3.2 [17] for haplotype phasing and 
IMPUTE2 [18] for genotype imputation, using 1000 Genomes Phase 3 (released 2nd 
May 2013) [19] as a reference panel in the genome build 19 (GRCh37/hg19). Post-
imputation QC consisted of deleting markers having info score of <0.3 and MAFs of 
<1%, resulting in a dataset containing 11,914,228 markers that were used for GWAS 
analysis with tumour and patient baseline characteristics. The exact thresholds 
applied and number of exclusions per step are outlined in detail in Figure 5.1.  
 
Figure 5.1. Flowchart for the data analysis on gene-tobacco (GxT) interactions 
in the BCPP cohort (BCPP-Bladder Cancer Prognosis Programme; HWE-
Hardy-Weinberg equilibrium; SD-standard deviation; IBS-identity-by-state; 
PCA-principal component analysis; MAF-minor allele frequency; NMIBC-non-
muscle invasive bladder cancer; PCA-principal component analysis; SD-
standard deviation; SNP-single nucleotide polymorphism).  
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Outcomes and exposure variables 
As studies on genetic associations with NMIBC baseline characteristics are scarce, 
we have used results of a previously-reported GWAS in the BCPP cohort [11]. Hence, 
a total of 61 discovered variants were used to test for GxT interaction. The outcomes 
were as follows: tumour size (centimetres), stage (T1 vs Ta/Tis), grade (G3/G2 vs G1), 
and patients’ age (years as a continuous outcome and a binary variable with sample 
mean as a cut-off value (</≥69.9 years)). Our analyses were restricted to NMIBC 
cases only (corresponding to recorded stage at the time of diagnosis of Ta, T1, or Tis) 
who also had valid records on tobacco use, resulting in 546 patients. 
Smoking exposure was modelled as two variables: smoking status (ever vs never 
smokers) and smoking intensity (number of cigarettes smoked daily for smokers only). 
GxT interaction with smoking status was considered as a primary analysis (including 
546 subjects), whilst analysis on smoking intensity was considered secondary 
(consisting of 322 smokers with valid data on number of cigarettes smoked per day). 
 
Statistical analysis 
To test interaction terms that account for the uncertainty of imputed genotypes, 
QUICKTEST software was used [20]. All analyses were adjusted for gender and first 
five genetic principal components to increase estimate precision.  
A total set of 61 SNPs that were discovered in the previous GWAS analysis of the 
BCPP cohort [11], were tested. GxT interaction term (depicted as SNPxSmoking or 
SNPxSmoking intensity) was modelled for each discovered association. An interaction 
term was deemed to be significant if p value<0.05.  
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Functional annotation and network analysis 
All identified significant SNPs were annotated to an overlapping or closest gene using 
a web-based SNPnexus tool [21, 22], with Ensembl [23] (Version 74) as a functional 
annotation system. Gene-Tissue Expression database (GTEx) [24] was queried for all 




BCPP and NBCS patient characteristics are presented in Table 5.1. Out of the total 
BCPP sample of 546 participants, 72 were never-smokers, whilst 474 had a history of 
tobacco use. In the NBCS, 246 participants have never smoked and 1061 were ever-
smokers. Overall, The BCPP cohort was older (mean age=70 years) than the NBCS 
sample (mean age=62.5 years). No striking differences were observed between the 
BCPP and the NBCS with regard to tumour stage and grade, as well as number of 
cigarettes smoked per day. However, although NBCS is a much larger sample overall, 
the information on tumour size was only available for 303 participants. 
Out of 61 tested SNPs tested for a GxT interaction in the BCPP cohort, 10 have 
reached p<0.05, all associated with tumour size (Table 5.2). Five of these SNPs were 
located in 6q14.1 (rs180910528, rs74603364, rs187040828, rs144383242, and 
rs117587674); two in 14q21.1 (rs188958632 and a SNP that has not yet been 
assigned an rsID (base-pair (BP): 38247577)); whilst the rest were mapped to 1p31.3 
(rs2937268), 3p26.1 (rs113705641), and 13q14.13 (rs35225990) (Table 5.2).
 134 
Table 5.1. Descriptive characteristics of the BCPP and NBCS samples for gene-environment interaction with smoking 
analysis. 























(cm), mean (SD) 
N=533 2.50 (1.90) 2.69 (2.14) 2.48 (1.86) N=303 2.4 (1.3) 2.4 (1.1) 2.4 (1.3) 
Age (years), 
mean (SD)  
N=546 70.0 (10.3) 72.2 (10.9) 69.7 (10.2) N=1307 62.5 (9.7) 60.8 (11.0) 62.5 (9.0) 
Grade  N=539       N=1307       
G3 (%)     49 (9.1) 312 (57.9)     56 (4.28) 237 (18.1) 
G2 and G1 (%)     22 (4.1) 156 (28.9)     190 (14.6) 824 (63.1) 
Tumour stage  N=546       N=1267       
T1 and Tis (%)     47 (12.6) 326 (87.4)     72 (5.7) 288 (22.7) 




N=322 N/A N/A 15.8 (12.9) N=1061 N/A N/A 15.5 (8.1) 
BCPP- Bladder Cancer Prognosis Programme; NBCS – Nijmegen Bladder Cancer Study; SD -Standard deviation.  
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The most significant interaction with smoking status was observed for a SNP in 
14q21.1 locus (BP: 14:38247577, p=0.0008), that maps to the TTC6 gene (Table 5.3). 
Another SNP in the same locus has also yielded statistical significance for interaction 
(rs188958632, p=0.008, TTC6), but the two variants show differential results for 
smokers and non-smokers. The SNP in 14:38247577 reaches significance among 
smokers only, with a large effect on tumour size (𝛃=7.1 cm, p=1.93E-13), and is 
suggestive of an interaction with smoking intensity (p=0.07). On the contrary, 
rs188958632 SNP is significant among both tobacco use groups, with a larger effect 
size for never-smokers (𝛃 (never-smokers) =9.9 cm, p=9.84E-05; 𝛃 (ever-smokers) 
=2.6 cm, p=6.98E-07), and no implications of interaction with smoking intensity 
(p=0.29) (Table 5.2, Figure 5.2).  
Five variants on 6q14.1 were statistically significantly associated with NMIBC tumour 
size among both strata of smoking behaviours; however, 𝛃 estimates for never-
smokers were universally higher, more than doubling the effect sizes of ever-smokers 
(Table 5.2). All five SNPs (rs180910528, rs74603364, rs187040828, rs144383242, 
and rs117587674) have mapped to intergenic regions (Table 5.3). 
Rs180910528 and rs187040828 are situated between PHIP and HMGN3 protein-
coding genes, whereas the remaining three are surrounded by long non-coding 
intergenic RNA (lincRNA) molecules. Interestingly, two of these SNPs (rs144383242 
and rs117587674) are recorded in the GTEx database as having an effect on the 
expression of HMGN3-AS1 in the tibial nerve tissue (Supplementary Figures 5.1, 
5.2) [24]. None of the 6q14.1-located SNPs have shown significant interaction 
between tumour size and smoking intensity in our sample. 
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Table 5.2. SNPs attaining statistical significance (p (SNP x Smoking status) <0.05) for interaction with smoking status in 














p (SNP x 
Smoking 
status) c 


















rs113705641 5375733 3p26.1 A G 0.02 9.5 2.68E-27 0.03 0.95 -3.1 1 2.4 2.39E-06 
Not yet 
assigned 
38247577 14q21.1 CTGG C 0.01 8.1 9.41E-14 0.0008 0.07 -1.6 1 7.1 1.93E-13 








rs2937268 66553607 1p31.3 C T 0.04 2.6 3.28E-11 0.04 0.06 1.4 0.29 2.3 7.08E-11 
rs117587674 79432536 6q14.1 G A 0.01 3.5 4.67E-11 0.03 0.24 8.1 0.0004 3.0 5.56E-09 
rs144383242 79489625 6q14.1 G T 0.01 3.5 5.74E-11 0.03 0.24 8.1 0.0004 3.0 6.55E-09 




rs187040828 79802426 6q14.1 T C 0.01 3.9 3.58E-11 0.02 0.33 9.3 0.0001 3.4 6.79E-09 




a An estimate coefficient calculated in linear regression. 
b Level of statistical significance achieved in linear regression between a SNP and tumour size in 
centimetres. 
c Multiplicative interaction with smoking status (never- or ever-smokers).       
d Multiplicative interaction with smoking intensity (number of cigarettes smoked per day). Restricted to smokers only.  
e An estimate coefficient calculated in linear regression only among never smokers. 
f Level of statistical significance achieved in linear regression between a SNP and tumour size in centimetres only among never smokers. 
g An estimate coefficient calculated in linear regression only among smokers 
h Level of statistical significance achieved in linear regression between a SNP and tumour size in centimetres only among smokers.  
BP-base pair; EAF-effect allele frequency; EFF-effect; SNP-single nucleotide polymorphism; REF-reference. 
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Table 5.3. Functional annotation of the variants that reached statistical significance for gene-environment 
interaction with smoking status.  









































6q14.1 C T - 
RP3-390M24.1 
(lincRNA) 








6q14.1 G T - 
RP3-390M24.1 
(lincRNA) 




6q14.1 G A - 
RP3-390M24.1 
(lincRNA) 
116783 RP11-173D14.3 (lincRNA) 86896 




1p31.3 C T PDE4B (intronic) - - - - 
BP-Base pair; EFF-Effect; REF-reference; rsID-SNP ID.       
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Rs113705641 on 3p26.1 (intergenic region) has shown to only be statistically 
significantly associated with tumour size among ever-smokers (𝛃=2.4 cm, p=2.39E-
06), and no interaction with smoking intensity. Similarly, rs2937268 on 1p31.3, 
mapped to the PDE4B gene, has not only reached significance among ever-smokers 
(𝛃=2.3 cm, p=7.08E-11), but has also shown suggestive interaction with smoking 
intensity (p=0.06) among tobacco users.  
It is notable that variants associated with a stronger effect among never-smokers, had 
higher estimates overall (ranging from 7.1 to 9.9 cm). In contrast, rs2937268 (1p31.3, 
PDE4B) and rs113705641 (3p26.1) variants, shown to be significant only for smokers, 
have been observed to carry a more modest increase in tumour size. The exception 
would be the 14:38247577 variant in 14q21.1 that was not significant among never-
smokers, but resulted in a very large tumour size increase of 7.1 cm in smokers (Table 
5.2, Figure 5.2). 
In the replication analyses, we were not able to test all of the SNPs of interest (Table 
5.4). Three SNPs, namely rs187040828, rs2937268, and one located in 14q21.1 (BP: 
38247577, no rsID assigned) were missing from the NBCS dataset. The remaining 




We hereby report findings for gene-environment interaction with smoking status for 
SNPs previously found to be significant in a GWAS for NMIBC baseline characteristics 
in the BCPP cohort [11]. 
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Figure 5.2. Group-specific patterns of the significant loci for gene-environment 




Table 5.4. Replication results of the gene-environment interaction with 
smoking on tumour size in the Netherlands Bladder Cancer Study.  
Phenotyp
e 



















38247577 14q21.1 CTGG C NA NA NA NA 
rs35225990 46117489 13q14.13 C T 0.20 0.37 0.78 0.05 
rs188958632 38266174 14q21.1 G A -0.50 0.09 0.39 0.04 
rs180910528 79821806 6q14.1 A C 0.52 0.26 1.00 0.01 
rs74603364 79509518 6q14.1 C T 0.60 0.12 0.84 0.02 
rs187040828 79802426 6q14.1 T C NA NA NA NA 
rs144383242 79489625 6q14.1 G T 0.36 0.41 0.32 0.02 
rs117587674 79432536 6q14.1 G A 0.36 0.41 0.32 0.02 
rs113705641 5375733 3p26.1 A G 0.75 0.13 0.15 0.02 
rs2937268 66553607 1p31.3 C T NA NA NA NA 
a Interaction with smoking status (Never or Ever smokers). 
BP-base pair; EFF – effect; MAF-minor allele frequency; SNP-single nucleotide polymorphism; REF - 
reference. 
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The study provides indication for ten variants interacting with smoking status for 
tumour size at the time of NMIBC diagnosis, and two of those additionally having 
suggestive interactions with smoking intensity. To the best of our knowledge, all of 
these loci are novel reports for GxE interaction. 
Previous studies on GxT interactions for UBC risk show repeating patterns that 
highlight potential biological mechanisms [2, 4, 25]. Smoker-specific UBC risk genes 
are associated with pathways of metabolite detoxification [25], offering a plausible 
explanation on why the effect is more penetrant among smokers. Alternatively, genes 
having more importance among never smokers are more often enriched in those 
regulating cell cycle and DNA integrity [25]. Additionally, results across multiple GxT 
studies on UBC demonstrate that variants significant for never-smokers carry a large 
effect (i.e. multiplicative interaction), whilst SNPs that are more important for smokers 
usually exhibit a milder effect (additive interaction) [5].  
Among smokers, the strongest evidence for GxT interaction in our sample was 
observed for variants rs113705641 (3p26.1) and rs2937268 (1p31.3, PDE4B).  
Rs113705641 maps to a long non-coding RNA molecule, and reports on its function 
are lacking, therefore we are unable to postulate on a potential biological mechanism 
of interaction.  
On the other hand, Phosphodiesterase 4B (PDE4B) enzymes are well described to 
regulate cyclic adenosine 3’,5’-monophosphate (cAMP) concentration in cells by 
breakdown to non-active molecules [26]. The PDE4 family is cAMP-specific, and four 
existing isoforms of PDE4B account for most cAMP-degradation in a cell [26].  
The beneficial effect of PDE inhibitors is well-known and they are commonly used for 
a variety of disorders: inflammatory conditions (namely chronic obstructive pulmonary 
disease (COPD) [27, 28], asthma [27], and psoriasis [27, 28]), overactive bladder [29, 
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30], and various cancer types [31-36]. Importantly, studies also suggest tumour PDE4 
expression can serve as a prognostic marker in colorectal cancer [36]. As cAMP 
signalling is pleiotropic, the mechanisms behind the observed benefit have garnered 
more than one explanation. For example, elevated cAMP levels supress cell invasion 
and migration by disrupting the microtubule cytoskeleton in bladder cancer cells [37], 
increase phosphatidylinositol 3-kinase (PI3K/AKT)-dependent apoptosis in B-cell 
malignancies [38], and prohibit proliferation via protein kinase (PKA) and cAMP 
response element binding (CREB) protein pathways in ovarian cancer [39].  
Interestingly, tobacco exposure also increases cAMP signalling in epithelial cells [40], 
specifically by polycyclic aromatic hydrocarbons (PAHs, found in tobacco smoke) 
binding to aryl hydrocarbon receptors (AhR) [40]. Stimulation of cAMP results in 
increased levels of amphiregulin (AR), which is hypothesized to eventually form a self-
sustainable loop of survival for neoplastic cells [40-42].  
In our analysis, cAMP seems to be the overlapping component between PDE4B and 
smoking, which results in a counter-effect of cAMP regulation (i.e. overexpressed 
PDE4B decreases cAMP, whilst smoking increases cAMP). Thus, we hypothesize that 
smoking interacts with PDE4B mutation status and results in a smaller tumour size 
increase than the PDE4B mutation itself. This pattern would explain the difference 
between a main effect exhibited by the SNP in PDE4B (resulting in 2.6 cm increase in 
tumour size) and a surprising reduced estimate of a joint effect of the SNP and 
smoking exposure (2.1 cm increase in tumour size).  
Smoking, when considered as an independent factor, is the main external risk factor 
for developing UBC [43]. Our described interaction is conditional on the 
overexpression of PDE4B enzyme; thus, it should be viewed not as a case for the 
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benefits of smoking, but one describing a potential cAMP-related pathway of bladder 
cancer pathogenesis. 
An additional variant in 14q21.1 (BP: 38247577) reached statistical significance 
among smokers only. However, a SNP in the same locus (rs188958632) showed 
contradicting results and had a significant effect regardless of smoking exposure. We 
suspect that the SNP on 14:38247577 is more likely to be a random result due to a 
lower imputation accuracy (info=0.59) than rs188958632 (info=0.95) (remaining SNPs 
have an info score of ≥0.90, with the exception for rs113705641, with info=0.62). 
In contrast, variants on 13q14.13 and 6q14.1 have reached significant values for main 
effects among all participants. However, the clinical importance might be higher for 
never smokers as they showed substantially higher effect sizes than for smokers. The 
mapped FAM194B (ERICH6B) gene (13q14.13) is recorded in the GTEx database as 
excessively expressed in testis tissue [24], but other reports on gene function or 
phenotype associations are scarce, thus precluding a discussion on its potential 
biological pathway. SNPs in 6q14.1 were mapped to intergenic regions, with 
rs180910528 and rs187040828 located between protein coding genes of PHIP and 
HMGN3. Interestingly, four of the total five SNPs in 6q14 region (rs180910528, 
rs187040828, rs144383242, and rs117587674) are recorded in the GTEx database 
as having a cis-regulatory effect on an RNA gene of HMGN3-AS1 [24]. Antisense 
RNAs bind to messenger RNA molecules, preventing them from being translated into 
protein [44]. Thus, lower expression of HMGN3-AS1 may cause higher levels of 
proteins coded by HMGN3 gene. HMGN is a family of nucleosome-binding proteins 
that alter chromatin structure and regulate essential cell functions, such as 
differentiation and development [45].  
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The current study has several limitations. Our analysis was carried out on a relatively 
small sample of individuals, and false-positives are naturally not to be excluded. The 
potential associations between genetic variation and NMIBC tumour size should be 
interpreted with caution, as they lack validation [11]. Besides tobacco, other variables, 
such as occupational-related exposures with aromatic amines might have 
independent gene-environment interaction effects and were not adjusted for in our 
analyses [46]. Most importantly, we attempted a replication of our results in an 
independent cohort of NMIBC in the NBCS, without any of the tested variants showing 
interaction with smoking. The sample size for replication was small, and some SNPs 
were unavailable to test for interaction terms altogether. Unfortunately, that includes 
rs2937268 in PDE4B, which is arguable the most important SNP to test. Larger 
samples with detailed clinical data are a next step to exploring and validating reported 
gene-environment interactions with smoking for NMIBC. Until robust evidence exists 
for including genetic variance into NMIBC prognostication tools, our study is 
complementary to other proof-of-principle reports [2]. In summary, our study suggests 
interaction between genetic variance and smoking behaviour for increased NMIBC 
tumour size at the time of diagnosis. These results may provide more evidence on the 
complexity of the joint influence of genetic background and external exposures on 
bladder cancer; however the failed replication also warrants careful consideration of 
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Multiple studies have reported genetic associations with prognostic outcomes of 
urinary bladder cancer. However, the lack of replication of these associations prohibits 
establishing further evidence-based research directions. Moreover, there is a lack of 
independent bladder cancer patient samples that contain prognostic measures, 
making genetic replication analyses even more challenging.  
MATERIALS AND METHODS 
We have identified 1,534 eligible patients and used data on Hospital Episode Statistics 
in the UK Biobank to model variables of otherwise non-collected events on bladder 
cancer recurrence and progression. Data on survival was extracted from the Death 
Registry. We have used SNPTEST software to replicate previously reports genetic 
associations with bladder cancer recurrence (N=69), progression (N=23), survival 
(N=53), and age at the time of diagnosis (N=20).  
RESULTS 
Using our algorithm, we have identified 618 recurrence and 58 UBC progression 
events. In total, there were 209 deaths (106 UBC-specific). In replication analyses, 
eight single nucleotide polymorphisms (SNPs) have reached nominal statistical 
significance (p<0.05). Rs2042329 (CWC27) for UBC recurrence; rs804256, rs4639, 
and rs804276 (in/close to NEIL2) for NMIBC recurrence; rs2293347 (EGFR) for UBC 
OS; rs3756712 (PDCD6) for NMIBC OS; rs2344673 (RGS5) for MIBC OS, and 
rs2297518 (NOS2) for UBC progression. However, none have remained significant 
after adjustments for multiple comparisons.  
CONCLUSION 
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External replication in genetic epidemiology is an essential step to identify credible 
findings. In our study, we identify potential genetic targets of higher interest for UBC 
prognosis. In addition, we propose an algorithm for identifying UBC recurrence and 




Urinary bladder cancer (UBC) is a disease of great burden; yet the diagnosis, clinical 
management, and patient survivorship has changed little over the last few decades [1, 
2]. Genetic studies may provide important clues on biological pathways underlying the 
development of UBC. Importantly, advances in understanding what drives a 
favourable UBC prognosis could aid in predicting patient outcomes. As a result, and 
informed and timely patient stratification would allow an individually-tailored cancer 
management plan, which is likely to better reflect patient needs than current group-
level recommendations [3].  
Multiple genetic associations with UBC prognostic outcomes (e.g. survival, 
recurrence) have been reported in the literature (Manuscript in submission, [4]). 
However, the number of potential genetic clues far exceeds the available resources 
for clinical and functional investigation. As such, the scientific community must take an 
approach of targeting most-promising associations first.  
There are multiple ways to define clinical relevance of a genetic variant, including 
external replication to reduce the chance of false-positives [5, 6]. However, replication 
of genetic associations includes many hurdles, such as a lack of independent 
participant cohorts with adequate sample sizes. Moreover, focus on a sub-phenotype 
(e.g. recurrence) makes it even more difficult due to required additional sources of 
data (e.g. hospital records).  
Increased availability of population-based electronic health records can help to 
alleviate the burden of investigating diseases for which adequate sample sizes are 
difficult to acquire. UK Biobank is the largest population-based cohort in the United 
Kingdom and serves as a powerful resource for investigating genetic associations [7] 
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and has not yet been widely used for investigating UBC. The presence of Hospital 
Episode Statistics (HES) in the UK Biobank offers an unprecedented opportunity to 
use these data to identify UBC recurrence and progression events, that are not a part 
of the usually-collected information.  
In the current study, we have aimed to identify UBC patients in the UK Biobank and 
use HES statistics to construct prognostic events. We have further used this data to 
externally replicate previously reported genetic associations on UBC survival, 




Single nucleotide polymorphism (SNP) selection 
We have aimed to replicate all SNPs that have been previously associated with UBC 
recurrence, progression, death (overall or cancer-specific), and age at the time of 
diagnosis. The polymorphisms were extracted from a recent review on prognostic 
UBC outcomes (Manuscript in submission [4]). To capture any associations reported 
since the review, we have updated the list of SNPs by querying PubMed database for 
new articles using identical search terms to those used in the review (Figure 6.1). The 
search was limited to articles published in English language between 13th November 
2018 and 19th February 2019. Eleven papers were identified in total, with one study 
being eligible for inclusion [8]. Additionally, we have included associations for age at 
the time of diagnosis from a genome-wide association study (GWAS) previously 
carried out in the Bladder Cancer Prognosis Programme (BCPP) [9].  
After removing duplicate entries, there were 69 SNPs to test for recurrence, 53 for 
survival, 20 for age, and 23 for progression (Supplementary Tables 6.1-4).  
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Figure 6.1. Selection process of the SNPs used in replication analyses. GWAS-
genome-wide association study; SNP-single nucleotide polymorphism; UBC-
urinary bladder cancer. 
 
Study population  
UK Biobank is a population-based cohort in the UK, having collected genetic and 
clinical data on over 500,000 participants, aged 40-69 at the time of recruitment in 
2006-2010. The design, data collection and processing are described in detail 
elsewhere [7, 10].  
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Our analysis was restricted to UBC patients (corresponding International Classification 
of Diseases (ICD) codes of C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, 
C67.8, C67.9, D09.0 (ICD10) and 1880, 1882, 1884, 1886, 1888, 1889, 2337 (ICD9). 
To prevent bias from analysing heterogeneous molecular UBC subtypes, histology 
was limited to the following ICD-O (ICD Oncology) codes: 8000 (Neoplasm), 8001 
(Tumour cells), 8010 (Carcinoma), 8020 (Carcinoma, undifferentiated), 8050 
(Papillary carcinoma), 8120 (Transitional cell carcinoma), and 8130 (Papillary 
transitional cell carcinoma).  





Age at the time of diagnosis was modelled both as a continuous and categorical 
variable. 
To replicate previous associations as accurately as possible, we have dichotomised 
age variables using the cut-off points reported in the original research articles (≥/< 50, 
55, 60, 65, and 70 years, Supplementary Table 6.3). 
Death 
Death was modelled as an overall (death vs no death) or a UBC-specific event (death 
vs no death, when primary cause of death was assigned C67- (ICD10) or 188-related 
(ICD9) codes).  
Recurrence  
The events of bladder recurrence and progression are not part of the routinely 
collected data in the Cancer Registry, or other national/regional datasets. However, 
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the HES in the UK Biobank make it possible to identify a fraction of these events using 
proxy data.  
HES contains admitted in-patient data starting with 1997 [11] and includes data on 
patients both under national health service (NHS) and private care. HES data is 
provided to the UK Biobank on an annual basis, covering the past financial year 
(starting 1st April of each year). In our analyses, the follow-up covers all in-hospital 
interventions registered until March 31st, 2017. Operative procedures use OPCS4 
(Office of Population, Censuses and Surveys: Classification of Interventions and 
Procedures, Version 4) coding system.  
For recurrence, we have considered three conditions to be representative of an event 
(Figure 2). First, a transurethral resection of a bladder tumour (TURBT) (OPCS4 code 
M42) is regarded to be enough to signify a UBC event. Secondly, a time gap of longer 
than 4 months between chemotherapeutic treatments into urinary bladder (OPCS4 
codes M494/M495) was considered to be substantial to correspond to two different 
events. Thirdly, we have assumed a UBC diagnosis if an examination of the urinary 
bladder (OPCS4 code M45) was led by an intervention within 6 months. Relevant 
interventions were chemotherapeutic treatments into urinary bladder, cystectomy, 
radiotherapy, and chemotherapy (corresponding to OPCS4 codes of M494/M495; 
M34; X65; X72; X292, X298, X308, X352, respectively). Currently presented list of 
chemotherapy-related OPCS4 is not exhaustive, but rather based on interventions 
observed in our data. Further development of the algorithm is likely to adjust the list 
as needed.  
Progression 
In our framework, all events of progression are recurrences by default. However, we 
have considered adding additional criteria would allow distinguishing which 
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recurrences were also representative of UBC progression. We have considered an 
event of UBC progression to have taken place if either a TURBT (OPCS4 code M42) 
or examination of the urinary bladder (OPCS4 code M45) was followed by 
interventions of cystectomy (OPCS4 code M34) and/or radiotherapy (OPCS4 code 
X65) within 6 months (Figure 6.2).  
To prevent registration duplicates, two recurrence and/or progression events were 
considered independent of one another if time in between the records was greater 
than 3 months.  
Invasiveness at the time of diagnosis 
Finally, UBC clinical management is heavily dependent on its’ invasiveness at the 
initial diagnosis. A UBC diagnosis that was followed by either cystectomy or 
radiotherapy was considered to represent a muscle-invasive bladder cancer (MIBC), 
whilst the remaining diagnoses are held to be non-muscle-invasive bladder cancer 
(NMIBC) cases (Figure 6.2).  
 
Ethics and consent  
All UK Biobank participants have provided informed consent. Current research has 
been conducted using the UK Biobank Resource under Application Number 42772.  
 
Genotype data quality control (QC) and imputation 
Detailed procedures on QC and imputation in the UK Biobank are described elsewhere 
[10]. To verify the high quality of all tested SNPs, we have extracted imputation 
accuracy measures (INFO scores) and MAF (minor allele frequencies) 
(Supplementary Table 6.5). To avoid population stratification bias, we have restricted 
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our sample to a homogenous group of White British participants, as previously 
identified by the UK Biobank team [10].  
 
Figure 6.2. Conditions for modelled events of UBC recurrence, progression, 
and invasiveness at baseline (MIBC-muscle-invasive bladder cancer, TURBT 




To test for an association between selected SNPs and UBC recurrence, progression, 
death, and age, we have utilized SNPTEST 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html). To estimate 
Linkage disequilibrium (LD), an online tool was used (https://ldlink.nci.nih.gov/). LD 
defines the correlation between alleles in a given population. Due to some SNPs being 
in high LD, it might be difficult to establish which allele is representing the cause, as 
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they are often inherited together. At the same time, linkage equilibrium suggests 
alleles are inherited independent of one another. Logistic regression using allele 
dosages was applied to estimate odds ratios (OR) and corresponding confidence 
intervals (CI) for death, recurrence, progression, and categorical age events; whilst 
linear regression was used to estimate the effect of age as a continuous variable. All 
associations were tested under additive model of inheritance and adjusted for 
participant sex. To reduce multiple testing, analyses were ran for the outcome that 
resembled the originally-reported association most closely (e.g. if a variant has been 
associated with NMIBC recurrence, we have only tested NMIBC patients instead of 
the whole UBC sample). To better estimate the strength of evidence for replication 
results, we additionally included calculation of the Bayes Factor (BF). In simple terms, 
BF can be considered as a ratio of probabilities for two competing hypotheses (for 
example, the probability of a SNP being associated with an outcome versus the SNP 
not influencing the outcome). The ratio provides an estimate that shows the extent on 
of one hypothesis being more (or less) likely than the alternative one. In contrast, the 
generically-used frequentist approach (resulting in a p value) evaluates the probability 
of data under a specific hypothesis, which alone does not provide indication of the 
association strength.  
Variants in the replication were considered promising if the nominal statistical 
significance (p value) has reached <0.05. Bonferroni adjustment per each outcome for 
multiple comparisons resulted in statistical significance level (p value) to be 0.0007 for 
recurrence (α=0.05/69), 0.002 for progression (α=0.05/23), 0.0009 for survival (α= 





In total, 1,534 UBC patients were available for replication analyses of prognostic 
events (Table 6.1).  
Mean age of UBC patients was 61 years, and most were males (78%). Using our 
algorithm on HES data, we could identify UBC invasiveness at baseline, recurrent, 
and progressive events for UBC patients in the UK Biobank cohort. Majority of UBC 
cases were NMIBC (93%). Death was recorded for 209 (13.6%) patients, out of which 
106 were UBC-specific. In addition, we estimate 618 patients (40%) have experienced 
a recurrence, and 58 (3.8%) have had a UBC progression. 
Table 6.1. Descriptive characteristics of the UBC 
patients in the UK Biobank. 
  N p value* 
Sex 1534 <0.001 
Males (%) 1197 (78.0)   
Females (%) 337 (22.0)   
Age (Mean (SD)) 61.3 (9.0)   
Death 1534 <0.001 
No (%) 1325 (86.4)   
Yes (%) 209 (13.6)   
UBC-specific death 1534 <0.001 
No (%) 1428 (93.1)   
Yes (%) 106 (6.9)   
Recurrence 1534 <0.001 
No (%) 916 (59.7)   
Yes (%) 618 (40.3)   
Progression 1534 <0.001 
No (%) 1476 (96.2)   
Yes (%) 58 (3.8)   
NMIBC at baseline 1534 <0.001 
No (%) 114 (7.4)   
Yes (%) 1420 (92.6)   
*Chi-square test for group independence. 
NMIBC-non-muscle-invasive bladder cancer; SD-
standard deviation; UBC-urinary bladder cancer. 
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In the replication analyses, eight SNPs have reached a p-value of <0.05 (Table 6.2). 
However, none of the variants remained significant after applying Bonferroni-
corrections for multiple comparisons (corrected for each tested outcome).  
Recurrence 
Four of these SNPs were associated with bladder cancer recurrence. Rs2042329 
(CWC27) was linked to an increased risk of UBC recurrence (OR=1.26, 95% CI: 1.10; 
1.48); whilst rs804256, rs4639, and rs804276, all located in/close to NEIL2 were 
associated with NMIBC-only recurrence (OR=1.23, 95% CI: 1.05-1.43; OR=1.20, 
95%CI: 1.03-1.39; OR=1.17, 95% CI: 1.01-1.36, respectively). All SNPs that were 
associated with recurrence showed consistent direction but were universally more 
modest in comparison to the original studies (HR=1.54 (1.10-2.16) for rs2042329 [12], 
HR=4.58 (2.61-8.02) for rs804256 [13], HR= 2.60 (1.68-4.03) for rs4639[13], and HR= 
2.71 (1.75-4.20) for rs804276 [13]).  
Although SNPs rs804256, rs4639, and rs804276 all map to the same locus, LD values 
imply they are independent results (R2 for rs804276 and rs804256 =0.09; R2 for 
rs804276 and rs4639 =0.43; R2 for rs4639 and rs804256=0.38).  
Death 
Three SNPs (rs2344673 (RGS5), rs3756712 (PDCD6), and rs2293347 (EGFR)) were 
associated with events of bladder cancer death, albeit in different subgroups. 
Rs2293347 (EGFR) was associated with lower death rates among all UBC patients 
(OR=0.69, 95% CI: 0.47-0.99), rs3756712 (PDCD6) was significant for NMIBC 
patients (OR=1.29, 95% CI: 1.02-1.63), and rs2344673 (RGS5) showed reduced rate 
of death among MIBC cases (OR=0.22, 95% CI: 0.05-0.98).  
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In comparison to the original study, replicated SNPs in PDCD6 showed effect in the 
same direction, but had a reduced estimate (HR=5.11 (1.43-18.22) [14]. 
However, inconsistency in direction of the effect was observed for SNPs in EGFR and 
RGS5 (HR=1.5 (1.0-2.3) for rs2293347 [15] and HR=1.55 (1.15-2.11) for rs2344673 
[16]. 
Progression 
Carrying a minor allele of rs2297518 in NOS2 corresponded to a lower chance of UBC 
progression (OR=0.56, 95% CI: 0.32-0.99). In the original study, rs2297518 was also 
associated with a lower risk of progression (HR=0.21 (0.05-0.87) [17].  
 
Bayes factor was highest for the variant associated with NMIBC recurrence in CWC27, 
reaching log10(BF)=1.56. For all remaining SNPs, Bayes statistic indicates replication 




In the current study, we describe an external replication of previously reported genetic 
associations for UBC recurrence, progression, death, and age at the time of diagnosis 
using HES data available the UK Biobank. 
The aim of our study is twofold. Firstly, mining routinely-collected data for identifying 
complex phenotypes is inevitable to become a common practice. In the light of current 
needs, we propose an algorithm that identifies UBC recurrences and progression 
events via recorded interventions in a hospital setting. 
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Table 6.2. Replication results that have reached nominal significance (p<0.05) in the UK Biobank cohort. 


































1.26 (1.10; 1.48) 0.001 1.56 CWC27 
NMIBC 
Recurrence 









1.23 (1.05; 1.43) 0.012 0.74 NEIL2 
MIBC  
Overall Survival 









0.22 (0.05; 0.98) 0.019 0.10 RGS5 
NMIBC  
Overall Survival 









1.29 (1.02; 1.63) 0.03 0.49 PDCD6 
NMIBC 
Recurrence 









1.20 (1.03; 1.39) 0.02 0.56 NEIL2 
NMIBC 
Recurrence 









1.17 (1.01; 1.36) 0.04 0.34 - 
UBC 
Overall Survival 









0.69 (0.47; 0.99) 0.04 0.35 EGFR 
UBC  
Progression 









0.56 (0.32; 0.99) 0.03 0.26 NOS2 
BF-Bayes’ factor; CI-confidence interval; EFF-effect allele; MAF-minor allele frequency NMIBC-non-muscle-invasive bladder cancer; 
OR-odds ratio; REF-reference allele; UBC-urinary bladder cancer. 
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Current approach uses OPCS4 classification system, but we are confident applied 
assumptions can be translated to other globally-used systems (e.g. International 
Classification of Health Interventions, ICHI). We acknowledge identified prognostic 
events make up only a fraction of the true event volume, and are likely to be an 
underestimate. The extent of the underestimation requires testing the algorithm in an 
external cohort and is a necessary subsequent step of refining the currently-described 
approach. The level of underestimation is likely to vary for differed outcomes, as some 
events are arguably easier to identify (e.g. recurrence), whilst progression requires 
more detailed data and is subject to a higher level of underrepresentation. However, 
we saw an overestimation resulting in a greater rate of error and data 
misrepresentation. Moreover, inclusion of other clinically-relevant characteristics 
(tumour stage, grade) would increase the accuracy of modelled prognostic events. 
The provisioned release of such data in the UK Biobank 
(https://biobank.ctsu.ox.ac.uk/crystal/exinfo.cgi?src=future_timelines) will provide 
further opportunities of updating the algorithm. Naturally, our proposed approach and 
used assumptions are subjective by nature and we encourage the expert field to 
contribute ideas to make the assumptions more accurate.  
Secondly, an external replication of genetic associations is a rare endeavour. 
Unfortunately, as simply put by Kraft et al. [5], “Genetic epidemiology learned the 
importance of replication the hard way”. External validation studies perform at much 
lower rates, which underscores the significance of such efforts [6]. Most genetic 
studies are still exploratory in nature, and false-positive results are inevitable. By 
prioritising evidence-based targets, more resources can be allocated towards 
investigating variants with better promise of true impact on human health.  
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For UBC recurrence, the strongest result was mapped to CWC27. Previous study 
reported rs2042329 to correspond to higher expression of CWC27 in bladder cancer 
cells [12]. Additional functional analyses showed CWC27 might affect bladder 
carcinogenesis via apoptosis. Interestingly, the original finding was made for Chinese 
patients, and authors failed to replicate the significance of rs2042329 on bladder 
cancer risk among Europeans [12]. However, it is unknown if the lack of effect was 
also present for recurrence. 
Additionally, it is surprising to see three SNPs in NEIL2 being significant for NMIBC 
recurrence, especially keeping in mind the low likelihood of successful replication. 
Despite the high number of SNPs, strength of evidence for these associations is low, 
as reflected in Bayes Factor. Nonetheless, they might be promising targets in future 
replications. NEIL2 is involved in DNA repair mechanisms, and research suggest it 
influences malignancies beyond bladder cancer. Alterations in normal NEIL2 activity 
most likely result in accumulated oxidative damage, as elegantly presented by 
Benitez-Buelga et al. [19]. 
For UBC progression, the replicated variant maps to NOS2. The gene has been 
specifically linked to progression of various cancers [20, 21]. It seems NOS2 affects 
multiple oncogenic pathways, that simultaneously affect tumour proliferation, 
angiogenesis, chemoresistance, and cell migration [20, 21]. 
As for UBC survival, three replicated SNPs are located in RGS5, PDCD6, and EGFR. 
Interestingly, a previous independent replication of SNPs associated with UBC 
prognosis has also successfully validated a variant in RGS5 (rs12035879) for overall 
survival (OS) of MIBC cases [22]. Comparison of two external replications offers 
potential insights – for example, the rs11585883 did not replicate in our study; 
however, another SNP in RGS5 was successful, and associated with the same 
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outcome (MIBC OS). These findings may be seen as cumulative towards the 
involvement of RGS5 in cancer survival, even if specific SNPs are yet to be identified. 
We have checked if previously and current replicated RGS5 SNPs are in LD, and they 
seem to represent independent signals in the gene (R2=0.03 for rs12035879 and 
rs2344673 among Europeans). One major weakness of the replicated rs2344673 in 
our study is small sample size (29 cases and 109 controls). A post-hoc analysis on 
the overall survival of the whole sample, regardless of UBC invasiveness (209 cases 
and 1,325 controls) was not significant. RGS5 may not be relevant for all UBC patients, 
or might reflect power issues, which highlights further investigation being essential. 
Remaining two genes implicated in UBC and NMIBC survival, namely EGFR and 
PDCD6, are both well-known cancer genes [14, 23]. PDCD6 seems to be heavily 
involved in apoptosis [14]; however, the exact role of PDCD6 is contrasting between 
various cancers [24], and further molecular research will help making evidence-based 
interpretations.   
A replicated SNP (rs2293347) in EGFR has also previously corresponded to a 
protective effect on survival of lung cancer patients [25]. The effect may be due to 
higher responsiveness to chemotherapy [26], which is a worthwhile investigation in 
future analyses.   
Or study is subject to limitations, with one of the largest drawbacks being the difference 
between founders’ and replication cohorts. A lot of studies have investigated 
populations of non-European ancestry, and it is possible we are not able to observe a 
true effect due to differences in LD of candidate SNPs in different samples. At the 
same time, the most reliable replication in our study was rs2042329, first reported in 
a Chinese population [12].  
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None of our replicated SNPs have passed the Bonferroni-corrected statistical 
significance level, suggesting some promising SNPs may have been identified by 
chance. 
Furthermore, current analyses have only focused on estimating the overall risk of a 
prognostic event, without considering the relevance of elapsed time to event. We see 
such and other more sophisticated analyses as a further direction in utilising the 
described approach. 
We were also unable to reliably estimate assigned treatment for UBC patients in the 
UK Biobank cohort, which would unquestionably confer to a more precise replication 
analysis.  However, as the detail of released HES is increasing, we do not see this 
data out of reach and likely to include in future algorithm updates.  
Finally, some replicated SNPs showed conflicting direction of the effect when 
compared to the original studies. These issues are likely to be clarified once more 
studies are ran to first of all, confirm the overall association and, secondly, to establish 
the effect.  
To summarise, we have carried out an external replication of previously reported SNPs 
for UBC recurrence, progression, death and age using a novel approach of identifying 
clinically-relevant outcomes using HES data. Our analysis suggests specific targets, 
namely CWC27, NEIL2, PDCD6, EGFR, and NOS2, might be prioritised in efforts to 
further study the role of genetics in UBC prognosis. We are cautious about our 
findings, as there is no one metric or design to provide unquestionable evidence; 
instead, it should be viewed as one of the studies in a long line of accelerating research 
on UBC.  
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The current thesis intended to investigate the possibility of established factors 
contributing to the prognosis in non-muscle-invasive bladder cancer (NMIBC). 
Broadly, the thesis is split into two parts; firstly, part one focuses on discovering loci 
that may be associated with NMIBC baseline characteristics, as well investigating if 
any of the discovered single nucleotide polymorphisms (SNPs) are implicated in a 
phenomenon of gene-environment (GxE) interaction with smoking. The second part 
of the thesis describes the attempted replication of both – findings of our own and 
those published previously.  
 
SUMMARY OF THE MAIN FINDINGS 
 
In Chapter 3, we have attempted to review all previous evidence on genetic 
polymorphisms and urinary bladder cancer (UBC) prognostic measures. In total, 112 
studies were summarised that reported 316 SNPs. Our review considered various 
outcomes, namely UBC recurrence, progression, and death, as well as key UBC 
characteristics of tumour stage, grade, size, risk group, and patients’ age. We have 
discovered extensive heterogeneity in the literature with regard to practiced 
methodologies and principal findings. There were few genes (OGG1, TP53, and 
MDM2) that were commonly reported for most outcomes, which may indicate 
overarching pathogenic pathways. However, the remaining substantial differences in 
reported associations across endpoints suggest that different prognostic outcomes 
(recurrence, progression, death) may have different mechanisms and represent 
distinct phenotypes. 
Chapter 4 describes explorations of new genetic variants that may influence specific 
characteristics of NMIBC patients and their tumours at the time of diagnosis. A 
genome-wide association study (GWAS) on 653 patients in the West Midlands 
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Bladder Cancer Prognosis Programme (BCPP) yielded 61 statistically significant 
SNPs for the characteristics of tumour size, stage, grade, and patient’s age. A 
replication study in the Nijmegen Bladder Cancer Study (NBCS, [1]) suggested that 
most of these associations might be spurious.  
Out of all significant hits in our discovery GWAS, ten have also demonstrated GxE 
interactions with smoking behaviour and tumour size in the BCCP sample (Chapter 
5). Chapter 5 additionally reports on an attempt to replicate variants showing the GxE 
interaction in an independent NMIBC cohort (NBCS), albeit with no success. However, 
there are important limitations in the replication analysis that suggest an equivocal 
rather than a conclusive result. 
Chapter 6 continues to address the reproducibility issue in the field of UBC genetics, 
using UK Biobank [2] as the main data source. In this chapter, we present a newly-
developed algorithm for inferring UBC prognostic outcomes from hospital episode 
statistics (HES), Cancer and Death Registries, alongside demographic data. 
Subsequently, we tested all previously reported genetic loci for UBC recurrence, 
progression, and death (identified in Chapter 3) for their significance in a newly-
developed UBC patient cohort in the UK Biobank. Out of 165 SNPs, eight have 




In the first part of the discovery phase, we performed a GWAS to look for SNPs that 
might be associated with tumour stage, grade, size, risk group, and patient’s age 
among NMIBC cases. A total of 653 patients were available for the analysis, resulting 
in 61 loci reaching a statistical significance level of p<5E-08 [3]. Most of the SNPs 
(N=47) were associated with tumour size, whilst the rest were scattered across the 
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outcomes of age at diagnosis, tumour grade, and stage. NMIBC risk-group, however, 
did not yield any associations [3].  
Most of our discovered loci have not been previously reported in the context of UBC 
and we did not replicate any previous associations [4]. This finding alone cannot be 
held as an argument for their validity or lack thereof, but it does prompt some 
considerations, presented below. 
Many of the previous genetic analyses in UBC have targeted specific candidates [4, 
5], and were not designed to test beyond a specific hypothesis. Previously investigated 
hypotheses are the product of a variety of rationales: evidence for involvement in UBC 
whilst implying a specific pathway (e.g. NAT2 [6-9]), genes of general interest (e.g. 
TP53 [5, 10-15]), or potential significance of the locus to a wide range of phenotypes 
(e.g. rs1052133/Ser326Cys variant in OGG1 [16-22]). Regardless of the exact 
reasoning, all other genetic variation in a candidate-gene (CG) design remains terra 
incognita and can only be addressed in either an almost-infinite amount of CG studies, 
or in an agnostic design of GWAS [23]. Since the number of GWASs investigating 
specific UBC characteristics and subsequent prognosis is severely lacking [3, 24, 25], 
and most information comes from CG studies [4], they cannot be held as a single 
reference point. Moreover, the studied populations differ, as do exact methodologies 
and endpoints [4]. Given these considerations, explorations of the genetics of UBC 
are still in their infancy, where emphasis should be placed on collecting as much 
evidence as possible, instead of providing conclusions.  
In addition, GWASs have a well-recognised issue of multiple hypothesis testing [26-
28] which warrants applying stringent thresholds for defining statistical significance. 
The commonly-used p value of <5E-08 is usually too low to validate any associations 
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from CG studies, as they often regard the p value of <0.05 being sufficient for statistical 
significance [29, 30]. 
Importantly, our study addressed phenotypes that have rarely been targeted directly. 
Firstly, we limited our research to NMIBC, instead of a merged group of UBC. A 
mounting evidence shows NMIBC and MIBC are heterogeneous in their development 
[31, 32] and optimally require separate investigations. 
Moreover, we shifted the focus from overarching and potentially nebulous outcomes 
of cancer susceptibility and prognosis to specific characteristics at the time of NMIBC 
diagnosis. Identifying genetic associations for baseline characteristics might reveal 
subtle differences among NMIBC patients and point to potential pathological 
mechanisms. It is known that NMIBC prognosis is dependent on many factors which, 
when combined, define a risk category [33, 34] (Figure 1.4). In practice, baseline 
NMIBC characteristics are known to differ in their relative weight; for example, high 
grade is more predictive for NMIBC prognosis than tumour stage [33] (Table 1.2). Our 
analyses point to an abundance of potential associations with NMIBC tumour size at 
the time of diagnosis. If continuously replicated, these associations may be used in 
clinical practice to provide a better understanding of individual course of disease; for 
example, patients who are at a higher risk of developing large tumours may require a 
more intensive monitoring schedule even if the tumour at diagnosis is of low grade 
and/or stage.  
As such, when broad outcomes of recurrence and/or progression are studied, the 
independent roles of each characteristic might be overlooked. Consequently, it 
remains unknown whether a genetic locus contributes to the prognosis overall or, 
rather, is associated with a specific characteristic that is predictive of disease course. 
These considerations do not encourage abandoning the phenotypes of UBC 
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recurrence and progression, as they are important clinical outcomes for NMIBC 
patients [33]. However, other constituents of these outcomes should also be 
investigated to gather more knowledge on the genetic landscape of bladder cancer 
prognosis.  
Taking account of the above differences between this and previous studies in terms 
of design and outcomes, it is not surprising that our analysis yielded novel 
associations. 
Nonetheless, a few SNPs associated with NMIBC stage (Tis+T1 vs Ta) have been 
mapped to the SLCO1B1 gene, located on 12p12.1 [35]. SLCO1B1 has already been 
reported to increase UBC susceptibility in a Japanese population [36]. The SNP 
reported before (rs2306283) and those observed in our study are in weak LD 
(R2=0.003 for rs76497895 and rs116946525 in a global population), showing that they 
are most likely independent associations in a shared gene. SLCO1B1 codes a 
membrane transporter protein in hepatic cells, responsible for the clearance of multiple 
chemical compounds [37-40]. These proteins are involved in detoxification of various 
substances [37], and potentially includes carcinogens introduced by tobacco smoking 
[41]. Malfunctions in smoking-related metabolite clearance due to genetic variation 
have long been implicated to have a role in NMIBC development [7], with our study 
contributing additional findings in the same direction.  
Importantly, one study, performed by Bui et al. [36], showed a variant in SLCO1B1 
increased the risk of NMIBC only, without an association for MIBC. It is known that the 
UBC patient population largely comprises of NMIBC (75-80% [33, 42, 43]), and those 
mostly develop via the papillary pathway [31, 32]. The papillary pathway is linked with 
a better disease course [44]; however, some papillary cancers are genomically 
unstable and can develop into invasive cancers (Figure 1.1) [32, 45]. The two studies 
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may complement each other in suggesting that SLCO1B1 has implications for NMIBC. 
Whereas Bui et al. [36] show SLCO1B1 is associated with the development of NMIBC 
overall, our study potentially provides an in-depth investigation into the relevance of 
SLCO1B1 for subgroups of NMIBC. Variations in SLCO1B1 might pose a risk for 
NMIBCs that progress beyond the Ta stage and, hence, would require a more rapid 
intervention instead of a passive tumour surveillance. Importantly, our sample has 
merged Tis and Ta staged tumours due to low number is Tis (N=10) (Table 4.1), but 
given that large samples are available, Tis likely represents yet another entity in the 
context of bladder cancer. Such patterns could be particularly helpful in distinguishing 
between papillary NMIBCs with different progression risks at baseline and, therefore, 
may pose an attractive topic for future research, primarily to identify the role of specific 
SNPs and comparability of the findings across different populations.  
Although other identified loci in our GWAS [3] have not been previously reported for 
UBC, they have nonetheless received attention in the context of other phenotypes 
(Figure 7.1) [46]. To date, there are a variety of traits associated with each gene, and 
the lack of any clear pattern is indicative of the highly pleiotropic nature of genetic 
variation [47]. 
With well-described evidence of UBC susceptibility loci being involved in a GxE 
interaction with smoking [48, 49], our investigations extended to testing our newly 
discovered loci for their involvement in GxE with tobacco use. 
Analyses on all identified SNPs in the discovery stage identified ten variants that were 
also suggestive of an interaction with smoking status (defined as ever- or never-
smokers). Importantly, we observed patterns for SNPs being significant either 
irrespective of tobacco use, or in smokers only (Figure 5.2). We considered that the 
most promising locus was in PDE4B, and hypothesize that it may affect NMIBC tumour 
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size via altering the levels of intracellular cAMP, whilst cAMP concentration is 
concurrently modified by tobacco exposure (Figure 7.2).  
It is worth noting that PDE4B has been reported to be associated with smoking 
behaviour (amongst other genes, namely SLCO1B1, GNG7, ADARB1, and CNTN4).  
(Figure 7.1), and thus presents an interesting target for further investigation of its role 
in bladder cancer, smoking, and both taken together. 
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Figure 7.1. A map of genes identified in our study and previously associated phenotypes (GWASCatalog [46]).  
 178 
 
Figure 7.2. Proposed interaction mechanism between PDE4B and smoking on 
NMIBC tumour size (AhR – aryl hydrocarbon receptor; cAMP – cyclic 
adenosine monophosphate; CREB – cAMP response element binding protein; 
EGFR – epidermal growth factor receptor; PDE4B – phosphodiesterase 4B; 
PKA – protein kinase A). 
 
Furthermore, it is intriguing not to see variants in SLCO1B1 having significant 
interaction effects with smoking, especially due to the gene’s proposed role in clearing 
carcinogens [36]. In fact, in our stratified analyses by smoking status, SNPs in 
SLCO1B1 have only reached significance among smokers, but the interaction term 
itself was not significant. This discrepancy is likely due to the lack of power, and we 
would encourage other research groups to test variants in SLCO1B1 for interaction 
with smoking in larger samples of NMIBC. There need for investigations into solute-
carrier family genes is also strengthened by having another study reporting borderline 
significance for GxE interaction with smoking for a SNP in SLC14A1 (p=0.053) [48].  
Overall, the current thesis has explored the potential of genetic variation having an 
impact on NMIBC baseline characteristics, both independently and combined with an 
external exposure of smoking. These investigations have produced novel and 
intriguing findings. However, the use and true utility of our results is highly conditional 
on their validity and existing limitations. The remaining, and arguably the most 
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important part of the General Discussion focuses on various attempts of result 
replication and essential considerations when interpreting the current work.  
 
REPLICATION, REPLICATION, REPLICATION 
 
Our first attempt at replicating discovery results concerned the significant hits from our 
GWAS on NMIBC tumour size, stage, grade, and patent’s age. 
A sample of 1,470 bladder patients from the NBCS was available to use as an 
independent cohort. However, not a single discovery SNP was successfully replicated. 
One variant, namely rs180940944 in the NBEA gene, has reached statistical 
significance in the meta-analysis of the two cohorts; however, the effect is mostly 
driven by the BCPP samples. As a result, the lack of validation puts our initial results 
at a very high risk of falsity. Not surprisingly, the replication of SNPs significant for GxE 
interaction with smoking have also failed to produce promising results in the NBCS 
cohort. 
The differences in tested variant significance between the two cohorts are unlikely to 
be due to ethnicity. All UBC samples are of European origin, thus the distribution of 
alleles is expected to have similar frequencies. In addition, NBCS contains a higher 
number of UBC patients, resulting in a higher statistical power, especially for testing 
only pre-selected candidate variants. The high comparability of phenotypes also 
prevents outcome misclassifications. Sources of data used to define endpoints in all 
cohorts are considered to be reliable (e.g. Cancer Registries, hospital records, or 
information gathered during cystoscopy, as in the case of tumour size). Naturally, all 
measurements are subject to error, but we would not expect the degree of error to 
differ between BCPP and NCBS.  
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However, validation analyses also have their own drawbacks that make the overall 
interpretation more complex. Firstly, we were unable to test a fraction of our 
discovered SNPs in the NBCS cohort, as only 50 variants were accessible in the 
NBCS cohort. Unfortunately, one of the most promising variant in our analyses 
(rs2937268, mapped to the PDE4B) was unavailable in the NBCS. Consequently, 
replication of its involvement in GxE interaction with smoking has also not taken place.  
Secondly, although NBCS in total consists of 1,470 participants, the sample has 
dropped to 302 cases for the outcome of tumour size. Of note, tumour size gathered 
an overwhelming majority of our significant associations (47 out of 61). Given that only 
50 SNPs were available for replication overall, it resulted in virtually all of our variants 
(94%) being tested in a sample half the size of ours.  
Regardless of the existing limitations of the replication analyses, the biggest problems 
with conducting GWAS have been well-described before, and apply extensively to our 
discovery analyses, as discussed below. 
Firstly, the burden of testing multiple hypotheses in each GWAS can result in detecting 
significant results just by chance alone. Moreover, synthetic associations, defined as 
a link between non-causative SNP and the phenotype, may be a by-product of either 
a SNP being in linkage to a rare causative variant or an unmeasured source of error 
[30, 50]. Current empirical evidence suggests synthetic associations due to the 
causative SNP being rare may occur, but are unlikely to be the norm in genetic 
association studies [30]. To reduce the amount of unmeasured error in the current 
work, we have applied rigorous quality control (QC) procedures and adjusted the p 
value to detect only highly significant variants; however, the likelihood of false positives 
remains high [50].  
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Moreover, even considering that we have observed multiple significant hits, it is almost 
certain there are many more genetic variants that our study was severely 
underpowered to detect [30, 51, 52]. Penalising GWAS with very low significance 
threshold contributes to overlooking many variants of modest effect [30, 51], which 
has been described as one of the largest problem of GWAS, known as “missing 
heritability” [53].  
In the GWAS field, no panacea to these problems has been found. However, there 
are two main options for reducing the impact of false-positives and low study power.  
Firstly, increasing the sample size has been demonstrated as very effective for 
increasing the GWAS quality and result interpretation [30, 51, 52]. International 
consortia on various phenotypes, such as diabetes [54], schizophrenia [55], height 
and BMI [56] have validated multiple associations and substantially increased the 
explained proportion of heritability [52]. However, dramatic increases in sample sizes 
are not possible for all traits, including bladder cancer. The relatively low prevalence 
of UBC makes it virtually impossible to assemble cohorts exceeding a few thousand 
patients. Moreover, maintenance of such samples is financially challenging, as is 
measuring clinically-important bladder cancer traits may require very long-term follow-
up and repeated access to medical records to establish phenotypic variation over time 
(i.e. recurrence, progression, and death) [57]. 
However, the increasing availability of large, deeply-phenotyped population-based 
cohorts may provide an unprecedented opportunity to boost UBC sample sizes without 
recruiting new patients. As a first known attempt, the current work provides an 
algorithm for inferring clinical phenotypes based on recorded interventions in the UK 
Biobank (Chapter 7). Merging multiple sources of data, namely Cancer and Death 
Registries, HES, clinical records, and genotyping, allows the formation of an entirely 
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new cohort of relevant outcomes, using only publicly-available population-level data. 
Our developed framework may be tested and applied by any research group, and is 
not limited to the OPCS4 (Office of Population, Censuses and Surveys: Classification 
of Interventions and Procedures, Version 4) coding system, as our defined rules can 
be translated to other intervention classification systems (e.g. International 
Classification of Health Interventions, ICHI). Naturally, our approach and algorithm 
assumptions must be calibrated according to further input by a wider net of 
professionals (both urologists and genetic epidemiologists), but it nonetheless marks 
the beginning of efforts to increase UBC sample sizes with meaningful phenotypes in 
observational research.  
Aside from increasing sample sizes, a second option for reducing the limitations of 
multiple testing in genetic studies is to reduce the number of comparisons [51]. CG 
studies have been widely regarded as inferior to GWAS [58], but investigation of well-
defined hypotheses cannot be undermined. For example, even though replication 
studies target only a subset of associations, they are of very high value for identifying 
the most–promising genetic loci [26]. Potentially, the lack of replication studies in 
genetic epidemiology is detrimental to setting appropriate guidance for future 
research. As most of the findings from the investigations of genetic factors for UBC 
prognosis have limited validation (Chapter 3), we have also addressed this issue by 
attempting to replicate all previously reported genetic loci for UBC prognosis in the UK 
Biobank. Eight SNPs have reached nominal statistical significance, located in CWC27 
(UBC recurrence), NEIL2 (NMIBC recurrence), EGFR (UBC overall survival), PDCD6 
(NMIBC overall survival), RGS5 (MIBC overall survival), and NOS2 (UBC 
progression). However, as discussed in our own effort to replicate genetic 
associations, one external validation study cannot be seen as providing definitive 
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results. There are many differences between discovery and replication cohorts for 
most SNPs, especially in terms of ethnicity. In fact, ancestral divergence in discovery 
and replication samples has been recognised as one of the main culprits for failure to 
replicate SNP signals [26].  
Our tested phenotypes were modelled as closely as possible to the originals, but 
complete identity is unlikely to have been achieved. Nonetheless, the most promising 
finding of a variant in CWC27 could be a target of interest in future studies on UBC 
recurrence. 
To summarise, replication of associations is an essential part of genetic epidemiology. 
These efforts are laborious and time-consuming, yet essential for prioritising loci of 
interest. The current dissertation contributes meaningful evidence to the 
understanding of genetic variation in bladder cancer. Arguably, another valuable 
contribution of this thesis is describing a first attempt for using large population-level 




Based on the currently described work, it is inevitable that bladder cancer research 
will expand in its complexity, and there are several directions that can be expected 
within the field in the upcoming years.  
Firstly, the era of genomics overlaps with the era of big data, where the need for 
merging multiple sources of information is well recognised and is in a constant process 
of implementation. As such, the potential for advanced analyses grows significantly. 
The use of conventional linear and logistic regression will likely be replaced by 
machine learning and artificial intelligence methods that are better equipped to handle 
large datasets [51]. Moreover, applying machine learning allows the data to “speak for 
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itself”, as there are fewer assumptions imposed by the researcher. Importantly, most 
statistical testing will also shift from a purely frequentist approach to Bayesian, which 
accounts for all possible hypotheses in a given dataset. Optimally, both tests are used 
simultaneously to identify most-promising results. For example, Bayes factor statistic 
was calculated in Chapter 6 for the validation of previously reported prognostic loci, 
and has provided meaningful information of the strength of each replicated SNP.  
Secondly, increasing UBC sample sizes for discovery and replication analyses is of 
major importance. The collaborations between different research groups are 
understandably difficult, but the success stories of other phenotypes may prove 
inspirational for accumulating data to provide high quality investigation into bladder 
cancer genetics [30, 51]. 
Finally, with advances in statistical analyses and increasing sample sizes, the field will 
be able to move from only detecting SNPs of interest to analysing more complex 
notions: epistatic and gene-environment interactions, biological pathways and their 
utility in a clinical setting, the level of pleiotropy of discovered loci, as well as aspects 




Genetic association studies for a complex and heterogeneous disease such as UBC 
have inherent limitations and demand careful interpretation. However, success likely 
follows resilient efforts, trial and error, as well as rumination. The current thesis should 
be viewed not as an isolated piece of work offering conclusive findings, but as a 
contribution into the field that can only be evaluated properly in a wider context of 
bladder cancer genetics. This thesis suggests bladder cancer baseline characteristics 
and prognosis are influenced by a variety of single nucleotide polymorphisms, albeit 
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requiring further validation. Moreover, genetic associations with bladder cancer 
phenotypes are expected to interact with tobacco exposure, and should be explored 
further. Data mining of multiple data sources may prove very useful to continue 
investigations into new discoveries and replications.  
Finally, the mixture of collaborative efforts in the era of big data offers endless 
opportunities, where methodology is equally driven by experience, creativity, and 
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Supplementary Table 3.1. A checklist for the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  64 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
65 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  66 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
66, 67 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
- 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
67- 69 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
67 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
67 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 





Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
- 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
69 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
69 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  - 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
69 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
69 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
69, 70 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
Figure 3.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 




Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  69 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Supplementary 
Tables 3.2-3.8 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  - 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  69 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 75, 76 
 193 
Item 16]).  
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
76-79 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
79 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
79 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
- 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Supplementary Table 3.2. Summary associations for previously reported SNPs on age at the time of diagnosis for urinary bladder 
cancer. 
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Supplementary Table 3.4. Summary associations for previously reported SNPs on stage at the time of diagnosis for urinary 
bladder cancer. 
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Associations for stages of T2+: 
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Supplementary Table 3.5. Summary associations for previously reported SNPs on tumour grade at the time of diagnosis for 
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Supplementary Table 3.6. Summary associations for previously reported SNPs on urinary bladder cancer risk group at the time of 
diagnosis. 
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Supplementary Table 3.7. Summary associations for previously reported SNPs on urinary bladder cancer recurrence. 
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BCG-Bacillus Calmette-Guérin; CI-confidence interval; CIS-carcinoma in situ; EA-effect allele; EAF-effect allele frequency; MIBC-muscle-invasive 
bladder cancer; NMIBC-non-muscle-invasive bladder cancer; OR-odds ratio; RA-reference allele; SNP-single nucleotide polymorphism; TUR-
transurethral resection; UBC-urinary bladder cancer; UC-urothelial carcinoma; 1KG-1000 Genomes Project. 
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Supplementary Table 3.8. Summary associations for previously reported SNPs on urinary bladder cancer progression. 
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BCG-Bacillus Calmette-Guérin; CI-confidence interval; CIS-carcinoma in situ; EA-effect allele; EAF-effect allele frequency; MIBC-muscle-invasive 
bladder cancer; NMIBC-non-muscle-invasive bladder cancer; OR-odds ratio; RA-reference allele; SNP-single nucleotide polymorphism; TUR-
transurethral resection; UBC-urinary bladder cancer; UC-urothelial carcinoma; 1KG-1000 Genomes Project. 
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Supplementary Table 3.9. Summary associations for previously reported SNPs on overall and cancer-specific survival for urinary 
bladder cancer. 
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CI-confidence interval; EA-effect allele; EAF-effect allele frequency; MIBC-muscle-invasive bladder cancer; NMIBC-non-muscle-invasive bladder 
cancer; OR-odds ratio; RA-reference allele; SNP-single nucleotide polymorphism; UBC-urinary bladder cancer; UC-urothelial carcinoma; 1KG-
1000 Genomes Project. 
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Supplementary Table 3.10. Gene clusters by functional annotation for urinary 















































GO:0007442~hindgut morphogenesis GLI2, GLI3, SHH 0.01 0.02 
hsa04340:Hedgehog signaling pathway GLI2, GLI3, SHH 0.29 3.34 
GO:0042475~odontogenesis of dentin-
containing tooth 








GLI2, GLI3, SHH 
0.95 6.76 
GO:0030324~lung development GLI2, GLI3, SHH 0.97 8.11 
h_shhPathway:Sonic Hedgehog (Shh) 
Pathway 
GLI2, GLI3, SHH 
0.45 8.75 
hsa05217:Basal cell carcinoma GLI2, GLI3, SHH 0.74 12.39 
GO:0007411~axon guidance GLI2, GLI3, SHH 1.00 29.44 
GO:0007507~heart development GLI2, GLI3, SHH 1.00 36.49 
* As listed in DAVID 
   
FDR-false discovery rate 
   
 
Supplementary Table 3.11. Enrichment in functional pathways for genes reported 
for bladder cancer recurrence (DAVID tool). 






hsa05200:Pathways in cancer CXCL8, NFKBIA, IGF1, CDH1, 




GLI2, GLI3, SHH 
0.008 0.02 
GO:0045944~positive regulation of 
transcription from RNA polymerase 
II promoter 
VDR, SLC11A1, IL17A, IFNG, 
NFKBIA, IGF1, GLI2, GLI3, SHH 0.04 0.09 
GO:0048566~embryonic digestive 
tract development 
CXCL8, GLI2, GLI3 
0.15 0.37 
IPR024066:Regulator of G-protein 
signaling domain 1 
RGS10, RGS16, RGS13 
0.04 0.43 
GO:0043066~negative regulation of 
apoptotic process 
NFKBIA, IGF1, BIRC5, GLI2, 
GLI3, SHH 
0.26 0.72 
domain:RGS RGS10, RGS16, RGS13 0.12 0.93 
GO:0000060~protein import into 
nucleus translocation 
SLC11A1, IFNG, NFKBIA 
0.39 1.16 
sequence variant ICAM1, CWC27, NEIL2, NFKBIA, 
IGF1, CDH1, BIRC5, SOD1, 
RGS16, GLI2, GLI3, MMP2, SHH, 
RGS13, GSS, DROSHA, 
SLC11A1, RGS10, VDR, ERCC6, 
GPX4, IFNG, ALDH2, DDX20 
0.13 1.01 
mutagenesis site DROSHA, VDR, GPX4, NEIL2, 
NFKBIA, CDH1, BIRC5, RGS16, 
SOD1, SHH 
0.13 1.05 
IPR016137:Regulator of G protein 
signalling superfamily 
RGS10, RGS16, RGS13 
0.11 1.35 
Signal transduction inhibitor RGS10, RGS16, RGS14 0.15 1.55 
SM00315:RGS RGS10, RGS16, RGS15 0.03 1.19 
GO:0005615~extracellular space ICAM1, IL17A, IFNG, CXCL8, 
IGF1, SOD1, MMP2, SHH 
0.15 1.90 
Disease mutation GSS, VDR, ERCC6, NFKBIA, 
CDH1, GLI2, SOD1, GLI3, MMP2, 
SHH 
0.23 2.45 
hsa05323:Rheumatoid arthritis ICAM1, IL17A, IFNG, CXCL8 0.23 2.56 
hsa04340:Hedgehog signaling 
pathway 












GSS, CXCL8, SOD1 
0.21 3.47 
*As listed in DAVID.  
FDR-false discovery rate    
 
Supplementary Table 3.12. Enrichment in functional pathways for genes reported 
for bladder cancer death (DAVID tool). 





hsa05212:Pancreatic cancer TGFBR1, BCL2L1, 
PIK3R1, AKT2 
0.05 0.47 
GO:0046326~positive regulation of glucose import PIK3R1, TERT, 
AKT2 
0.22 0.74 





hsa05220:Chronic myeloid leukemia TGFBR1, BCL2L1, 
PIK3R1, AKT2 
0.06 0.64 








































*As listed in DAVID    
FDR-false discovery rate.    
 
Supplementary Figure 5.1 eQTL effect of rs144383242 (6q14.1) across multiple 
tissues (source: GTEx). 
 
 
Supplementary Figure 5.2. Boxplot of an eQTL effect of rs144383242 (6q14.1) in 




Supplementary Table 6.1 Previously reported polymorphisms in association with bladder cancer recurrence. 
Outcome SNP Locus Gene EA RA EAF* Discovery population References 
High-risk NMIBC Recurrence (BCG-treated) rs2070744 7q36.1 NOS3 T C 0.77 European (Sweden) Ryk et al.[1] 
High-risk NMIBC Recurrence (BCG-treated) rs1799983 7q36.1 NOS3 G T 0.82 European (Sweden) Ryk et al.[1] 
Low-risk NMIBC recurrence rs744154 
16p13.1
2 
ERCC4 C A 0.22 Chinese Wang et al. [2] 
Low-risk NMIBC recurrence rs798766 4p16.3 
TACC3/FGFR
3 
T C 0.24 European (multiple) Kiemeney et al. [3] 
MIBC Recurrence rs4957014 5p15.33 PDCD6 G T 0.65 Chinese Zhou et al. [4] 
MIBC recurrence rs4758680 
12q24.3
1 
IL31 A C 0.29 Chinese Li et al. [5] 
















A T 0.57 Chinese Zhang et al. [6] 
NMIBC Recurrence rs2910164 5q33.3 MIR146A C G 
0.28 
(ExAC) 
Chinese Wang et al. [7] 
NMIBC Recurrence rs511918 1q25.3 RGS16 T G 0.47 Caucasian (Northern American) Lee et al. [8] 
NMIBC Recurrence rs16829458 1q31.2 RGS2 A G 0.12 Caucasian (Northern American) Lee et al. [8] 
NMIBC Recurrence rs3795617 1q31.2 RGS13 A G 0.38 Caucasian (Northern American) Lee et al. [8] 
NMIBC Recurrence rs11199005 
10q26.1
1 
RGS10 A G 0.35 Caucasian (Northern American) Lee et al. [8] 
NMIBC Recurrence rs1323291 1q31.2 RGS1 C A 0.15 Caucasian (Northern American) Lee et al. [8] 
NMIBC Recurrence rs5742714 12q23.2 IGF1 C G 0.9 Caucasian (Northern American) Andrew et al. [9] 
NMIBC Recurrence rs2238151 
12q24.1
2 
ALDH2 C T 0.7 Caucasian (Northern American) Andrew et al. [9] 
NMIBC Recurrence rs2169830 15q14 THBS1 G A 0.42 Chinese Yang et al. [10] 
NMIBC recurrence (<64-year-old group) rs1050450 3p21.31 GPX1 T C 0.22 Caucasian (Northern American) Zhao et al. [11] 
NMIBC recurrence (BCG-treated) rs16260 16q22.1 CDH1 A C 0.24 Caucasian (Northern American) Lin et al. [12] 
NMIBC recurrence (BCG-treated) rs4645978 1p36.21 CASP9 G A 0.42 Indian Gangwar et al. [13] 
NMIBC Recurrence (BCG-treated) rs7003908 8q11.21 PRKDC G T 0.33 Indian Gangwar et al. [14] 
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NMIBC Recurrence (BCG-treated) rs9904341 17q25.3 BIRC5 C G 0.39 Indian Jaiswal et al. [15] 
NMIBC Recurrence (BCG-treated) rs804267 8p23.1 NEIL2 C T 0.31 Caucasian (Northern American) Wei et al. [16] 
NMIBC Recurrence (BCG-treated) rs8191604 8p23.1 NEIL2 C A 0.18 Caucasian (Northern American) Wei et al. [16] 
NMIBC recurrence (BCG-treated) rs17235409 2q35 SLC11A1 A G 0.07 Caucasian (Canadian), Chinese 
Decobert et al. [17],  
Chiong et al. [18] 
NMIBC recurrence (BCG-treated) rs1799782 19q13.2 XRCC1 T C 0.12 Indian Mittal et al. [19] 
NMIBC recurrence (BCG-treated) rs2228526 
10q11.2
3 
ERCC6 C G 0.18 Caucasian (Northern American) Gu et al. [20] 
NMIBC recurrence (BCG-treated) rs25487 19q13.2 XRCC1 A G 0.26 Indian Mittal et al. [19] 
NMIBC recurrence (BCG-treated) rs1799793 19q13.3 ERCC2 A G 0.19 Indian 
Gangawar et al. 
[21] 
NMIBC recurrence (BCG-treated) rs2430561 12q15 IFN-G A T 0.28 Indian Ahirwar et al. [22] 
NMIBC Recurrence (BCG-treated) rs2228001 3p25.1 XPC C A 0.32 Indian Gangwar et al. [23] 
NMIBC Recurrence (BCG-treated) rs6463089 7p14.1 GLI3 A G 0.09 
Caucasians (Northern American) + 
European (Spain) for replication 
Chen et al. [24] 
NMIBC Recurrence (BCG-treated) rs3801192 7p14.1 GLI3 A G 0.07 
Caucasians (Northern American) + 
European (Spain) for replication 
Chen et al. [24] 
NMIBC Recurrence (BCG-treated) rs1233560 7q36.3 SHH G A 0.46 
Caucasians (Northern American) + 
European (Spain) for replication 
Chen et al. [24] 
NMIBC Recurrence (BCG-treated) rs11685068 2q14.2 GLI2 A G 0.06 
Caucasians (Northern American) + 
European (Spain) for replication 
Chen et al. [24] 
NMIBC Recurrence (BCG-treated) rs243865 16q12.2 MMP2 C T 0.86 Indian 
Srivastava et al. 
[25] 
NMIBC Recurrence (BCG-treated) rs804276 8p23.1 NEIL2 G A 0.62 Caucasian (Northern American) Wei et al. [16] 
NMIBC Recurrence (BCG-treated) rs4639 8p23.1 NEIL2 G A 0.47 Caucasian (Northern American) Wei et al. [16] 
NMIBC Recurrence (BCG-treated) rs2173962 
21q22.1
1 
SOD1 G A 0.06 Caucasian (Northern American) Wei et al. [16] 
NMIBC Recurrence (BCG-treated) rs187238 11q23.1 IL18 C G 0.79 Indian Jaiswal et al. [26] 
NMIBC Recurrence (BCG-treated) rs1695 11q13.2 GSTP1 G A 0.35 Chinese Deng et al. [27] 
NMIBC Recurrence (BCG-treated) rs4925 10q25.1 GSTO1 A C 0.1 Chinese Deng et al. [27] 
NMIBC Recurrence (BCG-treated) rs3138056 14q13.2 NFKBIA T? C? 0.38 (T) Northern American Williams et al. [28] 
NMIBC Recurrence (BCG-treated) rs1544410 
12q13.1
1 
VDR A G 0.3 Chinese Wang et al. [29] 
NMIBC Recurrence (BCG-treated), NMIBC 
Recurrence 
rs2279744 12q15 MDM2 G T 0.37 Indian, Chinese 
Gangwar et al. [30],  
Xie et al. [31] 
NMIBC recurrence (BCG-treated), NMIBC 
recurrence (maintenance BCG-treated) 
rs1800795 7p15.3 IL6 C G 0.14 Indian, Caucasian (White) 
Ahirwar et al. [32],  
Leibovici et al. [33] 
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NMIBC recurrence (BCG-treated), NMIBC 
Recurrence (TUR- and BCG-treated) 
rs1799964 6p21.33 TNFA C T 0.22 
Indian, 
European (Southern Portugal) 
Ahirwar et al. [34], 
 Lima et al. [35] 
NMIBC Recurrence (Epirubicin-treated) rs915927 19q13.2 XRCC1 G A 0.32 Chinese Li et al. [36] 
NMIBC Recurrence (Epirubicin-treated) rs2854501 19q13.2 XRCC1 T C 0.18 Chinese Li et al. [36] 
NMIBC recurrence (non-BCG-treated) rs1801282 3p25.2 PPARG G C 0.07 Caucasian (White) Leibovici et al. [33] 







3p21.31 CCR2 A G 0.41 European (Southern Portugal) Lima et al. [35] 
NMIBC Recurrence (TUR- and BCG-
treated) 
rs5498 19p13.2 ICAM1 G A 0.36 European (Southern Portugal) Lima et al. [35] 
NMIBC Recurrence (TUR- and BCG-
treated) 
rs2275913 6p12.2 IL17A A G 0.29 European (Southern Portugal) Lima et al. [35] 
NMIBC Recurrence (TUR- and BCG-
treated) 
rs13278062 8p21.3 TNFRSF10A G T 0.6 European (Southern Portugal) Lima et al. [35] 
NMIBC Recurrence (TUR- and BCG-
treated) 
rs3746162 19p13.3 GPX4 A G 0.16 Caucasians (European decent) Ke et al. [37] 





GSS A G 0.19 Caucasians (European decent) Ke et al. [37] 





GSS A C 0.26 Caucasians (European decent) Ke et al. [37] 





GSS A G 0.22 Caucasians (European decent) Ke et al. [37] 





GSS C A 0.28 Caucasians (European decent) Ke et al. [37] 





XRCC1 A C 0.82 Chinese Deng et al. [38] 





XRCC1 C T 0.32 Chinese Deng et al. [38] 
NMIBC Recurrence (TUR-treated) rs1042522 17p13.1 TP53 C G 0.54 Japanese Horikawa et al. [39] 
NMIBC Recurrence (TUR-treated) rs197412 1p13.2 DDX20 T C 0.53 Caucasian (Northern American) Ke et al. [40] 
NMIBC Recurrence (TUR-treated) rs12186785 5p13.3 DROSHA C T 0.05 Caucasian (Northern American) Ke et al. [40] 
NMIBC Recurrence-(BCG-treated) rs804256 8p23.1 NEIL2 C T 0.26 Caucasian (Northern American) Wei et al. [16] 
NMIBC Recurrence, NMIBC Recurrence 
(non-BCG-treated) 
rs1052133 3p25.3 OGG1 G C 0.3 Korean, Indian 
Kim et al. [41],  
Gangwar et al. [14] 
Recurrence rs2042329 5q12.3 CWC27 T G 0.34 Chinese Wang et al. [42] 
UBC Recurrence rs2292016 5p13.1 OSMR T G 0.08 Chinese Deng et al. [43] 
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UBC Recurrence rs2278329 5p13.1 OSMR A G 0.08 Chinese Deng et al. [43] 
UBC Recurrence (BCG-treated) rs4073 4q13.3 CXCL8 A T 0.52 Indian Ahirwar et al. [44] 
BCG-Bacillus Calmette-Guérin; EA-effect allele; EAF-effect allele frequency; MIBC-muscle-invasive bladder cancer; NMIBC-non-muscle-invasive bladder 
cancer; RA-reference allele; SNP-single nucleotide polymorphism; TUR-transurethral resection; UBC-urinary bladder cancer. 
*Global, based on 1000 Genomes Project. 
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Supplementary Table 6.2. Previously reported polymorphisms in association with bladder cancer death. 
Outcome SNP Locus Gene EA RA EAF* Discovery population References 
High-risk NMIBC Cancer-specific death 
(BCG-treated) 
rs1799983 7q36.1 NOS3 G T 0.82 European (Sweden) Ryk et al. [1] 
MIBC Cancer-specific death rs1800795 7p15.3 IL6 C G 0.14 Caucasian (White) Leibovici et al.[2] 
MIBC Cancer-specific death rs334358 9q22.33 TGFBR1 T G 0.12 European (Spain) Castillejo et al. [3] 
MIBC Cancer-specific death rs868 9q22.33 TGFBR1 G A 0.12 European (Spain) Castillejo et al. [3] 
MIBC Cancer-specific death 
(Cystectomy-treated) 
rs1042522 17p13.1 TP53 C G 0.54 Japanese Horikawa et al. [4] 
MIBC Cancer-specific death 
(Radiotherapy-treated) 
rs7180135 15q15.1 RAD51 G A 0.27 European (United Kingdom) Teo et al. [5] 
MIBC Cancer-specific death 
(Radiotherapy-treated) 
rs1805363 11q21 MRE11 A G 0.03 European (Denmark) Teo et al. [6] 
MIBC Overall survival rs9906827 17q25.3 RPTOR A G 0.42 
Caucasian (Northern 
American) 
Chen et al. [7] 
MIBC Overall survival rs1051013 9q32 RGS3 A/C T 0.84 
Caucasian (Northern 
American) 
Lee et al. [8] 
MIBC Overall survival rs1395960 1q23.3 RGS5 A G 0.24 
Caucasian (Northern 
American) 
Lee et al. [8] 
MIBC Overall survival rs762861 4p16.3 RGS12 C G 0.36 
Caucasian (Northern 
American) 
Lee et al. [8] 
MIBC Overall survival rs17855750 16p12.1-p11.2 IL27 G T 0.07 Chinese Zhou et al. [9]  
MIBC Overall survival rs10515074 5q13.1 PIK3R1 G A 0.2 
Caucasian (Northern 
American) 
Chen et al. [7] 
MIBC Overall survival rs3730050 19q13.2 AKT2 A G 0.25 
Caucasian (Northern 
American) 
Chen et al. [7] 
MIBC Overall survival rs2344673 1q23.3 RGS5 A G 0.05 
Caucasian (Northern 
American) 
Lee et al. [8] 
MIBC Overall survival rs10917690 1q23.3 RGS5 G A 0.29 
Caucasian (Northern 
American) 
Lee et al. [8] 
MIBC Overall survival rs1890398 1q31.2 RGS2 C T 0.56 
Caucasian (Northern 
American) 
Lee et al. [8] 
MIBC Overall survival rs12035879 1q23.3 RGS5 G A 0.68 
Caucasian (Northern 
American) 
Lee et al. [8] 
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MIBC Overall survival rs10753605 1q23.3 RGS5 C T 0.35 
Caucasian (Northern 
American) 
Lee et al. [8] 
MIBC Overall survival rs156697 10q25.1 GSTO2 G A 0.56 European (Serbia) Djukic et al. [10] 
MIBC Overall survival rs4925 10q25.1 GSTO1 A C 0.18 European (Serbia) Djukic et al. [10] 
MIBC Overall survival (Platinum-based 
chemotherapy-treated) 
rs11615 19q13.32 ERCC1 T C 0.33 Chinese Xu et al. [11] 
NMIBC Overall survival rs2662238 5q14.2 XRCC4 A G 0.36 
Caucasian (Northern 
American) 
Andrew et al. [12] 
NMIBC Overall survival rs4987059 11p15.5 DRD4 A G 0.04 
Caucasian (Northern 
American) 
Andrew et al. [12] 
NMIBC Overall survival rs3756712 5p15.33 PDCD6 G T 0.4 Chinese Zhou et al. [13] 
NMIBC Overall survival  rs2292016 5p13.1 OSMR T G 0.08 Chinese Deng et al. [14] 
UBC Cancer-specific death rs2279744 12q15 MDM2 G T 0.37 Japanese 
Shinohara et al. 
[15] 
UBC Cancer-specific death rs4129009 4p14 TLR10 T C 0.85 European (Spain) Guirado et al. [16] 
UBC Cancer-specific death rs1801133 1p36.22 MTHFR T C 0.25 European (Sweden) Sanyal et al. [17] 
UBC Cancer-specific death rs5443 12p13.31 GNB3 T C 0.49 European (Germany) 
Eisenhardt et al. 
[18] 
UBC Cancer-specific death rs9302752 16q12.1 NOD2 A G 0.5 European (Spain) Guirado et al. [16] 
UBC Overall survival rs13181 19q13.3 ERCC2 C A 0.24 European (Sweden) Sanyal et al. [19] 
UBC Overall survival rs2854461 1q42.12 EPHX1 C A 0.64 
Caucasian (Northern 
American) 
Andrew et al. [20] 
UBC Overall survival rs2279115 18q21.33 BCL2 A C 0.39 European (Germany) Hess et al. [21] 





7p11.2 EGFR A G 0.29 
Caucasian (Northern 
American) 
Mason et al. [22] 
UBC Overall survival rs2017000 7p11.2 EGFR G A 0.33 
Caucasian (Northern 
American) 
Mason et al. [22] 





16q22.1 NQO1 T C 0.02 European (Sweden) Sanyal et al. [17] 
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UBC Overall survival rs6024840 20q13.2 AURKA C T 0.45 
Caucasian (Northern 
American) 
Andrew et al. [20] 
UBC Overall survival rs1042640 2q37.1 UGT1A1 C G 0.82 
Caucasian (Northern 
American) 
Andrew et al. [20] 
UBC Overall survival rs1126579 2q35 CXCR2 C T 0.6 
Caucasian (Northern 
American) 
Andrew et al. [20] 
UBC Overall survival rs528778 10p14 GATA3 T C 0.14 
Caucasian (Northern 
American) 
Andrew et al. [20]  
UBC Overall survival rs1800067 16p13.12 ERCC4 A G 0.03 
Caucasian (Northern 
American) 
Andrew et al. [20] 
UBC Overall survival rs1994251 20q11.21 BCL2L1 C A 0.24 
Caucasian (Northern 
American) 
Andrew et al. [20] 
UBC Overall survival rs9282638 3q13.33 CD80 A G 0.87 
Caucasian (Northern 
American) 
Andrew et al. [20] 
UBC Overall survival rs35402311 8q11.23 RB1CC1 T C 0.02 
Caucasian (Northern 
American) 
Andrew et al. [20] 
UBC Overall survival rs1801018 18q21.33 BCL2 A G 0.76 European (Germany) Hess et al. [21] 
UBC Overall survival rs2293347 7p11.2 EGFR T C 0.14 
Caucasian (Northern 
American) 
Mason et al. [22] 
UBC Overall survival (Chemotherapy-
treated) 
rs915927 19q13.2 XRCC1 G A 0.32 European (Italy) 
Sacerdote et al. 
[23] 
UBC Overall survival (Chemotherapy-
treated) 
rs762507 19q13.2 XRCC1 A G 0.29 European (Italy) 
Sacerdote et al. 
[23] 
UBC Overall survival (Chemotherapy-
treated) 
rs2854501 19q13.2 XRCC1 T C 0.82 European (Italy) 
Sacerdote et al. 
[23] 
UBC Overall survival (Chemotherapy-
treated) 
rs2854509 19q13.2 XRCC1 A C 0.18 European (Italy) 
Sacerdote et al. 
[23] 
UBC Overall survival (Chemotherapy-
treated) 
rs3213255 19q13.2 XRCC1 C T 0.32 European (Italy) 
Sacerdote et al. 
[23] 
UBC Overall survival (Chemotherapy-
treated) 
rs171140 19q13.3 ERCC2 C A 0.37 European (Italy) 
Sacerdote et al. 
[23] 
BCG-Bacillus Calmette-Guérin; EA-effect allele; EAF-effect allele frequency; MIBC-muscle-invasive bladder cancer; NMIBC-non-muscle-invasive 
bladder cancer; RA-reference allele; SNP-single nucleotide polymorphism; TUR-transurethral resection; UBC-urinary bladder cancer. 
*Global, based on 1000 Genomes 
Project. 
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Supplementary Table 6.3. Previously reported polymorphisms in association with age at the time of bladder cancer diagnosis. 
Outcome SNP Locus Gene EA RA EAF* Discovery population References 
Age, years rs798766 4p16.3 TACC3/FGFR3 T C 0.24 European (Multiple) Kiemeney et al. [1] 
Age (≥50 years) rs25487 19q13.2 XRCC1 A G 0.26 
Caucasian (Northern 
American) 
Kelsey et al. [2] 
 Age (>56 years) rs710521 3q28 TP63 A G 0.8 
Caucasian (Northern 
American) 
Stern et al. [3] 
Age (>60 years) rs874945 12q13.13 HOTAIR A G 0.36 Chinese Wang et al. [4] 
Age (>60 years) rs710886 8q24.21 PCAT1 G A 0.47 Chinese Lin et al. [5] 
Age (≤60 years) rs217727 11p15.5 H19 (lncRNA) A G 0.2 Chinese Hua et al. [6] 
Age (>65 years) rs1052133 3p25.3 OGG1 G C 0.3 Chinese Ma et al. [7] 
Age (>65 years) rs884225 7p11.2 EGFR C T 0.19 Chinese Chu et al. [8] 
Age (>65 years) rs7003908 8q11.21 PRKDC T G 0.33 Chinese Wang et al. [9] 
Age (>65 years) rs1057868 7q11.23 POR T C 0.29 Chinese Xiao et al. [10] 
Age (≤65 years / Healthy controls) rs9642880 8q24.21 CASC11 T G 0.54 Chinese Wang et al. [11] 
Age (≥65 years / Healthy controls) rs9344 11q13.3 CCND1 A G 0.41 Chinese Yuan et al. [12] 
Age (</≥70.2) rs41515546 7q31.33 - C T 0.14 European Lipunova et al. [13] 
Age (</≥70.2) rs17149636 7q31.33 - G A 0.14 European Lipunova et al. [13] 
Age (</≥70.2) rs17149628 7q31.33 - T C 0.14 European Lipunova et al. [13] 
Age (</≥70.2) rs12666814 7q31.33 - T C 0.14 European Lipunova et al. [13] 
Age (</≥70.2) rs73223045 7q31.33 - C G 0.14 European Lipunova et al. [13] 
Age (</≥70.2) rs12673089 7q31.33 - T C 0.14 European Lipunova et al. [13] 
Age (</≥70.2) rs17149580 7q31.33 - G A 0.14 European Lipunova et al. [13] 
Age (</≥70.2) rs17149630 7q31.33 - T C 0.14 European Lipunova et al. [13] 
EA-effect allele; EAF-effect allele frequency; MIBC-muscle-invasive bladder cancer; NMIBC-non-muscle-invasive bladder cancer; RA-reference allele; 
SNP-single nucleotide polymorphism 
*Global, based on 1000 Genomes Project. 
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Supplementary Table 6.4. Previously reported polymorphisms in association with bladder cancer progression. 






11p15.5 HRAS C T 0.30 European (Sweden) Sanyal et al. [1] 
UBC Progression rs2297518 17q11.2 NOS2 T C 0.17  European (Sweden) Ryk et al. [2] 
NMIBC Progression rs10917690 1q23.3 RGS5 G A 0.29 Caucasian (Northern American) Lee et al. [3] 
NMIBC Progression rs4075958 5q35.3 RGS14 A G 0.18  Caucasian (Northern American) Lee et al. [3] 
NMIBC Progression rs10926466 1q23.1 RGS7 T C 0.63 Caucasian (Northern American) Lee et al. [3] 
NMIBC Progression rs12038803 1q23.1 RGS7 
C/G/T? (Not 
reported) 
A 0.66 Caucasian (Northern American) Lee et al. [3] 
High-risk NMIBC 
Progression (BCG-treated) 
rs2070744 7q36.1 NOS3 T C 0.77 European (Sweden) Ryk et al. [4] 
High-risk NMIBC 
Progression (BCG-treated) 
rs1799983 7q36.1 NOS3 G T 0.82 European (Sweden) Ryk et al. [4] 
UBC Progression 
(metastases present) 
rs2910164 5q33.3 MIR146A G C 
0.32 
(TOPMED) 
Chinese Deng et al. [5] 
NMIBC Progression rs3088440 9p21 CDKN2A T C 0.17  European (Sweden) Sakano et al. [6] 
NMIBC progression (BCG-
treated) 
rs1800896 1q32.1 IL10 G A 0.27 Turkish Basturk et al. [7] 
NMIBC progression (BCG-
treated) 
rs2243248 5q31.1 IL4 G T 0.11 Turkish Basturk et al. [7] 
NMIBC progression (BCG-
treated) 
rs1800470 19q13.2 TGFB1 T C 0.55 Turkish Basturk et al. [7]  
NMIBC progression (BCG-
treated) 
rs1800471 19q13.2 TGFB1 G C 0.05 Turkish Basturk et al. [7]  
Progression (metastases 
present) 
rs9302752 16q12.1 NOD2 G A 0.50 European (Spain) Guirado et al. [8] 
NMIBC Progression rs3890995 12q24.11 UNG C T 0.22  Caucasian (Northern American) Wei et al. [9] 
NMIBC Progression (TUR-
treated) 
rs720012 22q11.21 DGCR8 A G 0.22  Caucasian (Northern American) Ke et al. [10] 
NMIBC Progression (TUR-
treated) 
rs2073778 22q11.21 DGCR8 T C 0.22 Caucasian (Northern American) Ke et al. [10]  
NMIBC Progression rs1323291 1q31.2 RGS1 C A 0.15 Caucasian (Northern American) Lee et al. [3]  
NMIBC Progression rs6678136 1q23.3 RGS4 A G 0.46 Caucasian (Northern American) Lee et al. [3] 
NMIBC Progression rs11585883 1q23.3 RGS5 C T 0.03 Caucasian (Northern American) Lee et al. [3] 
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MIBC Progression  rs11615 19q13.32 ERCC1 T C 0.33 Chinese Xu et al. [11] 
UBC Progression rs1801018 18q21.33 BCL2 A G 0.76 European (Germany) Hess et al. [12] 
BCG-Bacillus Calmette-Guérin; EA-effect allele; EAF-effect allele frequency; MIBC-muscle-invasive bladder cancer; NMIBC-non-muscle-invasive bladder cancer; RA-
reference allele; SNP-single nucleotide polymorphism; TUR-transurethral resection; UBC-urinary bladder cancer. 
*Global, based on 1000 Genomes Project (unless otherwise specified).  
 
REFERENCES: 
[1] Sanyal S, De Verdier PJ, Steineck G, Larsson P, Onelov E, Hemminki K, Kumar R. Polymorphisms in Xpd, Xpc and the Risk of 
Death in Patients with Urinary Bladder Neoplasms. Acta oncologica (Stockholm, Sweden). 2007;46(1):31-41. 
[2] Ryk C, Wiklund NP, Nyberg T, De Verdier PJ. Ser608leu Polymorphisms in the Nitric Oxide Synthase-2 Gene May Influence Urinary 
Bladder Cancer Pathogenesis. Scandinavian journal of urology and nephrology. 2011;45(5):319-25. 
[3] Lee EK, Ye Y, Kamat AM, Wu X. Genetic Variations in Regulator of G-Protein Signaling (Rgs) Confer Risk of Bladder Cancer. 
Cancer. 2013;119(9):1643-51. 
[4] Ryk C, Koskela LR, Thiel T, Wiklund NP, Steineck G, Schumacher MC, de Verdier PJ. Outcome after Bcg Treatment for Urinary 
Bladder Cancer May Be Influenced by Polymorphisms in the Nos2 and Nos3 Genes. Redox biology. 2015;6:272-7. 
[5] Deng S, Wang W, Li X, Zhang P. Common Genetic Polymorphisms in Pre-Micrornas and Risk of Bladder Cancer. World journal of 
surgical oncology. 2015;13:297. 
[6] Sakano S, Berggren P, Kumar R, Steineck G, Adolfsson J, Onelov E, Hemminki K, Larsson P. Clinical Course of Bladder Neoplasms 
and Single Nucleotide Polymorphisms in the Cdkn2a Gene. International journal of cancer. 2003;104(1):98-103. 
[7] Basturk B, Yavascaoglu I, Oral B, Goral G, Oktay B. Cytokine Gene Polymorphisms Can Alter the Effect of Bacillus Calmette-Guerin 
(Bcg) Immunotherapy. Cytokine. 2006;35(1-2):1-5. 
[8] Guirado M, Gil H, Saenz-Lopez P, Reinboth J, Garrido F, Cozar JM, Ruiz-Cabello F, Carretero R. Association between C13orf31, 
Nod2, Ripk2 and Tlr10 Polymorphisms and Urothelial Bladder Cancer. Human immunology. 2012;73(6):668-72. 
[9] Wei H, Kamat A, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X. Association of Polymorphisms in Oxidative 
Stress Genes with Clinical Outcomes for Bladder Cancer Treated with Bacillus Calmette-Guerin. PloS one. 2012;7(6):e38533. 
[10] Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, Wei H, Huang M, Chang DW, Dinney CP, Wu X. Genetic Variations in Micro-Rna 
Biogenesis Genes and Clinical Outcomes in Non-Muscle-Invasive Bladder Cancer. Carcinogenesis. 2013;34(5):1006-11. 
[11] Xu ZC, Cai HZ, Li X, Xu WZ, Xu T, Yu B, Zou Q, Xu L. Ercc1 C118t Polymorphism Has Predictive Value for Platinum-Based 
Chemotherapy in Patients with Late-Stage Bladder Cancer. Genetics and molecular research : GMR. 2016;15(2). 
[12] Hess J, Stelmach P, Eisenhardt A, Rubben H, Reis H, Schmid KW, Bachmann HS. Impact of Bcl2 Polymorphisms on Survival in 
Transitional Cell Carcinoma of the Bladder. Journal of cancer research and clinical oncology. 2017;143(9):1659-70. 
 
Supplementary Table 6.5. Minor allele frequencies and imputation scores (info) for 
tested SNPs. 













rs1052133 9798773 C G 0.23 G 1 
rs710521 189645933 T C 0.27 C 1 
rs798766 1734239 T C 0.19 T 1 
rs884225 55274084 T C 0.10 C 1 
rs1057868 75615006 C T 0.28 T 1 
rs41515546 125998959 T C 0.15 C 0.99774 
rs17149636 126018952 A G 0.15 G 0.99804 
rs17149628 126006965 C T 0.15 T 0.997627 
rs12666814 125979540 C T 0.14 T 0.993985 
rs73223045 125992106 G C 0.15 C 0.99768 
rs12673089 126006133 C T 0.15 T 0.996984 
rs17149580 125978216 A G 0.15 G 0.991705 
rs17149630 126006996 C T 0.15 T 0.997626 
rs7003908 48770702 C A 0.33 C 0.824001 
rs710886 128026860 C T 0.37 T 0.998081 
rs9642880 128718068 G T 0.46 T 1 
rs9344 69462910 G A 0.44 A 1 
rs217727 2016908 G A 0.18 A 0.974512 
rs874945 54355451 C T 0.34 T 0.993033 
rs25487 44055726 T C 0.36 T 1 
Recurrence 
rs4645978 15852034 C T 0.47 C 0.999525 
rs197412 112308953 T C 0.40 C 1 
rs511918 182579602 G T 0.41 G 0.992327 
rs1323291 192548543 T G 0.09 G 0.993577 
rs3795617 192603690 C T 0.47 T 0.991678 
rs16829458 192768324 G A 0.07 A 1 
rs11685068 121541012 C T 0.06 T 0.9919 
rs17235409 219259732 G A 0.02 A 1 
rs1801282 12393125 C G 0.12 G 1 
rs1050450 49394834 G A 0.30 A 0.99929 
rs1052133 9798773 C G 0.23 G 1 
rs2228001 14187449 G T 0.40 G 0.995546 
rs1799864 46399208 G A 0.078308 A 1 
rs4073 74606024 A T 0.46 A 1 
rs798766 1734239 T C 0.19 T 1 
rs2910164 159912418 C G 0.24 C 0.999062 
rs12186785 31410608 T C 0.09 C 1 
rs4957014 288014 T G 0.24 T 0.997295 
rs2042329 64067752 T G 0.41 T 1 
rs2292016 38845860 G T 0.02 T 0.976753 
rs2278329 38921788 G A 0.01 A 1 
rs1799964 31542308 T C 0.21 C 1 
rs2275913 52051033 G A 0.35 A 0.968288 
rs1800795 22766645 C G 0.41 C 1 
rs2070744 150690079 C T 0.38 C 0.987305 
rs1799983 150696111 T G 0.33 T 0.983157 
rs6463089 42152856 G A 0.10 A 0.995015 
rs3801192 42161527 C T 0.09 T 1 
rs1233560 155593438 G A 0.47 G 0.845252 
rs7003908 48770702 C A 0.33 C 0.824001 
rs804267 11629241 G A 0.32 G 0.991159 
rs8191604 11636884 T G 0.26 G 0.988574 
rs804256 11636862 T C 0.35 C 0.99245 
rs804276 11625008 G A 0.42 A 0.990034 
rs4639 11644751 A G 0.44 G 0.992205 
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rs13278062 23082971 G T 0.50 G 1 
rs2228526 50678717 T C 0.20 C 1 
rs11199005 121296029 G A 0.09 A 1 
rs4925 106022789 C A 0.30 A 1 
rs2505568 36811336 T A 0.42 T 0.98455 
rs187238 112034988 C G 0.27 G 0.994289 
rs1695 67352689 A G 0.35 G 1 
rs2279744 69202580 T G 0.35 G 0.99522 
rs5742714 102789852 C G 0.09 G 0.994077 
rs2238151 112211833 T C 0.35 C 1 
rs4758680 122655352 T G 0.33 T 0.996788 
rs1544410 48239835 C T 0.40 T 1 
rs2430561 68552522 T A 0.12 A 0.612221 
rs3138056 35868514 C T 0.32 T 0.980789 
rs2169830 39872056 T C 0.30 C 0.991923 
rs744154 14015081 G C 0.28 C 0.996449 
rs243865 55511806 C T 0.25 T 1 
rs16260 68771034 C A 0.28 A 0.996119 
rs1042522 7579472 G C 0.26 G 1 
rs9904341 76210367 G C 0.31 C 0.992725 
rs2854509 44074597 T G 0.22 T 0.990178 
rs3213255 44077507 G A 0.42 G 0.991363 
rs915927 44057227 T C 0.44 C 0.999689 
rs2854501 44060001 A G 0.24 A 1 
rs1799782 44057574 G A 0.06 A 1 
rs25487 44055726 T C 0.36 T 1 
rs1799793 45867259 C T 0.33 T 1 
rs5498 10395683 A G 0.42 G 1 
rs3746162 1114119 C T 0.22 T 0.998325 
rs7265992 33525407 G A 0.18 A 0.976046 
rs6060124 33536897 C A 0.31 A 0.992465 
rs7260770 33552653 G A 0.33 A 0.996424 
rs4911455 33553062 A C 0.33 C 0.997023 
rs2173962 33022020 T C 0.04 C 0.98769 
Death 
rs1801133 11856378 G A 0.33 A 1 
rs1395960 163115522 C T 0.12 T 0.99613 
rs2854461 226011644 C A 0.35 A 0.994428 
rs2344673 163118052 G A 0.14 A 1 
rs10917690 163142168 A G 0.30 G 0.921387 
rs1890398 192771127 C T 0.35 T 0.997693 
rs12035879 163142555 G A 0.40 A 1 
rs10753605 163145390 T C 0.30 C 0.974848 
rs1126579 219000734 T C 0.47 T 0.999164 
rs1042640 234681544 G C 0.20 G 1 
rs9282638 119263770 T C 0.15 C 0.997356 
rs4129009 38774889 T C 0.15 C 1 
rs762861 3442011 G C 0.25 C 0.979271 
rs2662238 82499307 G A 0.45 A 0.992607 
rs10515074 67566193 A G 0.20 G 0.998354 
rs3756712 309096 A C 0.38 A 0.996364 
rs2292016 38845860 G T 0.02 T 0.976753 
rs1799983 150696111 T G 0.33 T 0.983157 
rs1800795 22766645 C G 0.41 C 1 
rs2227983 55229255 G A 0.26 A 1 
rs2017000 55242609 A G 0.28 G 0.996934 
rs2293347 55268916 C T 0.11 T 0.991363 
rs35402311 53627403 G A 0.04 A 1 
rs334358 101910613 G T 0.20 T 0.994179 
rs868 101911656 A G 0.20 G 0.994126 
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rs1051013 116359339 T C 0.25 T 1 
rs156697 106039185 A G 0.35 G 1 
rs4925 106022789 C A 0.30 A 1 
rs528778 8112143 T C 0.21 T 0.993889 
rs4987059 636433 G A 0.05 A 1 
rs1805363 94226952 C T 0.09 T 1 
rs2279744 69202580 T G 0.35 G 0.99522 
rs5443 6954875 C T 0.32 T 1 
rs7180135 41024094 G A 0.43 G 0.998991 
rs9302752 50719103 T C 0.29 T 1 
rs17855750 28515228 A C 0.05 C 1 
rs1800067 14029033 G A 0.08 A 1 
rs1131341 69748869 G A 0.04 A 1 
rs1042522 7579472 G C 0.26 G 1 
rs9906827 78665405 C T 0.45 T 0.997786 
rs1801018 60985879 T C 0.42 C 1 
rs2279115 60986837 G T 0.47 G 0.998126 
rs13181 45854919 T G 0.36 G 1 
rs915927 44057227 T C 0.44 C 0.999689 
rs762507 44058098 T C 0.43 T 0.999682 
rs2854501 44060001 A G 0.24 A 1 
rs2854509 44074597 T G 0.22 T 0.990178 
rs3213255 44077507 G A 0.42 G 0.991363 
rs3730050 40770982 T C 0.29 T 0.997599 
rs11615 45923653 A G 0.39 G 1 
rs171140 45865002 C A 0.45 C 0.995683 
rs1994251 30287328 T G 0.22 G 0.995433 
rs6024840 54956707 A G 0.25 G 0.980223 
Progression 
rs10917690 163142168 A G 0.30 G 0.921387 
rs10926466 241521721 C T 0.26 C 0.980052 
rs11585883 163104742 T C 0.06  C 0.995822 
rs12038803 241522325 A G 0.25 A 0.976809 
rs1323291 192548543 T G 0.10  G 0.993577 
rs1800896 206946897 T C 0.50 C 0.993185 
rs6678136 163037317 G A 0.42 A 0.9972 
rs2243248 132008644 T G 0.07 G 1 
rs2910164 159912418 C G 0.24 C 0.999062 
rs4075958 176784512 G A 0.26 A 1 
rs1799983 150696111 T G 0.33 T 0.983157 
rs2070744 150690079 C T 0.38 C 0.987305 
rs3088440 21968159 G A 0.09 A 0.992401 
rs12628 534242 A G 0.34 G 1 
rs3890995 109533529 T C 0.18 C 0.990296 
rs9302752 50719103 T C 0.29 T 1 
rs2297518 26096597 G A 0.19 A 1 
rs1801018 60985879 T C 0.42 C 1 
rs11615 45923653 A G 0.39 G 1 
rs1800470 41858921 G A 0.38 G 0.997955 
rs1800471 41858876 C G 0.08 G 1 
rs2073778 20074575 C T 0.13 T 0.995009 
rs720012 20098582 G A 0.13 A 0.99538 
MAF-Minor Allele Frequency; SNP-Single Nucleotide Polymorphism.
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